

| | |
|---|---|
| Proposal Subject: | Receptor Binding Assay (RBA) for Paralytic Shellfish Poisoning (PSP) Toxicity Determination |
| Specific NSSP Guide Reference: | NSSP Guide Section IV. Guidance Documents Chapter II. Growing Areas .11 Approved NSSP Laboratory Tests, 4. Approved Limited Use Methods for Marine Biotoxin Testing |
| Text of Proposal/ Requested Action | <p>This submission presents the ‘Receptor Binding Assay (RBA) for Paralytic Shellfish Poisoning (PSP) Toxicity Determination’ for consideration as an NSSP Approved Limited Use Method. The RBA is a competition-based assay that employs radiolabeled Saxitoxin (³H-STX) to compete with PSP toxins present in standards/samples for binding sites on natural receptors in the assay. Following incubation with the receptors, unbound ³H-STX is removed and the remaining labeled toxin is measured with a scintillation counter. The amount of remaining ³H-STX is inversely proportional to standard/sample toxicity.</p> <p>The RBA offers a high-throughput, sensitive, and quantitative alternative to the mouse bioassay (MBA), which has been the long-standing reference method for PSP toxicity. Further, the RBA eliminates the use of live animals for detection of these toxins. While the RBA still uses receptors prepared from animals, the number of animals required for analysis is significantly reduced. Using native receptors as the analytical recognition elements for the assay allows for a composite measure of overall toxicity, as opposed to toxin concentrations measured by liquid chromatographic methods that require conversion factors of equivalent toxicity to calculate the overall toxicity.</p> <p>The RBA has undergone AOAC single- and multi-laboratory validation and is designated through AOAC as an Official Method of Analysis (OMA 2011.27). Results from those studies, and additional data, are included in this proposal submission for the RBA to be considered for approval as an NSSP Approved Limited Use Method for Marine Biotoxin Testing.</p> |
| Public Health Significance: | <p>Paralytic shellfish poisoning intoxications result from the consumption of seafood (primarily bivalve molluscs) contaminated with neurotoxins known as paralytic shellfish toxins (PSTs). This suite of toxins binds to voltage-gated sodium channels and may result in paralysis if enough toxin is consumed. In extreme cases when respiratory support is not available to the patient, the intoxication may prove fatal. Since the toxins cannot be destroyed during cooking and there is no way to remove the toxins from seafood, the best control strategy is to ensure that contaminated product never reaches the market. To protect public health, harvesting closures are implemented when toxicity exceeds the guidance level of 80 micrograms Saxitoxin equivalents per 100 grams of shellfish tissue. As such, accurate analytical methods are needed to monitor shellfish toxicity for making decisions regarding opening and closing shellfish growing areas accordingly. Acceptance of the RBA as an NSSP Approved Limited Use Method for PSP toxicity determination would provide monitoring and management programs with an additional tool that can be used for monitoring toxin levels and making regulatory decisions. Not only does the RBA eliminate the need for live animals for PSP testing, it is also more sensitive than the MBA, thereby providing an early warning system for monitoring programs as toxin levels begin to rise.</p> |
| Cost Information (if available): | <p>The estimated cost for a full 96-well plate assay is ~\$95.00. Including standards and samples with triplicate measurements (as well as three dilutions per sample to ensure the unknown samples fall within linear range of assay), the cost per sample for quantitative results would be ~\$13.60. If running multiple plates or in screening mode, sample costs would be reduced. Further, the filter plates used in the RBA differ from ELISA plates in that all reagents are added to each well as needed rather than already being a component of the plate, making it more</p> |

practical and cost-effective to analyze samples when there is less than a full plate.

**Action by 2013
Laboratory
Method and
Quality Assurance
Review
Committee**

1. Recommended approval of this method as an alternative to the mouse bioassay for PSP in mussels.
2. Recommended approval of this method for Limited Use for clams and scallops for the purpose of screening and precautionary closure for PSP.
3. Recommended referral of this proposal to an appropriate committee as determined by the Conference Chairman to address this method in oysters.
4. Recommended Executive Office send a letter to submitter to request a checklist for evaluation of labs using this method with said checklist to be submitted within three (3) months

**Action by 2013
Task Force I**

Recommended adoption of Laboratory Method Review and Quality Assurance Committee recommendations on Proposal 13-114.

**Action by 2013
General Assembly**

Adopted recommendation of 2013 Task Force I on Proposal 13-114.

**Action by FDA
May 5, 2014**

Concurred with Conference action on Proposal 13-114.

NOTE:

[Click here for Proposal 13-114 Supporting Documentation](#)

ISSC Method Application and Single Lab Validation Checklist For Acceptance of a Method for Use in the NSSP

The purpose of single laboratory validation in the National Shellfish Sanitation Program (NSSP) is to ensure that the analytical method under consideration for adoption by the NSSP is fit for its intended use in the Program. A Checklist has been developed which explores and articulates the need for the method in the NSSP; provides an itemized list of method documentation requirements; and, sets forth the performance characteristics to be tested as part of the overall process of single laboratory validation. For ease in application, the performance characteristics listed under validation criteria on the Checklist have been defined and accompany the Checklist as part of the process of single laboratory validation. Further a generic protocol has been developed that provides the basic framework for integrating the requirements for the single laboratory validation of all analytical methods intended for adoption by the NSSP. Methods submitted to the Interstate Shellfish Sanitation Conference (ISSC) Laboratory Methods Review (LMR) Committee for acceptance will require, at a minimum, six (6) months for review from the date of submission.

| Name of the New Method | Receptor Binding Assay (RBA) for Paralytic Shellfish Poisoning (PSP) Toxicity Determination | |
|---|--|--|
| Name of the Method Developer | Dr. Fran Van Dolah | |
| Developer Contact Information | Tel: (843) 725-4864 Email: Fran.vandolah@noaa.gov | |
| Checklist | Y/N | Submitter Comments |
| A. Need for the New Method | | |
| 1. Clearly define the need for which the method has been developed. | Y | <p>Paralytic shellfish poisoning (PSP) is the human intoxication that results from the consumption of seafood, primarily bivalve molluscs, contaminated with natural, algal-derived toxins known as paralytic shellfish toxins (PSTs) or the saxitoxins (STXs). This family of neurotoxins binds to voltage-gated sodium channels, thereby attenuating action potentials by preventing the passage of sodium ions across the membrane. Symptoms include tingling, numbness, headaches, weakness, and difficulty breathing. Medical treatment is to provide respiratory support, without which the prognosis can be fatal. To protect human health, seafood harvesting bans are implemented when toxins exceed a safe guidance level (80 µg STX equivalents per 100 g tissue or 800 µg STX equivalents per kg). Successful monitoring and management programs are attributed with minimizing the number of PSP cases and associated deaths.</p> <p>The mouse bioassay (MBA) has long-served as the gold standard method for detecting PSP in regulatory environments. Even though the MBA is an NSSP Approved Method for Marine Biotxin Testing, there are numerous reasons for considering alternative methods for PSP detection. Disadvantages of the MBA include high variability and the use of live animals. Given these limitations of the MBA, particularly the ethical concerns of using live animals, there have been great strides in method development and validation for alternative approaches.</p> <p>Recently, the post-column oxidation liquid chromatographic method (PCOX) for PSP detection was accepted as an NSSP Approved Limited Use Method, providing an alternative to the MBA. While some laboratories are in the process of transitioning to this</p> |

| | | |
|---|---|--|
| | | <p>method, implementation requires costly instrumentation and skilled personnel. Furthermore, the PCOX method identifies and quantifies individual PSP toxins. Toxicity equivalency factors must then be taken into consideration to calculate the expected overall toxicity in µg STX equivalents per 100 g tissue.</p> <p>The proposed receptor binding assay (RBA) addresses the major shortcomings of the PCOX and MBA by quantitatively measuring the overall PSP toxicity and doing so without the need of live animals, respectively. The RBA relies on the interaction of the toxins with the native receptor site (i.e., voltage-gated sodium channels). In this functional assay toxins bind to their receptors according to their affinity, yielding an integrated toxic potency. The RBA is more sensitive than the MBA, allowing monitoring laboratories earlier warning capabilities as toxins become elevated. The RBA has successfully undergone AOAC single laboratory validation (Van Dolah et al. 2009 - Appendix II) and a full collaborative study (Van Dolah et al. 2012 - Appendix III). The RBA is now considered an AOAC Official Method of Analysis (OMA 2011.27 - Appendix IV). This proposal provides data from the AOAC studies as well as additional data to seek consideration for the RBA to be an NSSP Approved Limited Use Method.</p> |
| 2. What is the intended purpose of the method? | Y | This method is intended for use as an NSSP Approved Limited Use Method for screening for PSP toxicity in shellfish. Applications include: (1) Growing Area Survey & Classification and (2) Controlled Relaying. The RBA serves as an alternative to the MBA in these applications, offering a measure of integrated toxicity with high throughput and the elimination of live animal testing. |
| 3. Is there an acknowledged need for this method in the NSSP? | Y | Yes, there is an acknowledged need for this method in the NSSP. Even though the MBA and PCOX methods have been respectively NSSP Approved and Approved for Limited Use, there remains a need for the proposed method. The RBA would provide an alternative to (1) the MBA, which uses live animals, and (2) the PCOX method, which requires costly equipment and skilled personnel and offers low throughput. |
| 4. What type of method? i.e. chemical, molecular, culture, etc. | Y | Molecular. The RBA is a functional assay, whereby toxins present in the standard/sample bind to sodium channel preparations in the assay. Radiolabeled toxins are added to solution to compete with toxins present in the standard/sample for binding sites, and thus a decrease in signal from radiolabeled toxins represents an increase in standard/sample toxicity. This competitive RBA allows for quantitation that directly relates to the composite toxicity of the sample. |
| B. Method Documentation | | |
| 1. Method documentation includes the following information: | | |
| Method Title | Y | Receptor Binding Assay (RBA) for Paralytic Shellfish Poisoning (PSP) Toxicity Determination |
| Method Scope | Y | The RBA provides a high throughput, sensitive, accurate, quantitative assay for PSP toxins in shellfish. The method is being submitted for consideration as an NSSP Approved Limited Use Method for the purposes of screening for PSP toxicity. |

| | | |
|-------------------------|---|--|
| References | Y | <p>Van Dolah et al. 2009. Single-laboratory validation of the microplate receptor binding assay for paralytic shellfish toxins in shellfish. <i>Journal of AOAC International</i> 92(6): 1705-1713. See Appendix II.</p> <p>Van Dolah et al. 2012. Determination of paralytic shellfish poisoning toxins in shellfish by receptor binding assay: Collaborative study. <i>Journal of AOAC International</i> 95(3): 795-812. See Appendix III.</p> <p>OMA 2011.27. AOAC Official Method 2011.27 Paralytic shellfish toxins (PSTs) in shellfish, receptor binding assay. In <i>Official Methods of Analysis of AOAC International</i>. http://www.eoma.aoac.org. See Appendix IV.</p> |
| Principle | Y | <p>This assay is based on the interaction between the toxins and their native receptor, the voltage-gated sodium channels. All PSTs bind to site 1 of the voltage-gated sodium channels according to their potency, resulting in a measure of integrated potency (independent of knowing which toxin congeners are present) similar to mouse intraperitoneal potency. In the RBA, tritiated saxitoxin (³H-STX) competes with unlabeled PSTs in the homogenized and extracted shellfish sample for a finite number of available receptor sites in a rat brain membrane preparation. After a binding equilibrium is reached, unbound ³H-STX is removed by filtration and the remaining ³H-STX is measured with a scintillation counter (as counts per minute or CPM). The amount of ³H-STX present is indirectly related to the amount of unlabeled PSTs in the sample. Scintillation counting can be conducted using traditional scintillation counters or microplate counting. However, the microplate format is preferred as it minimizes sample handling and the amount of radioactivity used.</p> |
| Any Proprietary Aspects | N | None. All reagents can be prepared or purchased. |
| Equipment Required | Y | <p>The following list identifies the equipment and supplies needed for conducting the RBA.</p> <p>For the assay:</p> <ul style="list-style-type: none"> (a) Scintillation counter (traditional or microplate) (b) An 8-channel pipettor (5-200 µl variable volume and disposable tips) (c) Micropipettors (1-1000 µl variable volumes and disposable tips) (d) 96-well microtitre filter plate (1 µm pore size type GF/B glass fiber filter/0.65 µm pore size Durapore support membrane (Millipore, Bedford, MA; Cat. No. MSFB N6B 50) (e) MultiScreen vacuum manifold (Millipore; Cat. No. NSVMHTS00) (f) Vacuum pump (g) Centrifuge tubes (15 and 50 ml, conical, plastic) (h) Mini dilution tubes in 96-tube array (i) Reagent reservoirs (j) Ice bucket and ice (k) Vortex mixer (l) Sealing tape (Millipore; Cat. No. MATA HCL00) (m) Volumetric flask or graduated beaker (1 L) (n) -80 °C freezer (o) Refrigerator |

| | | |
|--------------------------|----------|---|
| | | <p>Additional supplies when using a traditional scintillation counter (as opposed to a microplate counter):</p> <p>(p) MultiScreen punch device (Millipore; Cat. No. MAMP 096 08)</p> <p>(q) MultiScreen disposable punch tips (Millipore; Cat. No. MADP 196 10)</p> <p>(r) MultiScreen punch kit B for 4 ml vials (Millipore; Cat. No. MAPK 896 0B)</p> <p>(s) Scintillation vials (4 ml)</p> <p>For sample extraction:</p> <p>(t) Blender or homogenizer for sample homogenization</p> <p>(u) Pipets</p> <p>(v) Centrifuge tubes (15 ml, conical, plastic)</p> <p>(w) pH meter or pH paper</p> <p>(x) Hot plate or water bath</p> <p>(y) Graduated centrifuge tubes (15 ml)</p> <p>(z) Centrifuge and rotor for 15 ml tubes</p> <p>For rat brain isolation:</p> <p>(aa) Teflon/glass homogenizer (Motorized tapered Teflon pestle and glass tube (15 ml)</p> <p>(bb) Motorized tissue homogenizer (Polytron or small handheld blender)</p> <p>(cc) High-speed centrifuge and fixed angle rotor (20 000 x g rcf)</p> <p>(dd) Centrifuge tubes (12-15 ml, rated for 20 000 x g)</p> <p>(ee) plastic cryovials (2 ml)</p> <p>(ff) Graduated beaker (300 or 500 ml)</p> <p>(hh) Pipets (5-10 ml, disposable)</p> <p>(ii) Forceps</p> <p>(jj) Ice bucket and ice</p> <p>(kk) top loading balance</p> |
| <p>Reagents Required</p> | <p>Y</p> | <p>For the assay:</p> <p>(a) STX diHCl standards (NIST RM 8642; available through the National Institute of Standards and Technology; www.nist.gov) [This is the same standard used for the MBA]</p> <p>(b) ³H-STX (0.1 mCi per ml, ≥10 Ci per mmol, ≥90% radiochemical purity; available through American Radiolabeled Chemicals, St. Louis, MO)</p> <p>(c) 3-Morpholinopropanesulfonic acid (MOPS; Sigma; St. Louis, MO; Cat. No. M3183-500G [or equivalent])</p> <p>(d) Choline chloride (Sigma; Cat. No. C7527-500G [or equivalent])</p> <p>For microplate counter only:</p> <p>(e) Ultima Gold liquid scintillation cocktail (PerkinElmer Inc.; Waltham, MA; Cat. No. 6013321 [or equivalent])</p> <p>For traditional counter only:</p> <p>(f) Scintiverse BD liquid scintillation cocktail (Fisher Scientific; Waltham, MA; Cat. No. SX-18 [or equivalent])</p> <p>For sample extraction:</p> <p>(g) Hydrochloric acid (HCl; 1.0 and 0.1 M)</p> <p>(h) Sodium hydroxide (0.1 M)</p> <p>(i) Water (distilled or deionized [18 μΩ])</p> <p>For rat brain isolation:</p> <p>(j) 20 rat brains (male, 6-week old Sprague-Dawley;</p> |

| | | |
|--|---|---|
| | | <p>available through Hilltop Lab Animals, Inc., Scottsdale, PA; www.hilltoplabs.com [or equivalent])</p> <p>(k) MOPS, pH 7.4 (Sigma, St. Louis, MO; Cat. No. M3183-500G [or equivalent])</p> <p>(l) Choline chloride (100 mM; Sigma; Cat. No. C7527-500G [or equivalent])</p> <p>(m) Phenyl methylsulfonyl fluoride (PMSF; Sigma, St. Louis, MO: Cat. No. P7626)</p> <p>(n) Isopropanol</p> <p>(o) Micro bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL)</p> |
| Sample Collection, Preservation and Storage Requirements | Y | <p>A representative shellfish sample should include 12 market size organisms pooled together (should be at least 100 g). Clean the outside of shellfish with running tap water. Open the shell by cutting into the adductor muscle, being careful to not cut or damage the viscera. Rinse the inside to remove sand and dirt and remove tissue from ~12 organisms. Collect the tissue on a number 10 sieve and allow to drain for ~5 minutes. Remove any obvious pieces of shell or debris. Transfer meat to blender or homogenizer and blend until homogeneous. This homogenate is then extracted for toxins. For the detailed sample extraction procedure see Sample Extraction in Appendix A. Shellfish homogenates must be tested immediately or stored frozen prior to analysis. Saxitoxin standards must be stored refrigerated and ³H-STX must be stored at -80 °C. The rat brain preparation can be produced in bulk, partitioned into aliquots, and stored long-term at -80 °C until use.</p> |
| Safety Requirements | Y | <p>General safety requirements (e.g., personal protective equipment including gloves, safety glasses, and laboratory coat) for working with toxins, biological reagents, and radioactive material must be followed. Users must be trained in and follow all in-house safety procedures for working with toxins and radiolabeled materials. Even though low levels of radiation are used for this assay, users must follow all local, state and federal laws and procedures regarding the receipt, use, and disposal of isotopes. Please see Appendix C for further safety requirements.</p> |
| Clear and Easy to Follow Step-by-Step Procedure | Y | <p>The protocol is very clear and easy to follow. Please see the detailed protocol below in Appendix A.</p> |
| Quality Control Steps Specific for this Method | Y | <p>Quality control steps are in place to determine if assay results are acceptable:</p> <p>(a) The slope of the standard curve must be between -0.8 and -1.2 (theoretical slope is -1). If the slope of a standard curve from a given assay falls outside of this range, the data should be considered unacceptable and the assay must be rerun.</p> <p>(b) The RSDs of triplicate counts per minute (CPMs) for the standards must be below 30%.</p> <p>(c) If the IC₅₀ (inhibitory concentration at which CPM is 50% max) is out of the acceptable range (2.0 nM ± 30%), the data should be considered unacceptable and the assay should be rerun.</p> <p>(d) A QC sample should always be included and found to be in range. Typically a 1.8 x 10⁻⁸ M STX concentration</p> |

| | | |
|-------------------------------|---|---|
| | | <p>(3 nM STX in-well concentration) is run as a QC and should be within 30%. Results outside of this range should trigger consideration of assay acceptance.</p> <p>The following criteria must be met to accept sample measurement:</p> <p>(e) For sample measurement, quantitation should only be done on sample dilutions that fall within the linear range. As such, binding (B, measured as counts per minute) scaled by the maximum binding (B_0) should be between 0.2-0.7 for sample quantitation to be performed (any sample falling outside of this range is considered out of the dynamic range). If $B/B_0 > 0.7$, the concentration is too low to be quantified and should be reported as below the limit of detection (LOD). If $B/B_0 < 0.2$, the sample should be diluted and rerun if quantitation is needed.</p> <p>(f) The RSDs for the sample CPMs should be $\leq 30\%$.</p> <p>These quality control criteria are also stated in section H in Appendix IV.</p> |
| C. Validation Criteria | | |
| 1. Accuracy / Trueness | Y | <p>Validation data presented in Section C are from both the SLV (Van Dolah et al. 2009) and the collaborative study (Van Dolah et al. 2012). Nine laboratories from six countries completed the collaborative study. There were a total of 21 shellfish homogenates tested in three different assays on independent days. Different shellfish species from a range of geographical locations were used in the study: blue mussel (<i>Mytilus edulis</i>) from the U.S. east and west coasts, California mussel (<i>Mytilus californianus</i>) from the U.S. west coast, chorito mussel (<i>Mytilus chilensis</i>) from Chile, green mussel (<i>Perna canaliculus</i>) from New Zealand, Atlantic surfclam (<i>Spisula solidissima</i>) from the U.S. east coast, butter clam (<i>Saxidomus gigantea</i>) from the U.S. west coast, almeja clam (<i>Venus antiqua</i>) from Chile, and Atlantic sea scallop (<i>Placopecten magellanicus</i>) from the U.S. east coast. Samples included those that were naturally contaminated, those that were spiked, and another that served as a negative control.</p> <p>Accuracy was evaluated based on recovery. As also stated under Section C. 4., Recovery of the QC check sample (3 nM in-well solution) was 99.3% (Appendix II).</p> <p>During the SLV recovery was evaluated for STX standard spiked into mussel tissue at concentrations below, at and above the regulatory guidance level. Recovery for the nominal spike at $40 \mu\text{g STX eq } 100 \text{ g}^{-1}$ was 115%. At $80 \mu\text{g STX eq } 100 \text{ g}^{-1}$, recovery was found to be 129%. At a nominal spike of $120 \mu\text{g STX eq } 100 \text{ g}^{-1}$, recovery was 121% (Appendix II).</p> <p>During the collaborative study, recovery of PSTs from shellfish was found to be 84.4% (when spiked with $20 \mu\text{g STX eq } 100 \text{ g}^{-1}$), 93.3% (when spiked with $50 \mu\text{g STX eq } 100 \text{ g}^{-1}$), and 88.1% (when spiked with $120 \mu\text{g STX eq } 100 \text{ g}^{-1}$). See Appendix III.</p> |
| 2. Measurement Uncertainty | Y | ND |

| | | |
|--|---|--|
| 3. Precision Characteristics (repeatability and reproducibility) | Y | <p>Repeatability (RSD_r) was determined during the SLV on six naturally contaminated shellfish samples on five independent days and was found to be 17.7%. See Appendix II.</p> <p>The reproducibility (RSD_R) during the collaborative study was found to be 33.2% for all laboratories. However, upon removing the results from the one laboratory that had no previous RBA experience, the RSD_R was 28.7%. If data from routine users of the RBA were evaluated, the RSD_R was 23.1%. See Appendix III.</p> <p>Repeatability (RSD_r) during the collaborative study ranged from 11.8-34.4%. For routine users of the RBA, the average $RSD_r = 17.1\%$, consistent with the RSD_r obtained during the SLV. See Appendix III.</p> |
| 4. Recovery | Y | <p>Recovery of the QC check sample (3 nM in-well solution) was 99.3% (Appendix II).</p> <p>During the SLV recovery was evaluated for STX standard spiked into mussel tissue at concentrations below, at and above the regulatory guidance level. Recovery for the nominal spike at $40 \mu\text{g STX eq } 100 \text{ g}^{-1}$ was 115%. At $80 \mu\text{g STX eq } 100 \text{ g}^{-1}$, recovery was found to be 129%. At a nominal spike of $120 \mu\text{g STX eq } 100 \text{ g}^{-1}$, recovery was 121% (Appendix II).</p> <p>During the collaborative study, recovery of PSTs from shellfish was found to be 84.4% (when spiked with $20 \mu\text{g STX eq } 100 \text{ g}^{-1}$), 93.3% (when spiked with $50 \mu\text{g STX eq } 100 \text{ g}^{-1}$), and 88.1% (when spiked with $120 \mu\text{g STX eq } 100 \text{ g}^{-1}$). See Appendix III.</p> |
| 5. Specificity | Y | <p>The RBA is specific to toxins that bind to site 1 of voltage-gated sodium channels. This includes all PSP congeners, whereby binding affinity is proportional to potency. Tetrodotoxin also binds to site 1 of the sodium channels, yet the typical combinations of sources, vectors, and geographical regions of tetrodotoxin and the saxitoxins differ.</p> |
| 6. Working and Linear Ranges | Y | <p>The dynamic range of the assay was determined to be 1.2-10.0 nM in-well concentration (Appendix II). Linearity assessment was conducted with three calibration standards (1.5, 3.0, and 6.0 nM STX in -well concentration) on five independent days. The linear regression yielded a slope of 0.98 and an $r^2 = 0.97$ (Appendix II).</p> <p>During the collaborative study, the assay was set for the critical range of shellfish toxicities below, near and just above the regulatory guidance level ($\sim 15\text{-}240 \mu\text{g STX eq } 100 \text{ g}^{-1}$ or $\sim 150\text{-}2400 \mu\text{g STX eq kg}^{-1}$). Appendix III.</p> |
| 7. Limit of Detection | Y | <p>The LOD, as determined in the collaborative study, is $4.5 \mu\text{g STX eq } 100 \text{ g}^{-1}$ or $45 \mu\text{g STX eq kg}^{-1}$ See Appendix III.</p> |
| 8. Limit of Quantitation / Sensitivity | Y | <p>The limit of quantitation (LOQ) was empirically determined as the concentration in a 10-fold diluted sample that resulted in a B/B0 of 0.7 (more conservative than the 0.8 typically used as the cut off for such assays). The LOQ was determined to be $5.3 \mu\text{g STX eq } 100 \text{ g}^{-1}$ during the SLV (Appendix II).</p> |

| | | |
|--|---|---|
| | | The LOQ of the RBA is 12.6 µg STX eq 100 g ⁻¹ or 126 µg STX eq kg ⁻¹ , as compared to the MBA LOQ of ~40 µg STX eq 100 g ⁻¹ (or ~400 µg STX eq kg ⁻¹). See Appendix III. |
| 9. Ruggedness | Y | <p>Ruggedness was addressed and critical steps were noted that could affect precision and accuracy. It was deemed important to clarify the shellfish extracts by centrifugation prior to performing the assay, particularly if the sample was refrigerated or frozen. The rat brain preparations should be vortexed frequently to ensure the synaptosomes are in suspension, and the buffer should be ice cold to ensure that toxins are not released from the receptor. Assay plate filtration should be at a rate of 2-5 seconds. Lastly, a minimum of 30 minutes should be allowed before reading the plates after scintillation liquid is added such that scintillant can penetrate the filters.</p> <p>For more detail please refer to Appendix II and Appendix III.</p> |
| 10. Matrix Effects | Y | No matrix effects were reported. Minimum dilutions of shellfish extracts were 10-fold and were found to be sufficient to eliminate matrix effects. See Appendix III. |
| 11. Comparability (if intended as a substitute for an established method accepted by the NSSP) | Y | <p>The RBA was compared to the MBA and the pre-column oxidation (Pre-COX) liquid chromatography with fluorescence detection (LC-FD) approach during the SLV.</p> <p>RBA results compared well to those obtained by the MBA in two separate studies. In one component of the SLV, six naturally contaminated samples (clams, mussels, and sea scallops) were tested by RBA and MBA. Between-assay RSDs ranged from 9 to 25% (mean 17.7%). An $r^2 = 0.98$ was obtained, with a slope of 1.29. In the second component of the SLV, which included 110 naturally contaminated shellfish, an $r^2 = 0.88$ and a slope of 1.32 was obtained (Appendix II).</p> <p>Nine naturally contaminated samples (six blue mussels and three scallops) were extracted and analyzed by RBA and Pre-COX. Samples were analyzed using the RBA following the typical extraction (0.1 M HCl), but also following the extraction procedure used for the Pre-COX method (1% acetic acid). A good correlation was found between the two methods for both extraction methods. When the RBA samples were extracted with HCl, the RBA compared to the Pre-COX yielded an $r^2 = 0.98$ and a slope of 1.39. When samples were extracted the same for both methods (acetic acid), the correlation was slightly improved with an $r^2 = 0.99$ and a slope of 1.32 (Appendix II).</p> <p>During the collaborative study, ten laboratories from seven countries performed the RBA. Additionally three of the laboratories conducted the MBA, and one laboratory tested the samples using the Pre-COX LC-FD. The MBA and RBA data comparison yielded an $r^2 = 0.84$ and a slope of 1.63. The LC-FD and RBA data comparison yielded an $r^2 = 0.92$ and a slope of 1.20. Both RBA and LC-FD methods generally report higher toxicity in shellfish, especially at or near the guidance level, relative to the MBA. This provides a conservative measure and allows for an earlier warning of developing</p> |

| | | |
|--|-------|--|
| | | toxicity. See Appendix III. |
| D. Other Information | | |
| 1. Cost of the Method | Y | The estimated cost per 96-well plate assay is ~\$95.00. Including standards and samples with triplicate measurements (as well as three dilutions per sample [ranging from 3.5-600 µg STX eq 100 g ⁻¹] to ensure the unknown samples fall within linear range of assay), the cost per sample for quantitation would be ~\$13.60. If running multiple plates or in screening mode, sample costs would be reduced. |
| 2. Special Technical Skills Required to Perform the Method | Y | General laboratory training is necessary (this would include being able to prepare reagent solutions, pipetting, centrifugation, and simple calculations). Additional training for working with low levels of radioactive material is required. |
| 3. Special Equipment Required and Associated Cost | Y | A microplate scintillation counter is needed and the cost is ~\$60-100K for a new counter, depending on the brand and number of simultaneous detectors. However, used instruments can be purchased for ~\$13K. |
| 4. Abbreviations and Acronyms Defined | Y | A list of abbreviations and acronyms is provided below in Appendix I. |
| 5. Details of Turn Around Times (time involved to complete the method) | Y | Microplate scintillation counting provides the ability to test multiple samples simultaneously with a turn around time for data in approximately 3 hours. Up to six plates per analyst are possible in one day, yielding a throughput of 42 samples per day. |
| 6. Provide Brief Overview of the Quality Systems Used in the Lab | Y | The Center for Food Safety and Applied Nutrition (CFSAN) Quality System (QS) provides guidance to (1) design and develop processes, products, and services related to CFSAN's mission, the FDA's regulatory mission, and critical management and administrative support services, and (2) continually improve and strengthen product and service quality. The Laboratory Quality Assurance program serves as CFSAN's logical application of QS to Center laboratories and lab-based activities. The third edition (October 2009) of the Laboratory Quality Manual was followed. Standard reference materials for saxitoxin are obtained through the National Institute of Standards and Technology (NIST) and are accompanied by a Report of Investigation (See Appendix V). The standard reference saxitoxin used in the RBA is the same as that employed with the MBA. The 3H-STX is obtained through American Radiolabeled Chemicals, Inc., and is accompanied by a Technical Data Sheet with lot specifications (Appendix VI). |
| | | |
| Submitters Signature | Date: | |
| Submission of Validation Data and Draft Method to Committee | Date: | |
| Reviewing Members | Date: | |

| | |
|----------------------------------|-------|
| Accepted | Date: |
| Recommendations for Further Work | Date: |
| Comments: | |

DEFINITIONS

1. **Accuracy/Trueness** - Closeness of agreement between a test result and the accepted reference value.
2. **Analyte/measurand** - The specific organism or chemical substance sought or determined in a sample.
3. **Blank** - Sample material containing no detectable level of the analyte or measurand of interest that is subjected to the analytical process and monitors contamination during analysis.
4. **Comparability** - The acceptability of a new or modified method as a substitute for an established method in the NSSP. Comparability must be demonstrated for each substrate or tissue type by season and geographic area if applicable.
5. **Fit for purpose** - The analytical method is appropriate to the purpose for which the results are likely to be used.
6. **HORRAT value** - HORRAT values give a measure of the acceptability of the precision characteristics of a method.⁴
7. **Limit of Detection** - the minimum concentration at which the analyte or measurand can be identified. Limit of detection is matrix and analyte/measurand dependent.⁴
8. **Limit of Quantitation/Sensitivity** - the minimum concentration of the analyte or measurand that can be quantified with an acceptable level of precision and accuracy under the conditions of the test.
9. **Linear Range** - the range within the working range where the results are proportional to the concentration of the analyte or measurand present in the sample.
10. **Measurement Uncertainty** - A single parameter (usually a standard deviation or confidence interval) expressing the possible range of values around the measured result within which the true value is expected to be with a stated degree of probability. It takes into account all recognized effects operating on the result including: overall precision of the complete method, the method and laboratory bias and matrix effects.
11. **Matrix** - The component or substrate of a test sample.
12. **Method Validation** - The process of verifying that a method is fit for purpose.¹
13. **Precision** - the closeness of agreement between independent test results obtained under stipulated conditions.^{1, 2}
There are two components of precision:
 - a. **Repeatability** - the measure of agreement of replicate tests carried out on the same sample in the same laboratory by the same analyst within short intervals of time.
 - b. **Reproducibility** - the measure of agreement between tests carried out in different laboratories. In single laboratory validation studies reproducibility is the closeness of agreement between results obtained with the same method on replicate analytical portions with different analysts or with the same analyst on different days.

14. **Quality System** - The laboratory's quality system is the process by which the laboratory conducts its activities so as to provide data of known and documented quality with which to demonstrate regulatory compliance and for other decision-making purposes. This system includes a process by which appropriate analytical methods are selected, their capability is evaluated, and their performance is documented. The quality system shall be documented in the laboratory's quality manual.
15. **Recovery** - The fraction or percentage of an analyte or measurand recovered following sample analysis.
16. **Ruggedness** - the ability of a particular method to withstand relatively minor changes in analytical technique, reagents, or environmental factors likely to arise in different test environments.⁴
17. **Specificity** - the ability of a method to measure only what it is intended to measure.¹
18. **Working Range** - the range of analyte or measurand concentration over which the method is applied.

REFERENCES:

1. Eurachem Guide, 1998. The Fitness for Purpose of Analytical Methods. A Laboratory Guide to Method Validation and Related Topics. LGC Ltd. Teddington, Middlesex, United Kingdom.
2. IUPAC Technical Report, 2002. Harmonized Guidelines for Single-Laboratory Validation of Methods of Analysis, Pure Appl. Chem., Vol. 74, (5): 835-855.
3. Joint FAO/IAEA Expert Consultation, 1999. Guidelines for Single-Laboratory Validation of Analytical Methods for Trace-Level Concentrations of Organic Chemicals.
4. MAF Food Assurance Authority, 2002. A Guide for the Validation and Approval of New Marine Biotxin Test Methods. Wellington, New Zealand.
5. National Environmental Laboratory Accreditation. , 2003. Standards. June 5.
6. EPA. 2004. EPA Microbiological Alternate Procedure Test Procedure (ATP) Protocol for Drinking Water, Ambient Water, and Wastewater Monitoring Methods: Guidance. U.S. Environmental Protection Agency (EPA), Office of Water Engineering and Analysis Division, 1200 Pennsylvania Avenue, NW, (4303T), Washington, DC 20460. April.

Appendix A: RBA Step-by-Step Procedure

A. Sample Extraction

- a. The extraction detailed below represents a small scale MBA extraction procedure. The actual MBA extraction could be used instead of the small scale version described here.
- b. Accurately weigh 5.0 g of tissue homogenate into a tared, labeled 15 ml conical tube.
- c. Add 5.0 ml of 0.1 M HCl, vortex, and check pH.
 - i. If necessary, adjust pH to 3.0-4.0 as determined by a pH meter or pH paper. To lower pH, add 1 M HCl dropwise with mixing; to raise pH, add 0.1 M NaOH dropwise with mixing.
- d. Place the tube in a beaker of boiling water on hot plate (or in a water bath) for 5 min with the caps loosened.
- e. Remove and cool to room temperature.
- f. Check pH and, if necessary, adjust cooled mixture to 3.0-4.0 as described above.
- g. Transfer entire contents to a labeled, graduated centrifuge tube and dilute volumetrically to 10 ml.
- h. Gently stir contents to homogeneity and then allow to settle until a portion of supernatant is translucent and can be decanted free of solids.
- i. Pour 5-7 ml of the translucent supernatant into a labeled centrifuge tube.
- j. Centrifuge at 3000 x *g* for 10 min.
- k. Retain clarified supernatant and transfer to a clean, labeled centrifuge tube.
- l. Store extracts at -20 °C until tested in RBA.

B. Preparation of Stock Solutions and Standards

- a. Assay buffer: 100 mM MOPS/100 mM choline chloride, pH 7.4
 - i. Weigh 20.9 g MOPS and 13.96 g choline chloride and add to 900 ml distilled or milli-Q water.
 - ii. Adjust pH to 7.4 with NaOH while stirring.
 - iii. Bring to a final volume of 1 L with distilled or milli-Q water.
 - iv. Store at 4 °C.
- b. Radioligand solution: ³H-STX
 - i. Calculate the concentration of ³H-STX stock provided by the supplier. Suppliers generally provide specific activity in Ci/mmol (~10-30 Ci/mmol) and activity in mCi/ml (~0.05-0.1 mCi/ml), from which the molar concentration can be calculated.
 - ii. Prepare 4 ml of a 15 nM working stock of ³H-STX fresh daily in 100 mM MOPS/100 mM choline chloride buffer. This will provide sufficient volume for one 96-well plate.
 - iii. Measure total counts of each working stock prior to running an assay. Add 36 µl of working stock ³H-STX in buffer to a liquid scintillation counter vial with 4 ml scintillant and count on a traditional liquid scintillation counter to confirm correct dilution. The CPM should be consistent and within 15% of expected value.

- c. Unlabeled STX standard working solution: The STX diHCl standard (NIST RM 8642 STX diHCl) is provided at a concentration of 268.8 μM (100 $\mu\text{g}/\text{ml}$).
 - i. A bulk standard curve can be made up in advance and stored at 4 $^{\circ}\text{C}$ for up to one month. The use of a bulk standard curve minimizes time needed for routine analyses and improves repeatability.
 - ii. Make up 3 mM HCl (e.g., from a 3 M stock, 50 μl in 50 ml) and use for the serial dilutions.
 - iii. Serial dilutions should result in the following stock concentrations (M):
 1. 6×10^{-6} [100 μl 268.8 μM STX + 4.38 ml 0.003 M HCl]
 2. 6×10^{-7} [500 μl 6×10^{-6} M STX + 4.5 ml 0.003 M HCl]
 3. 1.8×10^{-7} [1.5 ml 6×10^{-7} M STX + 3.5 ml 0.003 M HCl]
 4. 6×10^{-8} [500 μl 6×10^{-7} M STX + 4.5 ml 0.003 M HCl]
 5. 1.8×10^{-8} [500 μl 1.8×10^{-7} M STX + 4.5 ml 0.003 M HCl]
 6. 6×10^{-9} [500 μl 6×10^{-8} M STX + 4.5 ml 0.003 M HCl]
 7. 6×10^{-10} [500 μl 6×10^{-9} M STX + 4.5 ml 0.003 M HCl]
 8. 5 ml 0.003 M HCl.
 - d. Interassay calibration standard (QC check): Reference standard STX (1.8×10^{-8} M STX) in 3 mM HCl. For long-term storage keep at -80 $^{\circ}\text{C}$; for routine use (up to one month), store at 4 $^{\circ}\text{C}$.
 - e. Rat brain membrane preparation: Prepare bulk rat brain membrane preparations (Appendix B) and store at -80 $^{\circ}\text{C}$.
 - i. Thaw an aliquot of rat brain preparation on ice.
 - ii. Dilute membrane preparation with cold (4 $^{\circ}\text{C}$) 100 mM MOPS/100 mM choline chloride, pH 7.4 to yield a working stock with a protein concentration of 1.0 mg/ml.
 - iii. Vortex vigorously to achieve a visibly homogeneous suspension.
 - iv. Keep the diluted membrane preparation on ice.
- C. Performing the Assay
- a. Plate setup: When possible use a multichannel pipet to minimize effort and increase consistency.
 - i. Run standards, samples, and QC check in triplicate.
 - ii. For quantitation, multiple dilutions per extract should be analyzed in order to obtain a value that falls within the dynamic range of the assay. A minimum sample extract dilution of 1:10 is recommended to minimize potential matrix effects.
 - iii. Use of a standard plate layout (Figure 1) is recommended. This will improve ease of analysis and can help maximize the number of samples/standards that can be analyzed per plate.
 - b. Addition of samples/standards: Add in the following order to each well-
 - i. 35 μl assay buffer
 - ii. 35 μl STX standard/QC check/sample extract
 - iii. 35 μl ^3H -STX
 - iv. 105 μl membrane preparation (ensure solution is homogeneous)
 - v. Cover the plate and incubate at 4 $^{\circ}\text{C}$ for 1 h.

- c. Assay filtration: Use the vacuum manifold attached to the vacuum pump with an in-line side arm flask to catch filtrate from the plate filtration process.
 - i. Set the vacuum pressure gauge on the pump or manifold to ~4-8" Hg (~135-270 millibar).
 - ii. Place the 96-well plate on the vacuum manifold.
 - iii. Fill any empty wells with 200 μ l MOPS/choline chloride buffer to ensure even vacuum pressure and filtration across the plate.
 - iv. Turn on vacuum. Optimum vacuum will pull the wells dry in 2-5 s.
 - v. With vacuum pump running, quickly rinse each well twice with 200 μ l ice cold MOPS/choline chloride buffer using a multichannel pipet. Maintain vacuum until liquid is removed.
- d. Preparation of the assay for counting: Remove the plastic bottom from the plate and blot the plate bottom once on absorbent towel.
 - i. For counting in microplate scintillation counter:
 1. Seal the bottom of a counting cassette with sealing tape.
 2. Place the microplate in the counting cassette.
 3. Add 50 μ l scintillation cocktail per well using multichannel pipet.
 4. Seal the top of the plate with sealing tape.
 5. Incubate for 30 min at room temperature.
 6. Place the plate in the scintillation counter and count for 1 min per well.
 - ii. For counting in traditional scintillation counter:
 1. Place the microplate in the MultiScreen punch system apparatus and place the disposable punch tips on top of the microplate.
 2. Punch the filters from the wells into scintillation vials and fill with 4 ml scintillation cocktail.
 3. Place caps on the vials and vortex.
 4. Allow vials to sit overnight in the dark.
 5. Count using a tritium window in a traditional scintillation counter.

D. Analysis of Data

- a. Curve fitting: Perform curve fitting using a four-parameter logistic fit (sigmoidal dose response curve with variable slope).
 - i. $y = \text{min} + (\text{max} - \text{min}) / (1 + 10^{(x - \log \text{IC}_{50}) \text{Hill slope}})$
 - ii. where max is the top plateau representing maximum binding in CPM in the absence of competing nonradiolabeled STX (also known as B_0); min is the bottom plateau, equal to nonspecific binding in CPM in the presence of saturating nonradiolabeled STX; IC_{50} is the inhibitory concentration at which CPM are 50% of max-min; Hill slope is the slope of the curve; x axis is the log concentration of STX; and y axis is the total ligand binding in CPM (B/B_0).
- b. Sample quantification: Sample quantification is only carried out on dilutions having a B/B_0 in the range of 0.2-0.7.
 - i. Where B represents the bound ^3H -STX in CPM in the sample and B_0 represents the max bound ^3H -STX in the sample.

ii. Sample concentration is calculated in μg STX diHCl equivalents (eq)/kg shellfish as described below:

$$\begin{aligned} & (\text{nM STX eq}) \times (\text{sample dilution}) \times [(210 \mu\text{l total volume})/35 \mu\text{l sample}] \\ & = \text{nM STX eq in extract} \end{aligned}$$

$$\begin{aligned} & (\text{nM STX diHCl eq in extract}) \times (1 \text{ L}/1000 \text{ ml}) \times (372 \text{ ng/nmol}) \times (1 \mu\text{g}/1000 \text{ ng}) \\ & = \text{g STX diHCl eq/ml} \end{aligned}$$

$$\begin{aligned} & \mu\text{g STX diHCl eq/ml} \times (\text{ml extract/g shellfish}) \times (1000\text{g/kg}) \\ & = \mu\text{g STX diHCl eq/kg} \end{aligned}$$

Figure 1. Example plate layout.

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|----------|----------------------|----------------------|----------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| A | 10 ⁻⁶ | 10 ⁻⁶ | 10 ⁻⁶ | QC | QC | QC | U3 1:50 | U3 1:50 | U3 1:50 | U6 1:10 | U6 1:10 | U6 1:10 |
| B | 10 ⁻⁷ | 10 ⁻⁷ | 10 ⁻⁷ | U1 1:10 | U1 1:10 | U1 1:10 | U3 1:200 | U3 1:200 | U3 1:200 | U6 1:50 | U6 1:50 | U6 1:50 |
| C | 3 x 10 ⁻⁸ | 3 x 10 ⁻⁸ | 3 x 10 ⁻⁸ | U1 1:50 | U1 1:50 | U1 1:50 | U4 1:10 | U4 1:10 | U4 1:10 | U6 1:200 | U6 1:200 | U6 1:200 |
| D | 10 ⁻⁸ | 10 ⁻⁸ | 10 ⁻⁸ | U1 1:200 | U1 1:200 | U1 1:200 | U4 1:50 | U4 1:50 | U4 1:50 | U7 1:10 | U7 1:10 | U7 1:10 |
| E | 3 x 10 ⁻⁹ | 3 x 10 ⁻⁹ | 3 x 10 ⁻⁹ | U2 1:10 | U2 1:10 | U2 1:10 | U4 1:200 | U4 1:200 | U4 1:200 | U7 1:50 | U7 1:50 | U7 1:50 |
| F | 10 ⁻⁹ | 10 ⁻⁹ | 10 ⁻⁹ | U2 1:50 | U2 1:50 | U2 1:50 | U5 1:10 | U5 1:10 | U5 1:10 | U7 1:200 | U7 1:200 | U7 1:200 |
| G | 10 ⁻¹⁰ | 10 ⁻¹⁰ | 10 ⁻¹⁰ | U2 1:200 | U2 1:200 | U2 1:200 | U5 1:50 | U5 1:50 | U5 1:50 | | | |
| H | REF | REF | REF | U3 1:10 | U3 1:10 | U3 1:10 | U5 1:200 | U5 1:200 | U5 1:200 | | | |

Concentrations indicate those of the STX standard curve; REF = reference; QC = quality control; U = unknown sample (with dilutions indicated). The same standard curve made be used for additional plates run on the same day using the same reagents (i.e., 11 samples can be run on subsequent plates).

Appendix B: Rat Brain Membrane Preparations

A. Equipment/Supplies

- a. Teflon/glass homogenizer: Tapered Teflon pestle and glass tube, 15 ml
- b. Motorized tissue homogenizer: Polytron or small hand-held blender
- c. High-speed centrifuge and fixed angle rotor: capable of 20,000 x *g*
- d. Centrifuge tubes: 12-15 ml, rated for >20,000 x *g*
- e. Plastic cryovials: 2 ml
- f. Glass beaker: 300-500 ml
- g. Pipets: disposable 5 and 10 ml
- h. Forceps.

B. Reagents

- a. 20 rat brains: male, 6-week old Sprague-Dawley (Hilltop Lab Animals, Inc., Scottdale, PA) or equivalent
- b. MOPS: pH 7.4 (Sigma, St. Louis, MO; Cat. No. M3183-500G)
- c. Choline chloride: 100 mM (Sigma; Cat. No. C7527-500G)
- d. Phenyl methylsulfonyl fluoride (PMSF): (Sigma; Cat. No. P7626)
- e. Isopropanol.

C. Procedure

- a. Prepare 1 L of 100 mM MOPS, pH 7.4, containing 100 mM choline chloride (as described in Appendix A) and 0.1 mM PMSF. PMSF must first be dissolved in isopropanol: dissolve 0.174 g PMSF in 10 ml isopropanol to make 100 mM stock. Aliquot stock and store at -20 °C. Add PMSF (1/1000, 0.1 mM final concentration) to the MOPS/choline chloride buffer fresh in the day of use.
- b. Remove the medulla and cerebellum from each brain using forceps and discard. Place cerebral cortex in a small amount of ice-cold buffer and place on ice.
- c. Place one cerebral cortex in 12.5 ml MOPS/choline Cl/PMSF, pH 7.4, in glass/Teflon homogenizer. Homogenize at 70% full speed (385 rpm) with at least 10 up and down strokes and ensure there are no visible chinks remaining in the homogenate. Keep tube in ice at all times. Pour homogenized tissue into 250 ml beaker on ice and repeat procedure with remaining cortices.
- d. Transfer pooled homogenate tissue to centrifuge tubes, balance the tubes (pairwise: using ice-cold buffer to balance), and centrifuge at 20,000 x *g* for 15 min at 4 °C.
- e. Aspirate the supernatant and resuspend pellets in ice-cold MOPS/choline Cl/PMSF, using an adequate amount to fully resuspend the pellet (5-10 ml per brain).
- f. Pool resuspended membrane preparation in a small beaker. Rinse centrifuge tubes with a small amount of ice-cold buffer to recover all of the membrane preparation. Bring total volume up to 200 ml (keep on ice).
- g. Keeping the beaker on ice, polytron (or homogenize with small handheld blender) at 70% full speed for 20 s to obtain a homogeneous solution.
- h. Aliquot 2 ml per tube into cryovials. It is critical to keep the preparation well mixed while dispensing. Keep cryotubes on ice.
- i. Freeze and store at -80 °C. This preparation is stable for at least 6 months.

D. Protein Assay

- a. Determine the protein concentration of the membrane preparation using a Pierce Micro BCA Protein Assay Reagent Kit No. 23235 (microplate method) or No. 23225 (tube method) or equivalent. The above protocol should yield ~6-8 mg protein/ml of rat membrane preparation.
- b. Determine the membrane dilution needed for the assay. The protein concentration in the daily working stock should be 1 mg/ml (which yields a diluted concentration of 0.5 mg/ml in-assay concentration). Based on the protein concentration determined using the protein assay, dilute rat membrane preparation with buffer to 1 mg/ml. It is this diluted membrane preparation that is used in the assay.
- c. Protein concentrations must be determined and new dilutions calculated accordingly for each new batch of membranes prepared.

Appendix C: Radiation Safety Requirements

- A. All users must follow all local, state, and federal laws and procedures regarding receipt, use and disposal of isotopes.
- B. All users must be trained in and follow all in-house safety procedures for working with radiolabeled materials.
- C. All isotopes and work stations where isotopes are used should be controlled access areas. Any one with access to the area must also receive radiation safety training.
- D. Freezers where the isotopes are stored must be locked.
- E. Personal protective equipment must include lab coats (designated specifically for use with radioactive materials), safety glasses, and gloves.
- F. Radioactive materials will only be handled and manipulated in designated areas, which have been clearly identified and labeled accordingly.
- G. Work with source radiation material must be conducted in a fume hood.
- H. Radioactive materials will be stored and/or carried in secondary containment.
- I. When possible, disposable supplies such as pipet tips, absorbent paper, and kim wipes will be used so that contaminated supplies can be readily disposed of as radioactive waste.
- J. Wipe surveys will be conducted at the end of each experiment as well as monthly to ensure that there is no contamination in the laboratory.
- K. The filter plates used in the assay will be designated as solid radioactive waste, while the washes from the filter plates (containing buffer and unbound ^3H -STX) will be handled as liquid radioactive waste. There will be a dry active waste container to hold contaminated items such as the plates, gloves, absorbent paper and kim wipes. There will be a liquid waste jug to hold the contaminated liquid radioactive waste.
- L. All wastes must be disposed of according to state and local laws.

Appendix I. Abbreviations and Acronyms

| | |
|--------------------|---|
| ³ H-STX | Tritiated saxitoxin |
| AOAC | Association of Analytical Communities |
| ARC | American Radiolabeled Chemicals |
| B | Bound CPM |
| B ₀ | Maximum bound CPM |
| CFSAN | Center for Food Safety & Applied Nutrition |
| CPM | Counts per minute |
| diHCl | Dihydrochloride |
| Eq | Equivalents |
| HCl | Hydrochloric acid |
| IC ₅₀ | Inhibitory concentration at which CPMs are at 50% max |
| LC-FD | Liquid chromatography with fluorescence detection |
| LOD | Limit of detection |
| LOQ | Limit of quantitation |
| MBA | Mouse bioassay |
| MOPS | 3-Morpholinopropanesulfonic acid |
| NaOH | Sodium hydroxide |
| NIST | National Institute of Standards and Technology |
| NSSP | National Shellfish Sanitation Program |
| OMA | Official method of analysis |
| PMSF | Phenyl methylsulfonyl fluoride |
| PCOX | Post-column oxidation liquid chromatography with fluorescence detection |
| Pre-COX | Pre-column oxidation liquid chromatography with fluorescence detection |
| PSP | Paralytic shellfish poisoning |
| PSTs | Paralytic shellfish toxins |
| QC | Quality control |
| QS | Quality System |
| RBA | Receptor binding assay |
| RSD | Relative standard deviation |
| SLV | Single laboratory validation |
| STX | Saxitoxin |

Single-Laboratory Validation of the Microplate Receptor Binding Assay for Paralytic Shellfish Toxins in Shellfish

FRANCES M. VAN DOLAH, TOD A. LEIGHFIELD, and GREGORY J. DOUCETTE

NOAA National Ocean Service, Marine Biotoxins Program, 219 Fort Johnson Rd, Charleston, SC 29412

LAURIE BEAN

Maine Department of Natural Resources, McKown Point, W. Boothbay Harbor, ME 04575

BARBARA NIEDZWIADK and DOROTHEA F.K. RAWN

Health Canada, Food Research Division, Sir Frederick Banting Research Centre, Ottawa, ON, Canada K1A 0L2

A single-laboratory validation (SLV) study was conducted for the microplate receptor binding assay (RBA) for paralytic shellfish poisoning (PSP) toxins in shellfish. The basis of the assay is the competition between [3 H]saxitoxin (STX) and STX in a standard or sample for binding to the voltage dependent sodium channel. A calibration curve is generated by the addition of 0.01–1000 nM STX, which results in the concentration dependent decrease in [3 H]STX-receptor complexes formed and serves to quantify STX in unknown samples. This study established the LOQ, linearity, recovery, accuracy, and precision of the assay for determining PSP toxicity in shellfish extracts, as performed by a single analyst on multiple days. The standard curve obtained on 5 independent days resulted in a half-maximal inhibition (IC_{50}) of 2.3 nM STX \pm 0.3 (RSD = 10.8%) with a slope of 0.96 \pm 0.06 (RSD = 6.3%) and a dynamic range of 1.2–10.0 nM. The LOQ was 5.3 μ g STX equivalents/100 g shellfish. Linearity, established by quantification of three levels of purified STX (1.5, 3, and 6 nM), yielded an r^2 of 0.97. Recovery from mussels spiked with three levels (40, 80, and 120 μ g STX/100 g) averaged 121%. Repeatability (RSD_r), determined on six naturally contaminated shellfish samples on 5 independent days, was 17.7%. A method comparison with the AOAC mouse bioassay yielded $r^2 = 0.98$ (slope = 1.29) in the SLV study. The effects of the extraction method on RBA-based toxicity values were assessed on shellfish extracted for PSP toxins using the AOAC mouse bioassay method (0.1 M HCl) compared to that for the precolumn oxidation HPLC method (0.1% acetic acid). The two extraction methods showed linear correlation ($r^2 = 0.99$), with the HCl extraction method yielding slightly higher toxicity values (slope = 1.23). A similar relationship was

observed between HPLC quantification of the HCl- and acetic acid-extracted samples ($r^2 = 0.98$, slope 1.19). The RBA also had excellent linear correlation with HPLC analyses ($r^2 = 0.98$ for HCl, $r^2 = 0.99$ for acetic acid), but gave somewhat higher values than HPLC using either extraction method (slope = 1.39 for HCl extracts, slope = 1.32 for acetic acid). Overall, the excellent linear correlations with the both mouse bioassay and HPLC method and sufficient interassay repeatability suggest that the RBA can be effective as a high throughput screen for estimating PSP toxicity in shellfish.


Paralytic shellfish poisoning (PSP) is a seafood intoxication caused by the consumption of shellfish tainted with saxitoxins (STXs) produced by certain species of harmful algae. Saxitoxins are a suite of heterocyclic guanidinium toxins, of which currently more than 21 congeners are known (Figure 1). These congeners occur in varying proportions in the dinoflagellates that produce them and are further metabolized in shellfish that accumulate them, making analytical determination of PSP toxins in shellfish complex. The long-standing regulatory method for PSP toxins is the AOAC mouse bioassay (1), with a regulatory limit of 80 μ g/100 g shellfish generally applied. Increasing resistance to whole animal testing has driven the need to develop alternative methods suitable for use in a high throughput monitoring or regulatory setting. In the past decade, several alternatives to the mouse bioassay have been developed and validated to various degrees. The precolumn oxidation HPLC method (2) has received First Action approval by AOAC as an Official Method for PSP (2005.06; 3) and has been accepted into the European Food Hygiene Regulations as an alternative to the mouse bioassay and further refined to optimize its use in the United Kingdom Official Control monitoring of PSP toxins in mussels (4). However, although the HPLC method performs well quantitatively, it is quite time consuming for high throughput screening needed by many monitoring programs. A qualitative lateral flow antibody test for PSP toxins with a detection limit of 40 μ g/100 g, developed by

Jellett Rapid Testing Ltd (Chester Basin, NS, Canada), has been approved in the United States by the Interstate Shellfish Sanitation Conference and the U.S. Food and Drug Administration (FDA) as a screening method. This method performed well in a comparison study with the mouse bioassay, with a false-positive rate of 6% and a false-negative rate of <0.1% (5), but it has not been put through a full AOAC collaborative trial, and does not provide quantitative analysis. To date, a suitable quantitative, high throughput alternative to the mouse bioassay has not been validated through the AOAC Official Methods Program. The current study establishes the single laboratory performance characteristics of the microplate receptor binding assay (RBA) for PSP toxins in shellfish and identifies it as a candidate for fulfilling the requirements of high throughput, quantitative analysis that measures a composite toxic potency in a manner analogous to the mouse bioassay.

STX elicit their paralytic effects by binding to site 1 on the voltage dependent sodium channel, thereby blocking the transmission of neuronal and muscular action potentials. Because all STX congeners bind to site 1 with affinities proportional to their mouse intraperitoneal (IP) toxicity (6), a receptor binding competition assay can be used to measure the integrated toxic potency of STX congeners in a sample, independent of which toxin congeners are present. Moreover, any toxin metabolites originating in the shellfish matrix will also be detected by the assay according to their affinity for the sodium channel receptor. In this binding competition assay, [³H]STX competes with unlabeled STX and/or its derivatives for a finite number of available receptor sites in a rat brain membrane preparation. Following establishment of binding equilibrium, unbound [³H]STX is removed by filtration and

bound [³H]STX is quantified by liquid scintillation counting. The percent reduction in [³H]STX binding in the presence of unlabeled toxin is directly proportional to the amount of unlabeled toxin present. A standard curve is established using increasing concentrations of unlabeled STX, and the concentration of PSP toxins in an unknown sample is quantified using this standard curve.

The assay tested in this single laboratory trial is a modification of the method of Doucette et al. (7) to a 96-well microplate format described by Van Dolah et al. (8). Application of microplate scintillation counting to the PSP assay was first reported by Powell and Doucette (9), who applied it to phytoplankton analysis. The use of the microplate format, in conjunction with microplate scintillation counting, makes the assay suitable for use in a high throughput monitoring or regulatory setting. Several versions of the PSP receptor binding assay have undergone method comparisons in different laboratories with favorable correlations to the mouse bioassay and/or other assays for PSP toxins in shellfish. Suarez-Isla and Valez (10) showed excellent linear correlation ($r^2 = 0.97$) between the RBA and mouse bioassay of 41 shellfish extracts between 40 and 10 000 μg STX equivalents/100 g. Llewellyn et al. (11) found that the sodium channel receptor assay compared well to three other methods of analysis for PSP toxins in shellfish (HPLC, mouse bioassay, and N2A cytotoxicity assay). Ruberu et al. (12) optimized the microplate format assay for use in the Packard Top Count microplate scintillation counter (a single channel counter; GMI, Inc., Ramsey, MN), compared results with the same assay performed on the Wallac microplate counter (a two-channel coincidence counter; Perkin Elmer Wallace, Gaithersburg, MD), and provided further correlation data with



| | | R1 | R2 | R3 | R4 | MU/ μmol |
|------------------|-----------|----|--------------------|--------------------|------------------------|---------------------|
| Carbamate | STX | H | H | H | OCONH ₂ | 2483 |
| | Neo STX | OH | H | H | OCONH ₂ | 2295 |
| | GTX1 | OH | OSO ₃ - | H | OCONH ₂ | 2468 |
| | GTX2 | H | OSO ₃ - | H | OCONH ₂ | 892 |
| | GTX3 | H | H | OSO ₃ - | OCONH ₂ | 1584 |
| | GTX4 | OH | H | OSO ₃ - | OCONH ₂ | 1803 |
| Sulfocarbamoyl | GTX5 (B1) | H | H | H | OCONHSO ₃ - | 160 |
| | GTX6 (B2) | OH | H | H | OCONHSO ₃ - | - |
| | C1 | H | OSO ₃ - | H | OCONHSO ₃ - | 15 |
| | C2 | H | H | OSO ₃ - | OCONHSO ₃ - | 239 |
| | C3 | OH | OSO ₃ - | H | OCONHSO ₃ - | 33 |
| | C4 | OH | H | OSO ₃ - | OCONHSO ₃ - | 143 |
| Decarbamoyl | dcSTX | H | H | H | OH | 1274 |
| | dcNeoSTX | OH | H | H | OH | - |
| | dcGTX1 | OH | OSO ₃ - | H | OH | - |
| | dcGTX2 | H | OSO ₃ - | H | OH | 1617 |
| | dcGTX3 | H | H | OSO ₃ - | OH | 1872 |
| | dcGTX4 | OH | H | OSO ₃ - | OH | - |
| Deoxydecarbamoyl | doSTX | H | H | H | H | - |
| | doGTX2 | H | H | OSO ₃ - | H | - |
| | doGTX3 | H | OSO ₃ - | H | H | - |

Figure 1. Structures and toxic potency of 21 saxitoxin congeners. Toxic potency is listed as mouse units (MU)/ μmole , where a mouse unit is defined as the minimum amount required to kill a 20 g mouse in 15 min when administered by IP injection. The table is modified from ref. 15.

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|-------------------------|-------------------------|-------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| A | 10 ⁻⁶ | 10 ⁻⁶ | 10 ⁻⁶ | REF | REF | REF | U3 1:10 | U3 1:10 | U3 1:10 | U5 1:200 | U5 1:200 | U5 1:200 |
| B | 10 ⁻⁷ | 10 ⁻⁷ | 10 ⁻⁷ | QC | QC | QC | U3 1:50 | U3 1:50 | U3 1:50 | U6 1:10 | U6 1:10 | U6 1:10 |
| C | 3 x 10 ⁻⁸ | 3 x 10 ⁻⁸ | 3 x 10 ⁻⁸ | U1 1:10 | U1 1:10 | U1 1:10 | U3 1:200 | U3 1:200 | U3 1:200 | U6 1:50 | U6 1:50 | U6 1:50 |
| D | 10 ⁻⁸ | 10 ⁻⁸ | 10 ⁻⁸ | U1 1:50 | U1 1:50 | U1 1:50 | U4 1:10 | U4 1:10 | U4 1:10 | U6 1:200 | U6 1:200 | U6 1:200 |
| E | 3 x 10 ⁻⁹ | 3 x 10 ⁻⁹ | 3 x 10 ⁻⁹ | U1 1:200 | U1 1:200 | U1 1:200 | U4 1:50 | U4 1:50 | U4 1:50 | U7 1:10 | U7 1:10 | U7 1:10 |
| F | 10 ⁻⁹ | 10 ⁻⁹ | 10 ⁻⁹ | U2 1:10 | U2 1:10 | U2 1:10 | U4 1:200 | U4 1:200 | U 1:200 | U7 1:50 | U7 1:50 | U7 1:50 |
| G | 10 ⁻¹⁰ | 10 ⁻¹⁰ | 10 ⁻¹⁰ | U2 1:50 | U2 1:50 | U2 1:50 | U5 1:10 | U5 1:10 | U5 1:10 | U7 1:200 | U7 1:200 | U7 1:200 |
| H | 10 ⁻¹¹ | 10 ⁻¹¹ | 10 ⁻¹¹ | U2 1:200 | U2 1:200 | U2 1:200 | U5 1:50 | U5 1:50 | U5 1:50 | | | |

U = unknown sample

Figure 2. Standardized plate layout recommended for the microplate RBA for PSP toxins in shellfish extracts. U = unknown sample.

the mouse bioassay. Usup et al. (13) utilized the microplate RBA method to compare predicted toxicity values in samples spiked with different STX congeners as assayed by the mouse bioassay and the RBA. Llewellyn (14) defined the competitive behavior of PSP toxin mixtures in receptor binding assays, using both the sodium channel and saxiphilin receptors, which explains their composite toxicity. However, none of these previous studies fully characterized assay performance according to AOAC single-laboratory validation (SLV) criteria that are the underpinning required for proceeding with an AOAC collaborative trial. Therefore, the current study was carried out to fulfill those requirements.

Experimental

Apparatus

- (a) *Microplate scintillation counter*.—Wallac Microbeta, GMI Inc. (Ramsey, MN).
- (b) *Microplate filtration manifold*.—Millipore (Bedford, MA).
- (c) *Hot plate*.—Fisher Scientific (Suwanee, GA).
- (d) *Countertop centrifuge*.—For 15 mL tubes, capable of 3000 × g (Fisher Scientific).
- (e) *Microtiter filter plates (96 well) with 1.0 μm pore size type FB glass fiber filter/0.65 μm pore size Duropore support membrane*.—Cat. No. MSFB N6B 50 (Millipore Corp., Billerica, MA).
- (f) *Microplate sealing tape*.—Cat. No. MATA HCL00 (Millipore Corp.).

(g) *Vortex mixer*.—Daigger Vortex Genie II (Daigger Scientific, Vernon Hills, IL).

(h) *Teflon/glass tissue homogenizer*.—Wheaton (Millville, NJ).

(i) *Polytron homogenizer*.—Brinkmann Instruments (Westbury, NY).

Reagents

- (a) *Hydrochloric acid (HCl)*.—0.1 M.
- (b) [³H]STX.—0.1 mCi/mL, ≥10 Ci/mmol, ≥90% radiochemical purity (International Isotopes Clearinghouse, Leawood, KS).
- (c) *STX diHCl*.—FDA reference standard (Office of Seafood, Laurel, MD) or National Research Council (NRC) of Canada Institute of Marine Biosciences (Halifax, NS, Canada).
- (d) *Assay buffer*.—75 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; Cat. No. H9136]/140 mM NaCl, pH 7.5 (Sigma, St. Louis, MO).
- (e) *Liquid scintillation cocktail*.—Optiphase (PerkinElmer Life Sciences, Downers Grove, IL).

Preparation of Samples (0.1 M HCl Extraction)

Shellfish samples were shucked and homogenized according to the AOAC mouse bioassay protocol (1). For the HCl extraction method, 5.0 (±0.1) g of tissue homogenate was transferred to a tared 15 mL conical polypropylene centrifuge tube. A 5.0 mL volume of 0.1 M HCl was added, and the sample was mixed on a Vortex mixer. The pH was checked to




Figure 3. Average of five calibration curves obtained by one analyst in five independent assays on separate days. $IC_{50} = 2.23 \pm 0.23$ nM, slope = 0.96 ± 0.06 , error bars are \pm SD.

confirm it was between 3.0 and 4.0 in order to avoid alkalization and destruction of the toxin, and adjusted with 1 M HCl or 0.1 M NaOH as needed. Tubes were placed in a beaker of boiling water on a hot plate for 5 min with the caps loosened. Following removal from the boiling water bath, samples were allowed to cool to room temperature, and the pH was again confirmed to be between 3.0 and 4.0. The entire contents were then transferred to a graduated cylinder, diluted volumetrically to 10 mL, and centrifuged for 5 min at $1000 \times g$. The supernatant was transferred to a clean tube.

Preparation of Samples (Acetic Acid Extraction Method)

In a 50 mL plastic centrifuge tube, 5.0 ± 0.1 g homogenate was mixed with 3.0 mL 1% acetic acid on a vortex mixer. Tubes were capped loosely to avoid pressure buildup and placed in a boiling water bath for 5 min. Following removal from the water bath, samples were cooled in a beaker of cold water for 5 min, and then centrifuged for 10 min at $3000 \times g$. The supernatant was transferred to a 15 mL graduated conical test tube. A 3 mL amount of 1% acetic acid was added to the original tube with solid residue, mixed well on a vortex mixer, and centrifuged again for 10 min at $3000 \times g$. The second supernatant was combined with the first and diluted to 10 mL with water.

Preparation of Stock Solutions, Standards, and Reagents for Assay

(a) *Radioligand solution.*— $[^3H]$ STX stock is provided in 50 μ Ci ampules, 24 Ci/mmol, 0.1 mCi/mL (4.17 μ M). A 15 nM working stock of $[^3H]$ STX was prepared fresh daily in 75 mM HEPES/140 mM NaCl (for 2.5 nM final in-well concentration).

(b) *STX standard curve.*—FDA STX dihydrochloride reference standard (100 μ g/mL or 268.8 μ M) used to prepare a bulk standard curve made up in advance and stored at 4°C for up to 1 month. The stock standard curve was made consisted of eight concentrations of STX in 0.003 M HCl [6×10^{-6} , 6×10^{-7} , 1.8×10^{-7} , 6×10^{-8} , 1.8×10^{-8} , 6×10^{-9} , 6×10^{-10} , $6 \times$

Table 1. RBA measurements of calibration standards for assay linearity assessment (nM STX; $n = 5$)

| Nominal | Mean | SD | RSD |
|---------|------|------|-----|
| 1.5 | 1.7 | 0.16 | 10 |
| 3.0 | 3.0 | 0.52 | 17 |
| 6.0 | 6.0 | 0.34 | 6 |

10^{-11} , and 0.003 M only HCl (reference)], which when diluted 1:6 in the assay, resulted in a standard curve of 0.01 nM–1000 nM STX. The reference provided a measure of total $[^3H]$ STX binding in the absence of unlabeled STX.

(c) *Calibration standard (QC check).*—A reference standard containing 1.8×10^{-8} M STX standard (3.0×10^{-9} M STX in assay) was prepared in 0.003 M hydrochloric acid, aliquotted in 1 mL volumes, and stored at 4°C for routine use (stable up to 1 month). On the day of the assay, 200 μ L of each standard were pipetted into mini-dilution tubes for ease of pipetting into the microplate using an eight-channel pipettor.

(d) *Rat brain membrane homogenate.*—Cerebral cortices from 6-week-old male Holzman rats (Harlan Bioproducts, Indianapolis, IN) were homogenized on ice in a glass/Teflon tissue homogenizer in 75 mM HEPES/140 mM NaCl, pH 7.5, containing 0.1 mM PMSF (phenylmethanesulfonylfluoride; 12.5 mL/brain) at 385 rpm for 10 strokes. Pooled homogenates were centrifuged at $20\,000 \times g$ for 15 min at 4°C and the pellet was resuspended in HEPES buffer (12.5 mL/brain) and rehomogenized on ice using a Polytron homogenizer set at 70% power for 20 s to ensure a fine suspension. The brain homogenate was aliquotted 2 mL/tube in cryovials and stored at -80°C . The protein concentration of the brain homogenate was determined using the Micro bicinchoninic acid (BCA) Assay (Pierce, Rockford, IL). For each assay, an aliquot of brain homogenate was thawed on ice and diluted with ice cold 75 mM HEPES/150 mM NaCl, pH 7.5, to yield a final protein concentration of 0.5 mg/mL in the assay.

Table 2. Recovery of analyte from spiked samples (μ g STX equiv./100 g)

| Nominal | Mean | SD | Measured RSD _r | Recovery, % |
|---------|------------------|------|---------------------------|-------------|
| 0 | <dl ^a | | | |
| 40 | 47 | 8.6 | 18.7 | 115 |
| 80 | 103.7 | 21.8 | 21 | 129 |
| 120 | 145.5 | 15.2 | 10.5 | 121 |

^a <dl = Less than LOQ (5 μ g STX equiv./100 g).

Table 3. Comparison of receptor binding assay (RBA; $n = 5$) with AOAC mouse bioassay (MBA) of naturally contaminated shellfish (μg STX equiv./100 g)

| Sample | MBA | RBA mean | SD | RSD |
|--------|------|----------|-----|-----|
| LP1 | 340 | 438 | 74 | 17 |
| LP2 | 534 | 715 | 96 | 13 |
| LP3 | 1158 | 1533 | 329 | 21 |
| LP4 | 65 | 91 | 7 | 9 |
| LP5 | 350 | 608 | 150 | 25 |
| LP6 | 462 | 518 | 114 | 22 |

Assay Procedure

(a) *Plate setup and incubation.*—A standardized plate layout was used for all assays (Figure 2). All standards, reference, QC check, and shellfish extracts were run in triplicate wells. For shellfish extracts, a standardized dilution series was run for each sample (1:10, 1:50, and 1:200), which ensured that at least one dilution would fall on the linear part of the competition curve for shellfish that contains between approximately 5 and 1500 μg STX equiv./100 g. Reagents were added in the following order: 35 μL STX standard or sample, then 35 μL [^3H]STX, followed by 140 μL brain homogenate. The addition of brain homogenate was carried out with sufficient force to ensure mixing of the well contents, but without risk of splashing. The plate was then covered and incubated at 4°C for 1 h.

(b) *Assay filtration and counting.*—The plate was filtered using a microplate vacuum filtration manifold, and each well rinsed twice with 200 μL ice-cold HEPES buffer at a filtration rate that ensured all wells were dry within 2–5 s. The microplate was then placed in a microplate scintillation counter cassette, and the bottom was sealed with plate sealing tape. Lastly, 50 μL scintillation cocktail was added to each well, and the top of the plate was sealed with sealing tape. The plate was allowed to sit for 30 min to ensure impregnation of the filters with scintillant prior to counting for 1 min/well in the microplate scintillation counter.

Data Analysis

Curve fitting was performed using a four-parameter logistic curve fitting model for a one-site receptor binding using Wallac Multicalc software. The software reports the in-well sample concentration in nM equiv. STX. Sample concentration was then calculated in μg STX equivalents/100 g shellfish using the following formulas:

$$(\text{nM equiv. STX}) \times (\text{sample dilution}) \times \frac{(210 \mu\text{L total volume})}{35 \mu\text{L sample}} \\ = \text{nM equiv. STX in extract}$$




Figure 4. Linear correlation analysis between the RBA and mouse bioassay. (a) Average values of six naturally contaminated samples analyzed on five independent RBA assay days ($r^2 = 0.98$, slope = 1.29). (b) A separate study of 110 shellfish extracts analyzed by RBA and MBA yielded an r^2 of 0.88 with a slope of 1.32.

$$(\text{nm equiv. STX in extract}) \times \frac{1 \text{ L}}{1000 \text{ mL}} \times \frac{372 \text{ ng}}{\text{nmol}} \times \frac{1 \mu\text{g}}{1000 \text{ ng}} \\ = \mu\text{g STX equiv./mL} \\ \mu\text{g STX equiv./mL} \times \frac{\text{mL extract}}{\text{g shellfish extracted}} \times 100 \\ = \mu\text{g STX equiv./100 g shellfish}$$

Critical Control Points

(1) For a ligand that interacts specifically at one receptor site, the slope of the resulting competition curve should theoretically be 1.0. If the slope of the curve for a given assay is outside of the acceptable range of 0.8–1.2, linearity of the assay will be compromised, and quantification of the unknowns will be incorrect. Therefore, the assay should be re-run.

(2) The QC check standard should fall within $\pm 30\%$ of the stated value (3.0 nM). If the QC check standard does not fall within acceptable limits, the assay should be re-run.

Table 4. RBA-determined toxicities of nine naturally contaminated shellfish homogenates extracted using the 0.1 M HCl extraction method or the 1% acetic acid extraction method (μg STX equiv./100 g)

| Sample | HCl | | | Acetic acid | | |
|--------|------|-----|-----|-------------|-----|-----|
| | Mean | SD | RSD | Mean | SD | RSD |
| 1 | 11 | 4 | 36 | 19 | 7 | 39 |
| 2 | 600 | 143 | 24 | 488 | 104 | 21 |
| 3 | 690 | 142 | 21 | 584 | 167 | 29 |
| 4 | 136 | 8 | 6 | 131 | 41 | 31 |
| 5 | 152 | 27 | 18 | 167 | 21 | 13 |
| 6 | 302 | 87 | 29 | 270 | 72 | 27 |
| 7 | 340 | 88 | 26 | 264 | 63 | 24 |
| 8 | 262 | 79 | 30 | 252 | 48 | 19 |
| 9 | 63 | 26 | 41 | 54 | 19 | 34 |

(3) Sample quantification should be done only on dilutions that on the linear part of the curve [$b/b_0 = 0.2-0.7$, where B is the bound counts/min (CPM) in the sample and B_0 is the maximum CPM]. The RSD of the CPM must be $<30\%$.

(4) For a given sample, if none of the sample dilutions falls within the linear range (i.e., the concentration is too high, $b/b_0 < 0.2$), further dilutions must be made and the sample reanalyzed if a quantitative value is desired. If the sample concentration is too low to be quantified (i.e., $b/b_0 > 0.7$) at sample dilution 1:10, the sample must be reported as below the LOQ.

Mouse Bioassay and HPLC Procedures

Shellfish samples extracted in parallel using the HCl and acetic acid extraction methods described above were analyzed using the standard protocols prescribed by the AOAC methods for mouse bioassay (1) or precolumn oxidation HPLC method (2).

Results and Discussion

Calibration Curve

To establish the dynamic range and repeatability of the calibration curve, five assays were performed by one analyst on separate days. The composite curve (Figure 3) resulted in a half-maximal inhibition (IC_{50}) of $2.3 \text{ nM STX} \pm 0.3$ (RSD = 10.8%) with a slope of 0.96 ± 0.06 (RSD = 6.3%). Using the linear part of the curve ($0.2-0.7 b/b_0$) for quantification, a dynamic range of approximately one order of magnitude, $1.2-10.0 \text{ nM STX}$, was observed, as expected for a one-site binding assay. A QC check sample (3.0 nM STX) run in each assay averaged $3.0 \pm 0.5 \text{ nM}$ (RSD_r = 17.3%), with a recovery of 99.3% .

LOQ

Shellfish extracts were diluted a minimum of 10-fold prior to analysis to minimize matrix effects that can result in false positives. The LOQ was empirically determined as the

concentration, in a 10-fold diluted sample, that results in a b/b_0 of 0.7. This is a more conservative cutoff than the $0.8 b/b_0$ frequently used in receptor assays and was used because quantification was unacceptably variable above this b/b_0 cutoff. This results in an LOQ of approximately $5 \mu\text{g}$ equiv. STX/100 g shellfish, which provides a more than one order of magnitude margin relative to the regulatory limit of $80 \mu\text{g}/100 \text{ g}$.

Linearity

Linearity was assessed by five independent assays of three calibration standards that were expected to fall on the curve between 0.2 and $0.7 b/b_0$: $1.5, 3.0,$ and 6.0 nM STX prepared from FDA STX diHCl standard. Expected and measured values are listed in Table 1. Linear regression yielded a slope of 0.98 and an r^2 of 0.97 .




Figure 5. Linear correlation between HCl and acetic acid (HOAc) extracts analyzed by RBA. Results are average values of nine naturally contaminated samples obtained from four independent assays ($r^2 = 0.99$, slope = 1.23).

Table 5. HPLC analysis of nine naturally contaminated samples (1–9) extracted using 0.1 M HCl^a

| Sample | STX | NEO ^b | GTX1,4 ^c | GTX2,3 | B1 | C1,2 | Total PSP | As STX equivalent |
|--------|-------|------------------|---------------------|--------|------|-------|-----------|-------------------|
| HCl-1 | 3.5 | 0.0 | 0.0 | 7.3 | 0.0 | 0.0 | 10.8 | 6 |
| HCl-2 | 231.6 | 23.9 | 42.6 | 324.5 | 28.3 | 249.7 | 900.4 | 412 |
| HCl-3 | 220.8 | 53.7 | 74.9 | 436.3 | 43.4 | 338.1 | 1167.2 | 494 |
| HCl-4 | 48.3 | 2.7 | 8.6 | 85.1 | 10.7 | 17.1 | 172.5 | 90 |
| HCl-5 | 86.5 | 1.1 | 0.0 | 64.7 | 14.9 | 11.3 | 178.5 | 113 |
| HCl-6 | 114.5 | 0.0 | 0.0 | 166.6 | 15.1 | 36.8 | 333.0 | 180 |
| HCl-7 | 96.4 | 10.1 | 72.9 | 398.7 | 9.3 | 36.1 | 623.5 | 304 |
| HCl-8 | 84.6 | 6.0 | 32.8 | 225.7 | 4.9 | 18.5 | 372.5 | 197 |
| HCl-9 | 11.2 | 0.0 | 6.1 | 47.9 | 0.0 | 0.0 | 65.2 | 33 |

^a Values are in $\mu\text{g}/100\text{ g}$, as specific PSP congener or its STX equivalents, as indicated by the column headers.

^b NEO = Neosaxitoxin.

^c GTX = Gonyautoxin.

Recovery

Mussel tissue homogenates obtained from a local market were spiked with FDA STX diHCl standard at four levels bracketing the regulatory limit (0, 40, 80, and 120 $\mu\text{g}/100\text{ g}$) followed by thorough homogenization using a Polytron blender. Aliquots of spiked homogenate were stored at -80°C until extraction in 0.1 M HCl according to the protocol in the *Experimental* section. Extracts were analyzed in five assays performed on independent days. The mean recovery was 121% (Table 2).

Comparison of RBA-Reported Toxicity with the AOAC Mouse Bioassay

Six naturally contaminated shellfish samples were extracted in 0.1 M HCl according to the protocol in the *Experimental* section, and analyzed in five assays on

independent days (Table 3). Three shellfish species were represented: clam *Mya arenaria* (whole) LP1, LP4; mussel *Mytilus edulis* (whole) LP2, LP3; and scallop *Plactopecten magellanicus* (viscera) LP5, LP6. Between-assay RSDs ranged from 9 to 25% (mean 17.7%). An r^2 of 0.98 was obtained relative to the mouse bioassay, with a slope of 1.29 (Figure 4a).

A separate study of 110 naturally contaminated shellfish samples, extracted using the 0.1 M HCl method, and analyzed by RBA and mouse bioassay, yielded similar results with an r^2 of 0.88 and a slope of 1.32 (Figure 4b).

Effect of Extraction Method on RBA-Reported Toxicities

The recent approval of the precolumn oxidation HPLC method for PSP toxins as AOAC Official Method **2005.06** (3) and its potential recognition as a reference method for PSP

Table 6. HPLC analysis of the same nine naturally contaminated samples (1–9) extracted using 1% acetic acid^a

| Sample | STX | NEO | GTX1,4 | GTX2,3 | B1 | C1,2 | Total PSP | As STX equivalent |
|--------|-------|------|--------|--------|------|-------|-----------|-------------------|
| HOAc-1 | 3.4 | 0.0 | 0.0 | 7.3 | 0.0 | 0.0 | 10.7 | 6 |
| HOAc-2 | 187.6 | 13.1 | 21.7 | 280.7 | 25.1 | 248.9 | 777.1 | 329 |
| HOAc-3 | 175.2 | 35.6 | 79.2 | 335.9 | 37.2 | 237.7 | 900.9 | 393 |
| HOAc-4 | 33.4 | 3.1 | 11.3 | 61.8 | 6.0 | 15.5 | 131.1 | 68 |
| HOAc-5 | 59.3 | 3.1 | 0.0 | 67.6 | 10.8 | 19.3 | 160.0 | 89 |
| HOAc-6 | 100.8 | 0.0 | 0.0 | 158.0 | 11.8 | 28.4 | 299.0 | 162 |
| HOAc-7 | 67.4 | 11.2 | 42.7 | 228.4 | 5.2 | 15.6 | 370.5 | 192 |
| HOAc-8 | 71.0 | 8.3 | 34.4 | 190.3 | 4.3 | 12.6 | 320.8 | 173 |
| HOAc-9 | 11.2 | 0.0 | 11.7 | 38.1 | 0.0 | 61.0 | 122.1 | 33 |

^a Values are in $\mu\text{g}/100\text{ g}$, as specific PSP congener or its STX equivalents, as indicated by the column headers.





Figure 6. Linear correlation between HCl and acetic acid (HOAc) extracts analyzed by HPLC (slope = 1.16, $r^2 = 0.97$).

toxins prompted an investigation of the effects of extraction method on toxicity values reported by the RBA. Whereas the AOAC mouse bioassay prescribes shellfish extraction in 0.1 M HCl, the HPLC method uses extraction in 1% acetic acid. The 0.1 M HCl extraction procedure is known to result in the partial conversion of certain low-toxicity sulfocarbamoyl congeners to more highly toxic congeners in shellfish extracts, especially gonyautoxins, GTX5 and GTX6, to STX and neoSTX, and, thus, may result in somewhat higher toxicity values. To assess the effects of extraction procedure on RBA-reported toxicity, nine naturally contaminated shellfish samples (six blue mussel and three scallop) were homogenized and extracted independently using 0.1 M HCl and 1% acetic acid as described in the *Experimental* section. PSP toxicity in the extracts was then determined in four RBA assays run on independent days (Table 4). The between-assay RSD did not differ for samples prepared using the two extraction methods (25.8 and 26.3%, respectively). In general, the HCl extraction method resulted in slightly higher total toxicity values than reported for the acetic acid extracts (slope 1.23, $r^2 = 0.99$; Figure 5). The higher values reported for the HCl extracts are not explained by the conversion of sulfocarbamoyl toxins to more potent congeners in the HCl extracts, as can be seen in the toxin profiles determined by HPLC (Tables 5 and 6). Rather, the recovery of most congeners appears to be higher in the HCl extract. The higher concentrations reported in the HCl extract may reflect differences in the method by which volume is adjusted in the two extraction procedures. In the HCl method, final extract volume adjustment is made with the shellfish matrix present. In the acetic acid extraction, the matrix is first removed, the pellet re-extracted, the two extracts pooled, and then the final volume adjusted. HPLC analysis of the same samples showed a similar relationship between values reported for the HCl and acetic acid extracts (slope = 1.16, $r^2 = 0.97$; Figure 6) as seen in the RBA, with the HCl extracts containing greater STX equivalent/100 g.

(a)



(b)




Figure 7. Linear correlation between RBA and HPLC for samples extracted (a) by the HCl method ($r^2 = 0.98$, slope = 1.39) and (b) by the acetic acid method ($r^2 = 0.99$, slope = 1.32).

Comparison of RBA with HPLC

The RBA showed good linear correlation with HPLC analysis of both HCl ($r^2 = 0.98$, slope = 1.39) and acetic acid ($r^2 = 0.99$, slope = 1.32) extracts, in both cases giving somewhat higher toxicities than the HPLC method (Figure 7). A number of factors may contribute to the difference in results for total toxic potencies by these two methods. The higher toxicity values given by the RBA may result in part from the fact that the HPLC method uses the STX free base molecular weight (300 Da), whereas the receptor assay (and mouse bioassay) uses the STX dihydrochloride molecular weight (372 Da) to calculate concentration, which would result in approximately 20% higher values in the RBA. Additional differences may result from the use of FDA as compared to the NRC saxitoxin standards in the RBA and HPLC methods, respectively. Higher RBA results may also result from the dominance of the more potent PSP congeners over the weaker congeners in mixtures competing for binding to the receptor, as detailed in ref. 13, which reflects their binding affinities. In

contrast to this complex behavior, the HPLC method adds linearly the concentrations of each congener based on toxic potencies determined by mouse bioassay for isolated congeners. In some cases, e.g., 11-hydroxysulfate epimers, the concentrations of separate epimers pairs are not resolved by HPLC, although their potencies differ widely as do their ratios in shellfish samples. Lastly, higher toxicity values reported by the RBA may reflect the presence of congeners or metabolites not reported by the HPLC method.

Ruggedness

Although formal ruggedness testing was not carried out during this SLV study, several steps in the procedure might be noted that can affect the precision and accuracy of the results. First, it is important to clarify shellfish extracts by centrifugation prior to running the assay, particularly if extracts are stored refrigerated or frozen before analysis, as precipitates in the extract may cause nonspecific binding that may result in overestimates of PSP toxin concentrations. Second, since the rat brain homogenate is a suspension, it is important to ensure that it remains evenly suspended by frequent vortex mixing or pipetting prior to and during its addition to the plate. The rate of assay plate filtration should ensure that the wells clear in 2–5 s, and the rinse buffer should be ice cold in order to minimize the rate of toxin release from the receptor. Lastly, following addition of liquid scintillant to the microplate wells, it is essential to allow a minimum of 30 min for the scintillant to penetrate the filters before counting. Counting prematurely can result in increased variability between wells and lower counts/well, thus increasing RSD. A count time of 1 min/well was chosen for this study as a compromise between optimum RSD and assay throughput. Increasing the count time to 5 min/well has been shown to improve the between-well RSD in this assay when using the Packard Top Count scintillation counter, a single detector instrument with somewhat lower efficiency than the Wallac Microbeta used in the current study (11).

Summary

This SLV and method comparison study demonstrates excellent linear correlation ($r^2 > 0.98$) between the microplate receptor binding assay and both the mouse bioassay and the precolumn oxidation HPLC method for the determination of PSP toxins in shellfish. The microplate format of the assay, when coupled with microplate scintillation counting, provides a quantitative high throughput screening tool for PSP toxin testing in shellfish. The tendency of the RBA to overestimate PSP toxicity relative to the reference methods minimizes the chance of returning false negatives. Where RBA-measured

toxicity results in STX equivalent values close to the regulatory limit, confirmation with a reference method is necessary if a regulatory decision is being made. Nonetheless, application of the assay as a high throughput screen can alleviate the unnecessarily large numbers of animals used for the mouse bioassay on negative samples and, similarly, alleviate the lengthy analysis of samples by HPLC at very high or very low concentrations. We propose that this method be collaboratively tested to establish if it is robust enough to be used in monitoring and regulatory laboratories.

Acknowledgments

We thank Karen Mao and Steven Eaker for excellent technical support in the conduct of this study.

References

- (1) *Official Methods of Analysis* (1999) 17th Ed., AOAC INTERNATIONAL, Gaithersburg, MD, Method **959.08**
- (2) Lawrence, J.F., Niedzwiadek, B., & Menard, C. (2006) *J. AOAC Int.* **88**, 1714–1732
- (3) *Official Methods of Analysis* (2005) 18th Ed., AOAC INTERNATIONAL, Gaithersburg, MD, Method **2005.06**
- (4) Turner, A.D., Norton, D.M., Hatfield, R.G., Morris, S., Reese, A.R., Algoet, M., & Lees, D.N. (2009) *J. AOAC Int.* **92**, 190–207
- (5) Jellett, J.F., Robert, R.L., Laycock, M.V., Quilliam, M.A., & Barrett, R.E. (2002) *Toxicon* **40**, 1407–1425
- (6) Hall, S., Strichartz, G., Moczydlowski, E., Ravindran, A., & Reichardt, P.B. (1990) in *Marine Toxins: Origins, Structure, and Molecular Pharmacology*, S. Hall & G. Strichartz (Eds), ACS Symposium Series No. 418, American Chemical Society, Washington, DC, pp 29–65
- (7) Doucette, G.J., Logan, M.L., Ramsdell, J.S., & Van Dolah, F.M. (1997) *Toxicon* **35**, 625–636
- (8) Van Dolah, F.M., Finley, E.L., Haynes, B.L., Doucette, G.J., Moeller, P.D., & Ramsdell, J.S. (1994) *Nat. Toxins* **2**, 189–196
- (9) Powell, C.L., & Doucette, G.J. (1999) *Nat. Toxins* **7**, 393–400
- (10) Suarez-Isla, B.A., & Valez, P. (2000) in *Seafood and Freshwater Toxins*, L.M. Botana (Ed.), Marcel Dekker Inc., New York, NY, pp 187–202
- (11) Llewellyn, L.E., Doyle, J., Jellett, J., Barrett, R., Alison, C., Bentz, C., & Quilliam, M. (2001) *Food Addit. Contam.* **18**, 970–980
- (12) Ruberu, S.R., Liu, Y.-G., Wong, C.T., & Perera, S.K. (2003) *J. AOAC Int.* **86**, 1–9
- (13) Usup, G., Leaw, C.-P., Cheah, M.-Y., Ahmad, A., & Ng, B.-K. (2004) *Toxicon* **44**, 37–43
- (14) Llewellyn, L.E. (2006) *Chem. Res. Toxicol.* **19**, 661–667
- (15) Oshima, Y. (1995) *J. AOAC Int.* **78**, 528–532

Determination of Paralytic Shellfish Toxins in Shellfish by Receptor Binding Assay: Collaborative Study

FRANCES M. VAN DOLAH, SPENCER E. FIRE, TOD A. LEIGHFIELD, CHRISTINA M. MIKULSKI, and GREGORY J. DOUCETTE
Center for Coastal Environmental Health and Biomolecular Research, NOAA Marine Biotoxins Program, 219 Fort Johnson Rd, Charleston, SC 29412

Collaborators: Å. Andersson; L. Bean; D. Couture; S. DeGrasse; A. DeLeon; V. Dell'Ovo; L. Flewelling; P. Holland; G. Langlois; R. Lewis; M. Masuda; P. McNabb; C. Mikulski; B. Niedzwiadek; B. Porntepkasemsan; D. Rawn; E. Sombrito; K. Srisuksawad; B. Suarez; S. Subsinserm; A. Tubaro

A collaborative study was conducted on a microplate format receptor binding assay (RBA) for paralytic shellfish toxins (PST). The assay quantifies the composite PST toxicity in shellfish samples based on the ability of sample extracts to compete with ^3H saxitoxin (STX) diHCl for binding to voltage-gated sodium channels in a rat brain membrane preparation. Quantification of binding can be carried out using either a microplate or traditional scintillation counter; both end points were included in this study. Nine laboratories from six countries completed the study. One laboratory analyzed the samples using the precolumn oxidation HPLC method (AOAC Method 2005.06) to determine the STX congener composition. Three laboratories performed the mouse bioassay (AOAC Method 959.08). The study focused on the ability of the assay to measure the PST toxicity of samples below, near, or slightly above the regulatory limit of 800 (μg STX diHCl equiv./kg). A total of 21 shellfish homogenates were extracted in 0.1 M HCl, and the extracts were analyzed by RBA in three assays on separate days. Samples included naturally contaminated shellfish samples of different species collected from several geographic regions, which contained varying STX congener profiles due to their exposure to different PST-producing dinoflagellate species or differences in toxin metabolism: blue mussel (*Mytilus edulis*) from the U.S. east and west coasts, California mussel (*Mytilus californianus*) from the U.S. west coast, chorito mussel (*Mytilus chilensis*) from Chile, green mussel (*Perna canaliculus*) from New Zealand,

Atlantic surf clam (*Spisula solidissima*) from the U.S. east coast, butter clam (*Saxidomus gigantea*) from the west coast of the United States, almeja clam (*Venus antiqua*) from Chile, and Atlantic sea scallop (*Plactopecten magellanicus*) from the U.S. east coast. All samples were provided as whole animal homogenates, except Atlantic sea scallop and green mussel, from which only the hepatopancreas was homogenized. Among the naturally contaminated samples, five were blind duplicates used for calculation of RSD_r . The interlaboratory RSD_R of the assay for 21 samples tested in nine laboratories was 33.1%, yielding a HorRat value of 2.0. Removal of results for one laboratory that reported systematically low values resulted in an average RSD_R of 28.7% and average HorRat value of 1.8. Intralaboratory RSD_r , based on five blind duplicate samples tested in separate assays, was 25.1%. RSD_r obtained by individual laboratories ranged from 11.8 to 34.9%. Laboratories that are routine users of the assay performed better than nonroutine users, with an average RSD_r of 17.1%. Recovery of STX from spiked shellfish homogenates was 88.1–93.3%. Correlation with the mouse bioassay yielded a slope of 1.64 and correlation coefficient (r^2) of 0.84, while correlation with the precolumn oxidation HPLC method yielded a slope of 1.20 and an r^2 of 0.92. When samples were sorted according to increasing toxin concentration (μg STX diHCl equiv./kg) as assessed by the mouse bioassay, the RBA returned no false negatives relative to the 800 μg STX diHCl equiv./kg regulatory limit for shellfish. Currently, no validated methods other than the mouse bioassay directly measure a composite toxic potency for PST in shellfish. The results of this interlaboratory study demonstrate that the RBA is suitable for the routine determination of PST in shellfish in appropriately equipped laboratories.

Submitted for publication December 3, 2011.

The recommendation was approved by the Method Committee on Paralytic Shellfish Toxins as First Action. See "Methods News," (2011) *Inside Laboratory Management*, January/February issue.

This publication does not constitute an endorsement of any commercial product or intend to be an opinion beyond scientific or other results obtained by the National Oceanic and Atmospheric Administration (NOAA). No reference shall be made to NOAA, or this publication furnished by NOAA, to any advertising or sales promotion which would indicate or imply that NOAA recommends or endorses any proprietary product mentioned herein, or which has as its purpose an interest to cause the advertised product to be used or purchased because of this publication.

Corresponding author's e-mail: Fran.vandolah@noaa.gov

DOI: 10.5740/jaoacint.CS2011_27

Paralytic shellfish poisoning (PSP) is caused by a suite of heterocyclic guanidinium toxins collectively called saxitoxins (STXs). Currently more than 21 congeners of STX are known; they occur in varying proportions in the dinoflagellates that produce them and may be further

Table 1. Shellfish homogenate samples analyzed for PSTs in the collaborative study^a

| Sample No. | Sample ID | Shellfish species and origin | Blind duplicate |
|------------|-----------|--|-----------------|
| 1 | MLV05 | Atlantic sea scallop (<i>Plactopecten magellanicus</i>) from the U.S. east coast | x |
| 2 | MLV06 | California mussel (<i>Mytilus californianus</i>) from the U.S. west coast | x |
| 3 | MLV08 | Green mussel (<i>Perna canaliculus</i>) from New Zealand | |
| 4 | MLV09 | Blue mussel (<i>M. edulis</i>) from the U.S. west coast | x |
| 5 | MLV12 | Blue mussel (<i>M. edulis</i>) east coast U.S., spiked with 200 µg/kg STX diHCl | |
| 6 | MLV14 | Blue mussel (<i>M. edulis</i>) east coast U.S., spiked with 1200 µg/kg STX diHCl | |
| 7 | MLV16 | Almeja clam (<i>Venus antique</i>) from Chile | |
| 8 | MLV01 | Surf clam (<i>Spisula solidissima</i>) from the U.S. east coast | |
| 9 | MLV02 | Chorito mussel (<i>M. chilensis</i>) from Chile | |
| 10 | MLV04 | Scallop (<i>Plactopecten magellanicus</i>) from the U.S. east coast | |
| 11 | MLV07 | Blue mussel (<i>M. edulis</i>) east coast U.S. | x |
| 12 | MLV09 | Blue mussel (<i>M. edulis</i>) from the U.S. west coast | x |
| 13 | MLV11 | Almeja clam (<i>Venus antique</i>) from Chile clam | x |
| 14 | MLV13 | Blue mussel (<i>M. edulis</i>) east coast U.S., spiked with 500 µg/kg STX diHCl | |
| 15 | MLV03 | Chorito mussel (<i>M. chilensis</i>) from Chile | |
| 16 | MLV05 | Atlantic sea scallop (<i>Plactopecten magellanicus</i>) from the U.S. east coast | x |
| 17 | MLV06 | California mussel (<i>M. californianus</i>) from the U.S. west coast | x |
| 18 | MLV07 | Blue mussel (<i>M. edulis</i>) east coast U.S. | x |
| 19 | MLV10 | Butterclam (<i>Saxidomus gigantea</i>) from the U.S. west coast | |
| 20 | MLV11 | Almeja clam (<i>Venus antique</i>) from Chile clam | x |
| 21 | MLV15 | Blue mussel (<i>M. edulis</i>) negative control, east coast U.S. | |

^a Sample number identifies the individual samples analyzed in the assays, with 1–7 analyzed in assay 1, 8–14 in assay 2, and 15–21 in assay 3. Sample identification (MLV for multilaboratory validation) describes the 16 unique samples, among which five were assayed as blind duplicates, to make a total of 21 samples. Blind duplicates, run in different assays, are identified by an “x.”

metabolized in shellfish that accumulate them, making analytical determination of paralytic shellfish toxins (PST) in shellfish complex. The long-standing regulatory method for PST is the AOAC mouse bioassay (1; AOAC Method **959.08**), with a regulatory limit of 800 µg STX di HCl equiv./kg shellfish generally applied, but established at 400 µg STX diHCl equiv./kg in certain countries (e.g., the Philippines). However, at concentrations near the regulatory limit, the mouse bioassay can significantly underestimate PST in shellfish (2). This, in addition to increasing resistance to live animal testing in both the United States and the European Union (EU), has increased the need to develop alternative methods suitable for use in a high-throughput monitoring or regulatory setting.

In the past decade, several alternatives to the mouse bioassay have been developed. In the EU, the mouse bioassay remains the reference method for PST in shellfish, but European Commission (EC) Regulation 1664/2006 specifies that other internationally recognized methods may be used. Two HPLC methods, a precolumn oxidation method (3, 4; AOAC Method **2005.06**) and a postcolumn oxidation method (5; AOAC Method **2011.02**), have been approved by AOAC as *Official Methods*SM for PSP toxin analysis. The EC directive recognizes the precolumn oxidation HPLC method (AOAC Method **2005.06**) as an alternative to the mouse bioassay, but retains the mouse bioassay as the reference method in instances where results are challenged. HPLC methods separate and quantify individual

STX congeners, which are then recombined according to their toxic equivalencies to yield a composite PST toxicity value. Although the HPLC methods perform well quantitatively, a high-throughput screening method capable of reporting toxic potency directly is still desirable for monitoring programs that often screen large numbers of negative samples. A qualitative lateral flow antibody test for PST with a reported detection limit of 400 µg STX equiv./kg was developed by Jellett Rapid Testing Ltd (Chester Basin, NS, Canada) and approved by the U.S. Interstate Shellfish Sanitation Conference and the U.S. Food and Drug Administration as a screening method in specific circumstances. This method performed well in a comparison study with the mouse bioassay (6), but is not fully quantitative and has not been subjected to a full AOAC collaborative trial. To date, a suitable quantitative, high-throughput alternative to the mouse bioassay has not been validated through the AOAC Official Methods Program. The receptor binding assay (RBA) for PST is an excellent candidate for fulfilling the requirements of a high-throughput, quantitative assay that directly reports a composite toxic potency.

The basis of the RBA is the interaction between the toxins and their pharmacological target. All STX congeners bind to site 1 on the alpha subunit of the voltage-gated sodium channel with binding affinities proportional to their toxic potency (7). Therefore, an RBA can quantitatively measure the combined toxic potency of mixtures of STX congeners in a sample,

independent of the toxin congeners present (8). In the RBA for PST, tritiated STX ($[^3\text{H}]$ STX) competes with unlabeled STX and/or its congeners for a finite number of available receptor sites in a rat brain membrane preparation. Following establishment of binding equilibrium, unbound $[^3\text{H}]$ STX is removed by filtration and receptor bound $[^3\text{H}]$ STX quantified by liquid scintillation counting. The reduction in $[^3\text{H}]$ STX binding is directly proportional to the amount of unlabeled toxin present. A standard curve is generated using increasing concentrations of nonradiolabeled STX standard from 10^{-10} to 10^{-6} M STX. The concentration of toxin in samples is determined in reference to the standard curve.

The assay being tested in this collaborative trial is a modification of the method of Doucette et al. (9) to incorporate a 96-well microtiter plate format, which increases sample throughput and minimizes error by reducing sample handling and pipetting steps. This microplate PST RBA was evaluated in a single-laboratory validation (SLV) study (10), which established an interassay repeatability (RSD_r) of 17.7% and good correlation with the mouse bioassay and precolumn oxidation HPLC methods. The toxin concentrations in shellfish tested in the SLV study ranged from near to well above the regulatory limit (approximately 900–15 000 μg STX diHCl equiv./kg). The current study focuses more specifically on the performance of the RBA in the critical range of shellfish toxicities below, near, and slightly above the regulatory limit (approximately 150–2400 μg STX diHCl equiv./kg).

The results of the collaborative study suggest that the RBA for PST is a suitable high-throughput screen for PST in shellfish. Although HPLC methods offer quantitative information on congener composition of samples, often the desired information is composite toxic potency, which requires the summation of individual congeners, corrected for their individual toxic equivalencies. The RBA provides a single integrated toxic potency value that reflects activity of all known and potential unknown congeners present in the sample. Use of the microtiter plate format, in conjunction with microplate scintillation counting, provides the ability to screen multiple samples simultaneously in a total assay time of less than 3 h. The assay format described in the current study provides for the quantitative determination of composite PST toxicity in seven shellfish extracts per 96-well microplate, each run in triplicate at three dilutions, covering toxicity ranges of approximately 35–6000 μg STX diHCl equiv./kg. In a high-throughput assay setting, multiple plates can be set up simultaneously, so that six assay plates can easily be accommodated each day by a single analyst, for a throughput of 42 samples/day. This compares favorably to an estimated throughput of 20–25 samples a day by the precolumn HPLC method (B. Niedzwiadek, Health Canada, personal communication) or 30–35 by mouse bioassay (B. Suarez, University of Chile, personal communication).

Collaborative Study

The focus of this study was to assess the performance of the RBA to determine PST toxicity in samples of commercially important shellfish at a range of concentrations below and above the regulatory limit. Twenty-one shellfish homogenates were included in the study, which represented 16 unique samples (Table 1). The homogenates included 12 naturally contaminated shellfish samples of different species collected from several

geographic regions: blue mussel (*M. edulis*) from the U.S. east and west coasts, California mussel (*M. californianus*) from the U.S. west coast, chorito mussel (*M. chilensis*) from Chile, green mussel (*Perna canaliculus*) from New Zealand, Atlantic surf clam (*Spisula solidissima*) from the U.S. east coast, butter clam (*Saxidomus gigantea*) from U.S. west coast, almeja clam (*Venus antiqua*) from Chile, and Atlantic sea scallop (*Plactopecten magellanicus*) from the U.S. east coast. All samples were provided as whole animal homogenates, except Atlantic sea scallop and green mussel, which included hepatopancreas only. Among the naturally contaminated samples, five were blind duplicates tested on separate days that were used for calculation of RSD_r . Samples run as duplicates are indicated in Table 1. Three samples consisting of STX-spiked mussel homogenate (*M. edulis*) at levels that bracketed the regulatory limits of 800 $\mu\text{g}/\text{kg}$ (500 and 1200 $\mu\text{g}/\text{kg}$ spike) and 400 $\mu\text{g}/\text{kg}$ (200 $\mu\text{g}/\text{kg}$ spike) were included to calculate recovery. One sample was the negative control homogenate of *M. edulis* to which the STX spikes were added. All homogenates were extracted by the study participants and the extracts analyzed by RBA in three assays on separate days.

Study Participants

Ten laboratories from seven countries agreed to carry out RBAs for this study, including the United States, Italy, Australia, New Zealand, Thailand, the Philippines, and South Africa. Participants included laboratories from regulatory authorities, as well as government and academic laboratories with monitoring needs. Five of the participating laboratories (Laboratories 1–5) have this method well established and may be considered routine users. Two laboratories had previous experience running this format of the PST RBA, but have not implemented it routinely. One laboratory had previous experience with receptor assays, but had not used the microplate filtration format of the assay. One laboratory had no previous experience with RBAs. Three laboratories from different countries, United States, Chile, and Thailand, carried out the AOAC official mouse bioassay method (AOAC Method 959.08) on the same set of samples. All mouse bioassay laboratories were experienced regulatory authorities with monitoring responsibilities. One laboratory (Health Canada) performed the precolumn oxidation HPLC method for PST (AOAC Method 2005.06).

Preparation of Homogenates

All shellfish samples were thoroughly homogenized using a polytron blender. For spiked samples, saxitoxin standard reference material (STX diHCl) was added to the specified concentration, and the sample was thoroughly rehomogenized to ensure homogeneity. The toxin congener profiles and concentrations of all samples were determined by the precolumn oxidation HPLC method (performed by Health Canada). STX equivalents were determined by mouse bioassay (performed by Maine Department of Marine Resources). Subsamples of each homogenate (12 g) were packaged in polycarbonate tubes and stored at -80°C until shipment to collaborating laboratories by courier. All samples were coded prior to distributing to collaborating laboratories, with the codes to each laboratory being unique, and provided blind. Coding consisted of two letters followed by a number in the form X A1-7, X B1-7, and

X C1-7, where the X indicated the laboratory, the second letter indicated the three assays to be conducted, and the numerical code indicated sample number within that assay. Three practice homogenates were similarly produced.

Shipment of Study Material

The following reagents were provided to the collaborating laboratories in a single shipment containing enough dry ice to keep the contents frozen for 5 days: [³H] STX; STX diHCl standard; rat brain membrane preparation; 21 coded shellfish homogenates; three practice homogenates; and a QC check sample consisting of 18 nM STX diHCl. Sufficient homogenate (12 g) was provided to ensure an accurate weight of material could be removed from the storage vial if an additional extraction were necessary due to unexpected circumstances. The identity of the samples was not released to collaborators. All reagents were received frozen and in good condition. Each participant received electronically a detailed assay protocol, comprehensive instructions for conducting the study and data reporting, and data reporting forms.

Analysis

Participants extracted all homogenates using a modification of the 0.1 M HCl extraction method used in the AOAC standard mouse bioassay protocol (modified only by scale). They were asked to perform three RBAs, each on separate days. Each assay consisted of one 96-well plate that included a standard curve, QC check sample, and seven shellfish extracts. All samples and standards were tested in triplicate wells. All shellfish extracts were run at three dilutions (1/10, 1/50, and 1/200), which ensured that at least one dilution would fall on the linear part of the standard curve. Participants were instructed to analyze samples coded A, B, or C in the first, second, or third assay, respectively, in numerical order. The five blind duplicate samples were coded so that they were tested in two independent assays, with the combination of assays differing between duplicates. Before performing the official study, participants were asked to run a practice assay that included three shellfish homogenates in the same format to ensure that any unexpected problems were encountered and addressed prior to the official study. The practice samples consisted of a negative control mussel homogenate (MLV15), and two naturally contaminated samples that were also included in the full study (MLV05 and MLV11). The identity of the practice samples was not made known to participants. Results of the practice run were submitted by e-mail to the coordinating laboratory for review before proceeding with the full study.

For the mouse bioassay, participants followed the AOAC official mouse bioassay method (AOAC Method **959.08**), with the exception of a modified 0.1 M HCl extraction protocol used in the RBA protocol, which was modified only by scale so that 5 mL 0.1 M HCl was added to 5 g of shellfish homogenate, with all other aspects of the extraction protocol being identical. The HPLC laboratory followed the precolumn oxidation HPLC method for PST (AOAC Method **2005.06**); however, final concentrations in µg/kg and µg STX equiv./kg were calculated using the formula weight of STX diHCl [372 daltons (da)], as opposed to the free base (299.3 da) in the standard HPLC protocol, to more directly compare with the RBA.

Data Analysis and Reporting

Participants were asked to report whether they used a standard or microplate scintillation counter for the study and, if a microplate counter was used, which model, because of differences in inherent counting efficiency between current commercially available counters. For data analysis, participants were instructed to use GraphPad Prism software (La Jolla, CA) or the on-board curve-fitting software provided with their microplate scintillation counter e.g., PerkinElmer Wallac MultiCalc (Gaithersburg, MD) or Packard Top Count software (Packard Instrument Co., Meriden, CT), and to report what software was used. For analysis, a four parameter logistic fit, also known as a sigmoidal dose response with variable slope, or Hill equation, was prescribed. Participants presented their analyzed data on the spreadsheet template provided, including assay quality parameters (slope, IC₅₀, and quantification of the QC check sample), between-well CVs for each sample dilution that fell within the linear part of the standard curve (0.2–0.7 B/B₀), and calculated values for these samples in the well (nM), in the extract (µg STX equiv./mL), and in the shellfish tissue (µg STX equiv./kg). Participants were also asked to report all raw count data so that all results could be analyzed by the coordinating laboratory using identical software (GraphPad Prism 4.0) to assess whether systematic differences in quantification arose from using different curve-fitting software. All data were reported via e-mail to the coordinating laboratory.

The calculated results sheets were reviewed by the coordinating laboratory for obvious errors in dilutions and calculations and for use of the prescribed curve-fitting model. Obvious errors were corrected and the participant laboratory was consulted for concurrence. The reviewed results were then used for evaluation in the collaborative study.

Statistical Evaluation of the Collaborative Study

For each sample analyzed, outliers were first determined using the Grubbs test at a probability value of 1% (www.graphpad.com), with no more than one outlier removed, so that valid data remained from a minimum of eight laboratories. The mean, S_R, and RSD_R, and HorRat values were then calculated for each sample. For blind duplicates, the AOAC INTERNATIONAL Interlaboratory Study Workbook for Blind Duplicates, v2.0, was used to further evaluate for outliers and determine S_r and RSD_r. GraphPad Prism was used to determine correlation among the RBA, mouse bioassay, and HPLC results.

AOAC Official Method 2011.27 Paralytic Shellfish Toxins (PSTs) in Shellfish Receptor Binding Assay First Action 2011

[Applicable to the determination of paralytic shellfish toxins (PSTs), as µg STX diHCl equiv./kg, in shellfish (mussels, clams, scallops) at levels >149 µg STX diHCl equiv./kg, with a limit of detection (LOD) of 45 STX diHCl equiv./kg shellfish and a limit of quantification (LOQ) of 126 µg STX diHCl equiv./kg shellfish.]

Caution: Wear disposable gloves and protective laboratory coat while performing the assay. PSTs are neurotoxins that are harmful if ingested. The assay uses a tritium labeled tracer, [³H] STX, at low concentration.

All laboratories performing the assay must have approved radiation laboratory space and must follow procedures prescribed by their nuclear regulatory agency for receipt, use, and disposal of isotopes.

See Tables 2011.27A–E for results of the interlaboratory study supporting acceptance of the method.

A. Principle

Test portions of shellfish homogenates are extracted using the AOAC mouse bioassay extraction protocol (959.08), modified by scale. The PST receptor assay is a competitive binding assay in which [³H] STX competes with unlabeled STX in standards or mixtures of PST in samples for a finite number of available receptor sites (site 1 on the voltage gated sodium channel) in a rat brain membrane preparation. Following establishment of binding equilibrium at 4°C, unbound [³H] STX is removed by filtration and bound [³H] STX is quantified by liquid scintillation counting. A standard curve is generated using increasing concentrations of STX standard from 10⁻¹⁰ to 10⁻⁶ M STX, which results in a reduction in bound [³H] STX that is directly proportional to the amount of unlabeled toxin present. The concentration of toxin in samples is determined in reference to the standard curve. Incubation is carried out in a microplate format to minimize sample handling and the amount of radioactivity used. Bound [³H] STX (as counts per minute; CPM) can be determined either by conventional or by microplate scintillation counting. Both methods are included in this protocol.

B. Apparatus and Supplies

- (a) *Traditional or microplate scintillation counter.*
 - (b) *Micropipettors.*—1–1000 µL variable volumes and disposable tips.
 - (c) *Eight channel pipettor.*—5–200 µL variable volume and disposable tips.
 - (d) *96-Well microtiter filter plate.*—With 1.0 µm pore size type GF/B glass fiber filter/0.65 µm pore size Durapore support membrane (Millipore, Bedford, MA; Cat. No. MSFB N6B 50).
 - (e) *MultiScreen vacuum manifold.*—Millipore; Cat. No. NSVMHTS00.
 - (f) *Vacuum pump.*
 - (g) *Centrifuge tubes.*—15 and 50 mL, conical, plastic.
 - (h) *Mini dilution tubes in 96-tube array.*
 - (i) *Reagent reservoirs.*
 - (j) *Ice bucket and ice.*
 - (k) *Vortex mixer.*
 - (l) *Sealing tape.*—Millipore; Cat. No. MATA HCL00.
 - (m) *Volumetric flask.*—1 L.
 - (n) *-80°C freezer.*
 - (o) *Refrigerator.*
- For traditional scintillation counter only:
- (p) *MultiScreen punch device.*—Millipore; Cat No. MAMP 096 08.
 - (q) *MultiScreen disposable punch tips.*—Millipore; Cat. No. MADP 196 10.
 - (r) *MultiScreen punch kit B for 4 mL vials.*—Millipore; Cat. No. MAPK 896 0B.
 - (s) *Scintillation vials.*—4 mL.
- For sample extraction:
- (t) *Pipets.*
 - (u) *Centrifuge tubes.*—15 mL, conical, plastic.

- (v) *Vacuum pump or house vacuum.*
- (w) *pH meter or pH paper.*
- (x) *Hot plate.*
- (y) *Graduated centrifuge tubes.*—15 mL.
- (z) *Centrifuge and rotor for 15 mL tubes.*

C. Reagents

- (a) [³H] STX.—0.1 mCi/mL, ≥10 Ci/mmol, ≥90% radiochemical purity (American Radiolabeled Chemicals, St. Louis, MO, or International Isotopes Clearinghouse, Leawood, KS).
 - (b) STX diHCl.—NIST RM 8642 (www.nist.gov).
 - (c) *3-Morpholinopropanesulfonic acid (MOPS).*—Sigma (St. Louis, MO; Cat. No. M3183-500G), or equivalent.
 - (d) *Choline chloride.*—Sigma (Cat. No. C7527-500G), or equivalent.
 - (e) *Rat brain membrane preparation.*—See Appendix.
- For traditional counter:
- (f) *Scintiverse BD liquid scintillation cocktail.*—Fisher Scientific (Waltham, MA; Cat. No. SX-18), or equivalent.
- For microplate counter:
- (g) *Optiphase liquid scintillation cocktail.*—PerkinElmer Life Sciences (Downers Grove, IL; Cat. No. 1200-139), or equivalent.
- For sample extraction:
- (h) *Hydrochloric acid (HCl).*—1.0 and 0.1 M.
 - (i) *Sodium hydroxide.*—0.1 M.
 - (j) *Water.*—Distilled or deionized (18 µΩ).

D. Sample Extraction

Accurately weigh 5.0 g tissue homogenate into a tared 15 mL conical tube. Add 5.0 mL of 0.1 M HCl, vortex, and check pH. If necessary, adjust pH to 3.0–4.0 as determined by a pH meter or pH paper. To lower pH, add 1 M HCl dropwise with mixing; to raise pH, add 0.1 M NaOH dropwise with mixing to prevent local alkalization and consequent destruction of toxin. Place the tube in a beaker of boiling water on a hot plate for 5 min with the caps loosened. Remove and cool to room temperature. Check pH and adjust cooled mixture to pH 3.0–4.0 as described above. Transfer entire contents to graduated centrifuge tube and dilute volumetrically to 10 mL. Gently stir contents to homogeneity and allow to settle until portion of supernatant is translucent and can be decanted free of solid particles. Pour approximately 5 to 7 mL of the translucent supernatant into a centrifuge tube. Centrifuge at 3000 × g for 10 min. Retain clarified supernatant and transfer to a clean centrifuge tube. Store extracts at -20°C until tested in receptor assay.

E. Preparation of Stock Solutions and Standards

- (a) *Assay buffer.*—100 mM MOPS/100 mM choline chloride, pH 7.4. Weigh out 20.9 g MOPS and 13.96 g choline chloride and add to 900 mL dH₂O. Adjust pH to 7.4 with NaOH while stirring and bring to a final volume of 1 L with dH₂O. Store at 4°C.
- (b) *Radioligand solution.*—Calculate the concentration of [³H] STX stock provided by the supplier, which may vary between lots. Suppliers generally provide the specific activity in Ci/mmol (generally 10–30 Ci/mmol) and activity in mCi/mL (0.05–0.1 mCi/mL), from which the molar concentration can be calculated. Prepare 4 mL of a 15 nM working stock of [³H] STX fresh daily in 100 mM MOPS/100 mM choline chloride

Table 2011.27A. Receptor binding assay results on individual samples (values are in µg STX diHCl equiv./kg shellfish tissue); summary statistics on all samples; summary statistics excluding Laboratory 9

| Assay | No. | Sample | | | | | | | | | | | | | | | All labs | | | | Labs 1-8 | | |
|-------|-----------------------|--------|------------------|-------------------|------|------|------|------|-------------------|-------------------|------|----------------|----------------------|--------|------|----------------|----------------------|----------------|----------------------|--------|----------|----------------|----------------------|
| | | Lab | | | | | | | | | | | | | | | Mean | S _R | RSD _R , % | HorRat | Mean | S _R | RSD _R , % |
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Mean | S _R | RSD _R , % | HorRat | Mean | S _R | RSD _R , % | HorRat | | | | | |
| Day 1 | 1 | MLV05 | 370 | 610 | 620 | 410 | 690 | 1070 | 630 | 660 | 330 | 599 | 222 | 37.1 | 2.2 | 633 | 212 | 33.5 | 2.0 | | | | |
| | 2 | MLV06 | 1100 | 1340 | 1320 | 1440 | 1260 | 1720 | 2080 | 2130 | 890 | 1476 | 422 | 28.6 | 1.9 | 1549 | 386 | 24.9 | 1.7 | | | | |
| | 3 | MLV08 | 80 | 190 | 140 | 90 | 130 | 160 | 230 | 220 | 100 | 149 | 55 | 37.2 | 1.8 | 155 | 56 | 36.0 | 1.7 | | | | |
| | 4 | MLV09 | 860 | 680 | 950 | 870 | 980 | 1120 | 1460 | 820 | 590 | 926 | 255 | 27.5 | 1.7 | 968 | 237 | 24.5 | 1.5 | | | | |
| | 5 | MLV12 | 180 ^a | 200 | 200 | 150 | 150 | 100 | 290 | 290 | 100 | 168 | 62 | 37.2 | 1.8 | 177 | 60 | 34.1 | 1.7 | | | | |
| | 6 | MLV14 | 950 | 940 | 1060 | 1130 | 1040 | 750 | 1460 | 1320 | 810 | 1051 | 228 | 21.7 | 1.4 | 1081 | 224 | 20.7 | 1.3 | | | | |
| | 7 | MLV16 | 660 | 930 | 1080 | 870 | 840 | 1320 | 1490 | 2420 ^b | 490 | 960 | 329 | 34.3 | 2.1 | 1027 | 291 | 28.3 | 1.8 | | | | |
| Day 2 | 8 | MLV01 | 1360 | 1520 | 1580 | 1110 | 1700 | 3180 | 1400 | 2780 | 520 | 1683 | 818 | 48.6 | 3.3 | 1829 | 739 | 40.4 | 2.8 | | | | |
| | 9 | MVL02 | 830 | 1180 | 1130 | 1150 | 1130 | 1780 | 1340 | 980 | 690 | 1134 | 311 | 27.4 | 1.8 | 1190 | 281 | 23.6 | 1.5 | | | | |
| | 10 | MLV04 | 2440 | 2840 | 2910 | 1740 | 2150 | 1810 | 2690 | 2490 | 1210 | 2253 | 572 | 25.4 | 1.8 | 2384 | 446 | 18.7 | 1.3 | | | | |
| | 11 | MLV07 | 1260 | 1540 | 1220 | 1980 | 1760 | 1530 | 1660 | 1210 | 840 | 1444 | 345 | 23.9 | 1.6 | 1520 | 279 | 18.3 | 1.2 | | | | |
| | 12 | MLV09 | 810 | 1190 | 1130 | 810 | 1630 | 1390 | 1880 | 1120 | 870 | 1203 | 372 | 30.9 | 2.0 | 1245 | 375 | 30.1 | 2.0 | | | | |
| | 13 | MLV11 | 270 | 370 | 480 | 340 | 640 | 490 | 240 | 600 | 110 | 393 | 174 | 44.3 | 2.4 | 429 | 148 | 34.4 | 1.9 | | | | |
| | 14 | MLV13 | 400 | 1240 ^b | 560 | 450 | 650 | 530 | 500 | 440 | 200 | 466 | 133 | 28.5 | 1.6 | 504 | 85 | 16.8 | 1.0 | | | | |
| Day 3 | 15 | MLV03 | 330 | 270 | 410 | 180 | 590 | 680 | 370 | 1570 ^b | 90 | 365 | 197 | 54.0 | 2.9 | 404 | 176 | 43.5 | 2.4 | | | | |
| | 16 | MLV05 | 580 | 670 | 250 | 430 | 910 | 700 | 860 | 940 | 300 | 627 | 257 | 41.1 | 2.4 | 668 | 242 | 36.2 | 2.1 | | | | |
| | 17 | MLV06 | 1290 | 1520 | 1460 | 970 | 1800 | 2520 | 1470 | 870 | 1250 | 1461 | 488 | 33.4 | 2.2 | 1488 | 515 | 34.6 | 2.3 | | | | |
| | 18 | MLV07 | 1010 | 1600 | 1390 | 1000 | 1720 | 1860 | 1520 | 2150 | 890 | 1460 | 429 | 29.4 | 2.0 | 1531 | 397 | 26.0 | 1.7 | | | | |
| | 19 | MLV10 | 1640 | 2130 | 2800 | 2660 | 2330 | 1850 | 3390 | 2740 | 1830 | 2374 | 570 | 24.0 | 1.7 | 2443 | 569 | 23.3 | 1.7 | | | | |
| | 20 | MLV11 | 430 | 350 | 460 | 280 | 550 | 620 | 1149 ^b | 410 | 250 | 419 | 127 | 30.2 | 1.7 | 443 | 115 | 26.0 | 1.4 | | | | |
| | 21 | MLV15 | ND ^c | ND | ND | ND | ND | ND | 180 | ND | ND | — | — | — | — | — | — | — | — | | | | |
| | Avg. RSD _R | | | | | | | | | | | | | 33.2 | | | | | 28.7 | | | | |
| | Avg. HorRat | | | | | | | | | | | | | 2.0 | | | | | 1.8 | | | | |

^a CV 41%; not used in calculations.

^b Outlier; not used in calculations.

^c ND = Not detected.

Table 2011.27B. Summary statistics on blind duplicates, run in separate assays (values are in μg STX diHCl equiv./kg)

| Lab | MLV05 | | MLV06 | | MLV07 | | MLV09 | | MLV11 | | Avg. |
|----------------------|---------|---------|---------|---------|---------|---------|---------|---------|------------------|-------------------|------|
| | Assay 1 | Assay 2 | Assay 1 | Assay 2 | Assay 1 | Assay 2 | Assay 1 | Assay 2 | Assay 1 | Assay 2 | |
| 1 | 370 | 580 | 1100 | 1290 | 1260 | 1010 | 860 | 810 | 270 | 430 | |
| 2 | 610 | 670 | 1340 | 1520 | 1540 | 1530 | 680 | 1190 | 370 | 350 | |
| 3 | 620 | 250 | 1320 | 1460 | 1220 | 1390 | 950 | 1130 | 480 | 401 | |
| 4 | 410 | 430 | 1440 | 970 | 1980 | 1000 | 870 | 810 | 340 | 280 | |
| 5 | 690 | 910 | 1260 | 1790 | 1760 | 1720 | 980 | 1630 | 640 | 550 | |
| 6 | 1070 | 700 | 1720 | 2520 | 1530 | 1860 | 1120 | 1390 | 490 | 620 | |
| 7 | 630 | 880 | 2090 | 1240 | 1750 | 1150 | 1460 | 1830 | 230 ^a | 1149 ^a | |
| 8 | 660 | 940 | 2130 | 870 | 1210 | 2150 | 820 | 1120 | 600 | 410 | |
| 9 | 330 | 300 | 890 | 1250 | 840 | 890 | 590 | 870 | 110 | 250 | |
| Avg. | | 614 | | 1453 | | 1433 | | 1062 | | 416 | |
| S _r | | 169 | | 432 | | 366 | | 247 | | 83 | |
| S _R | | 239 | | 444 | | 387 | | 338 | | 152 | |
| RSD _r , % | | 27.5 | | 29.4 | | 25.5 | | 23.3 | | 20.0 | 25.1 |
| RSD _R , % | | 38.9 | | 30.2 | | 27.0 | | 31.9 | | 36.5 | 32.9 |
| HorRat | | 2.3 | | 2.0 | | 1.8 | | 2.0 | | 2.0 | 2.0 |

^a Outlier; not used in calculation.

buffer. This will provide sufficient volume for one 96-well plate at an in-well concentration of 2.5 nM. Measure total counts of each working stock prior to running an assay: add 35 μL of the working stock [^3H] STX in buffer to a liquid scintillation vial with 4 mL scintillant and count on a traditional liquid scintillation counter. This is done to confirm correct dilution prior to running the assay. Depending on the efficiency of the scintillation counter used, the corresponding CPM will vary, but should be consistent day-to-day and within 15% of the expected value.

(c) *Unlabeled STX standard working solution.*—The STX diHCl standard is provided at a concentration of 268.8 μM (100 $\mu\text{g}/\text{mL}$). A “bulk” standard curve can be made up in advance and stored at 4°C for up to 1 month. The use of a bulk standard curve minimizes the pipetting needed for setting up an assay routinely and improves day-to-day repeatability. Make up 3 mM HCl (e.g., from a 3 M stock, 50 μL in 50 mL), then perform the serial dilutions (see Table 2011.27F) of NIST RM 8642 STX diHCl (100 $\mu\text{g}/\text{mL}$ = 268.8 μM) to make up the standard curve in 3 mM HCl. These standard stock solutions will be diluted 1/6 in the assay to yield the designated in-assay concentrations (see Table 2011.27F).

(d) *Interassay calibration standard (QC check).*—Prepare a reference standard containing 1.8×10^{-8} M STX standard (3.0×10^{-9} M STX in assay) in advance in 3 mM HCl and keep frozen (−80°C) in 1 mL aliquots for long-term storage. Aliquots should be thawed and stored at 4°C for routine use (stable up to 1 month) and analyzed in each assay. This serves as a QC check and confirms day-to-day performance of the assay.

(e) *Rat brain membrane preparation.*—Prepare rat brain membrane preparation in bulk (see Appendix: *Rat Brain Membrane Preparation*) and store at −80°C until used in the assay. Thaw an aliquot of rat brain membrane preparation on ice. Dilute membrane preparation with cold (4°C) 100 mM

MOPS/100 mM choline chloride, pH 7.4, to yield a working stock with a protein concentration of 1.0 mg/mL (this will be diluted in the assay plate to 0.5 mg/mL in-well concentration). Vortex vigorously to achieve a visibly homogeneous suspension. Keep the diluted membrane preparation on ice until ready to use.

F. Performing the Assay

(a) *Plate setup.*—When possible, use a multichannel pipet to minimize pipetting effort and increase consistency. Standard curve, QC check, and sample extracts are run in triplicate wells. Multiple dilutions of sample extracts should be analyzed in order to obtain a value that falls between 0.2–0.7 B/B₀ on the standard curve for quantification. For ease of analysis, it is convenient to use a standard plate layout that maximizes the number of samples and standards that can be analyzed on one plate. For shellfish extracts, a minimum dilution of 1:10 is used, which minimizes potential matrix effects, while still providing an LOQ of approximately 126 $\mu\text{g}/\text{kg}$ shellfish (see Table 2011.27G).

(b) *Addition of samples and standards.*—Add in the following order to each of the 96 wells: 35 μL assay buffer; 35 μL STX standard, QC check, or sample extract; 35 μL [^3H] STX; 105 μL membrane preparation. The assay buffer is added first in order to wet the filter membrane. It is critical to continuously mix the membrane preparation by careful up-and-down pipetting immediately prior to dispensing into the 96-well plate to maintain an even suspension across the entire plate. Cover and incubate plate at 4°C for 1 h.

(c) *Assay filtration.*—Attach the vacuum manifold to the vacuum pump with an in-line side arm flask to catch filtrate from the plate filtration process. Set the vacuum pressure gauge on the pump or vacuum manifold to 4–8” Hg (135–270 millibar), as specified in the instructions provided with the filtration plates. Place the 96-well plate on the vacuum manifold. Fill empty wells with 200 μL MOPS/choline chloride buffer to

Table 2011.27C. Performance of individual laboratories on blind duplicates (values are in µg STX diHCl equiv./kg)

| Lab | ID | Day 1 | Day 2 | Mean | s _r | RSD _r , % |
|------|-------|------------------|-------------------|------|----------------|----------------------|
| 1 | MLV05 | 370 | 580 | 475 | 148 | 31.3 |
| | MLV06 | 1100 | 1290 | 1195 | 134 | 11.2 |
| | MLV07 | 1260 | 1010 | 1135 | 177 | 15.6 |
| | MLV09 | 860 | 810 | 835 | 35 | 4.2 |
| | MLV11 | 270 | 430 | 350 | 113 | 32.3 |
| Avg. | | | | | | 18.9 |
| 2 | MLV05 | 605 | 670 | 638 | 46 | 7.2 |
| | MLV06 | 1340 | 1520 | 1430 | 127 | 8.9 |
| | MLV07 | 1540 | 1530 | 1535 | 7 | 0.5 |
| | MLV09 | 680 | 1190 | 935 | 361 | 38.6 |
| | MLV11 | 370 | 350 | 360 | 14 | 3.9 |
| Avg. | | | | | | 11.8 |
| 3 | MLV05 | 620 | 250 | 435 | 262 | 60.1 |
| | MLV06 | 1320 | 1460 | 1390 | 99 | 7.1 |
| | MLV07 | 1220 | 1303 | 1262 | 59 | 4.7 |
| | MLV09 | 950 | 1130 | 1040 | 127 | 12.2 |
| | MLV11 | 480 | 460 | 470 | 14 | 3.0 |
| Avg. | | | | | | 17.4 |
| 4 | MLV05 | 410 | 430 | 420 | 14 | 3.4 |
| | MLV06 | 1440 | 970 | 1205 | 332 | 27.6 |
| | MLV07 | 1980 | 1000 | 1490 | 693 | 46.5 |
| | MLV09 | 870 | 810 | 840 | 42 | 5.1 |
| | MLV11 | 340 | 280 | 310 | 42 | 13.7 |
| Avg. | | | | | | 19.2 |
| 5 | MLV05 | 690 | 910 | 800 | 156 | 19.4 |
| | MLV06 | 1260 | 1790 | 1525 | 375 | 24.6 |
| | MLV07 | 1760 | 1720 | 1740 | 28 | 1.6 |
| | MLV09 | 980 | 1630 | 1305 | 460 | 35.2 |
| | MLV11 | 640 | 550 | 595 | 64 | 10.7 |
| Avg. | | | | | | 18.3 |
| 6 | MLV05 | 1070 | 700 | 885 | 262 | 29.6 |
| | MLV06 | 1720 | 2520 | 2120 | 566 | 26.7 |
| | MLV07 | 1530 | 1860 | 1695 | 233 | 13.8 |
| | MLV09 | 1120 | 1390 | 1255 | 191 | 15.2 |
| | MLV11 | 490 | 620 | 555 | 92 | 16.6 |
| Avg. | | | | | | 20.4 |
| 7 | MLV05 | 630 | 880 | 755 | 177 | 23.4 |
| | MLV06 | 2090 | 1240 | 1665 | 601 | 36.1 |
| | MLV07 | 1750 | 1150 | 1450 | 424 | 29.3 |
| | MLV09 | 1460 | 1830 | 1645 | 262 | 15.9 |
| | MLV11 | 230 ^a | 1150 ^a | | | |
| Avg. | | | | | | 26.2 |
| 8 | MLV05 | 660 | 940 | 800 | 198 | 24.7 |
| | MLV06 | 2130 | 870 | 1500 | 891 | 59.4 |
| | MLV07 | 1210 | 2150 | 1680 | 665 | 39.6 |
| | MLV09 | 820 | 1120 | 970 | 212 | 21.9 |
| | MLV11 | 600 | 410 | 505 | 134 | 26.6 |
| Avg. | | | | | | 34.4 |

Table 2011.27C. (continued)

| Lab | ID | Day 1 | Day 2 | Mean | s _r | RSD _r , % |
|--------------|-------|-------|-------|------|----------------|----------------------|
| 9 | MLV05 | 330 | 300 | 315 | 21 | 6.7 |
| | MLV06 | 890 | 1250 | 1070 | 255 | 23.8 |
| | MLV07 | 840 | 890 | 865 | 35 | 4.1 |
| | MLV09 | 590 | 870 | 730 | 198 | 27.1 |
| | MLV11 | 110 | 250 | 180 | 99 | 55.0 |
| Avg. | | | | | | 23.3 |
| Overall avg. | | | | | | 22.2 |

^a Outlier; not used in calculations.

ensure even vacuum pressure and filtration across the plate. Turn on vacuum. Optimum vacuum will pull the wells to dryness in 2–5 s. Pull contents of all wells through until all liquid is removed. (*Note:* Too low a vacuum will result in slow well clearance, but too high will result in an airlock and no well clearance.) With vacuum pump running, quickly rinse each well twice with 200 µL ice cold MOPS/choline chloride buffer using multichannel pipet. Maintain vacuum until liquid is removed.

(d) *Preparation of the assay for counting.*—Remove the plastic bottom from the plate. Blot the bottom once on absorbent toweling.

(1) *For counting in microplate scintillation counter.*—Place the microplate in a counting cassette. Seal the bottom of the 96-well plate with sealing tape. Add 50 µL Optiphase scintillation cocktail per well using multichannel pipet. Seal the top of the plate with sealing tape. Allow to incubate 30 min at room temperature. Place the plate in a counting cassette and count in a microplate scintillation counter for 1 min/well.

(2) *For counting in traditional scintillation counter.*—Place the microplate in the MultiScreen punch system apparatus. Place the disposable punch tips on top of the microplate. Punch the filters from the wells into scintillation vials and fill with 4 mL scintillation cocktail (Scintiverse or equivalent). Place caps on the vials and vortex. Allow vials to sit overnight in the dark, then count using a tritium window in a traditional scintillation counter.

G. Analysis of Data

For assays performed using the traditional counter, curve fitting is performed using a four-parameter logistic fit, also known as a sigmoidal dose response curve (variable slope; *see* Figure 2011.27), or Hill equation:

$$y = \min + \frac{\max - \min}{1 + 10^{(x - \log\text{-EC}_{50} \text{ Hill slope})}}$$

where max is the top plateau representing maximum binding in CPM in the absence of competing nonradiolabeled STX, also known as B₀; min is the bottom plateau, equal to nonspecific binding (in CPM) in the presence of saturating nonradiolabeled toxin; IC₅₀ is the inhibitory concentration at which CPM are 50% of max-min (dashed lines; Figure 2011.27); Hill slope is the slope of the curve; x axis is the log concentration of STX; and y axis is total ligand binding in CPM (here represented as B/B₀, or bound/max bound). A curve fitting package such as Prism (GraphPad Software, Inc.) is recommended. For the microplate counter users, receptor

Table 2011.27D. Calibration curve and QC check parameters in three receptor binding assays performed in nine participant laboratories

| Lab | Assay day | Slope | IC ₅₀ , nM | QC, nM | Reference, CPM | IC ₇₀ , nM | Standards where RSD >30%; action | Curve fitting software | Scintillation counter | Manual/microplate |
|-----|-----------|-------|-----------------------|------------------|----------------|-----------------------|----------------------------------|------------------------|-----------------------|-------------------|
| 1 | 1 | -0.9 | 1.9 | 2.4 | 720 | 0.90 | None | Prism v 3.02 | Packard Top Count | Microplate |
| | 2 | -1.0 | 2.0 | 2.6 | 733 | 0.96 | None | | | |
| | 3 | -1.1 | 2.1 | 3.2 | 1038 | 0.92 | None | | | |
| 2 | 1 | -1.1 | 1.8 | 3.8 | 1160 | 0.66 | 3 nM; 1 well removed | Prism v 5.0 | Packard Top Count | Microplate |
| | 2 | -1.2 | 2.2 | 3.9 | 1260 | 0.85 | None | | | |
| | 3 | -1.0 | 1.6 | 3.2 | 1262 | 0.46 | 3 nM, 1 nM removed | | | |
| 3 | 1 | -1.0 | 2.0 | 2.3 | 2529 | 0.41 | First column removed | Prism v 5.0 | Wallac Microbeta | Microplate |
| | 2 | -0.9 | 2.0 | 2.5 | 1463 | 0.92 | 1000 nM; 1 well removed | | | |
| | 3 | 1.0 | 1.6 | 2.8 | 2088 | 0.80 | None | | | |
| 4 | 1 | -0.9 | 1.7 | 3.4 | 1125 | 0.61 | None | Prism v 3.03 | PerkinElmer Tricarb | Manual |
| | 2 | -1.2 | 1.7 | 3.2 ^a | 1611 | 0.77 | None | | | |
| | 3 | -0.9 | 1.2 | 2.9 | 1324 | 0.45 | 30 nM 35%; 1 well removed | | | |
| 5 | 1 | -0.9 | 1.4 | 3.3 | 1566 | 0.64 | 1.0 nM; 1 well removed | MultiCalc | Wallac Microbeta | Microplate |
| | 2 | -1.2 | 1.8 | 3.6 | 1528 | 1.05 | 0.1 nM and 30 nM; 1 well removed | | | |
| | 3 | -1.2 | 1.8 | 2.9 | 1052 | 0.67 | None | | | |
| 6 | 1 | -1.1 | 2.6 | 3.0 | 670 | 1.15 | None | Prism v 4.0 | Wallac Microbeta | Microplate |
| | 2 | -1.0 | 2.0 | 4.0 ^b | 1124 | 1.08 | None | | | |
| | 3 | -1.1 | 3.4 | 6.5 ^b | 1030 | 2.04 ^c | None | | | |
| 7 | 1 | -0.8 | 1.0 | 2.8 ^a | 919 | 0.33 | None | Prism | Wallac Microbeta | Microplate |
| | 2 | -1.0 | 1.6 | 2.7 | 619 | 0.70 | None | | | |
| | 3 | -0.9 | 2.1 | 3.2 ^a | 693 | 0.82 | None | | | |
| 8 | 1 | -1.2 | 1.7 | 3.7 | 1146 | 0.86 | None | Prism | Wallac Microbeta | Microplate |
| | 2 | -1.1 | 1.4 | 1.5 ^b | 1095 | 0.78 | None | | | |
| | 3 | -1.1 | 2.4 | 2.3 | 886 | 1.04 | None | | | |
| 9 | 1 | -1.0 | 2.2 | 4.0 ^b | 1363 | 0.97 | None | Prism | Wallac Microbeta | Microplate |
| | 2 | -1.0 | 2.0 | 3.2 | 1380 | 0.85 | 100 nM 33%; left in | | | |
| | 3 | -1.0 | 2.1 | 3.7 | 1532 | 0.92 | None | | | |

^a One well removed.^b Outside of specifications.^c Outlier by Grubbs test.

assay applications provided by the manufacturer may be used (e.g., MultiCalc; PerkinElmer Wallac, Gaithersburg, MD).

(a) *Sample quantification.*—Sample quantification is carried out only on dilutions that fall within B/B₀ of 0.2–0.7, where B represents the bound [³H]STX (in CPM) in the sample and B₀ represents the max bound [³H]STX (in CPM). Where more than one dilution falls within B/B₀ of 0.2–0.7 on the curve, all sample wells corresponding to these dilutions are used to calculate sample concentration. Sample concentration is calculated in µg STX diHCl equiv./kg shellfish, from the in-well nM concentration obtained from the curve fitting software using the following formulas:

$$(\text{nM STX equiv}) \times (\text{sample dilution}) \times \frac{(210 \mu\text{L total volume})}{35 \mu\text{L sample}} = \text{nM STX equiv in extract}$$

$$(\text{nM STX diHCl equiv. in extract}) \times \frac{1 \text{ L}}{1000 \text{ mL}} \times \frac{372 \text{ ng}}{\text{nmol}} \times \frac{1 \mu\text{g}}{1000 \text{ ng}} = \mu\text{g STX diHCl equiv./mL}$$

$$\mu\text{g STX diHCl equiv./mL} \times \frac{\text{mL extract}}{\text{g shellfish}} \times \frac{1000 \text{ g}}{\text{kg}} = \mu\text{g STX diHCl equiv./kg}$$

H. Assay Performance Standards

The following criteria must be met for assay acceptance:

Table 2011.27E. Results of the receptor binding assay (RBA), mouse bioassay (MBA), and HPLC analyses of 21 shellfish extracts, sorted by mouse bioassay value (all values are in μg STX diHCl equiv./kg shellfish tissue; results in bold indicate toxicity above the 800 μg STX diHCl equiv./kg regulatory limit; all other results indicate toxicity below the regulatory limit)

| Sample | Lab 1 | Lab 2 | Lab 3 | Lab 4 | Lab 5 | Lab 6 | Lab 7 | Lab 8 | Lab 9 | RBA, avg. | HPLC | MBA |
|--------|-----------------|-------------------------|-------------|-------------|-------------|-------------------------|-------------------------|-------------------------|-------------|-------------|-------------|-------------|
| 21 | ND ^a | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 5 | 180 | 200 | 200 | 150 | 150 | 100 | 150 | 290 | 100 | 168 | 108 | ND |
| 15 | 330 | 270 | 410 | 180 | 590 | 680 | 370 | 1570^b | 90 | 365 | 196 | 182 |
| 13 | 270 | 370 | 480 | 340 | 640 | 290 | 240 | 600 | 110 | 371 | 236 | 299 |
| 20 | 430 | 350 | 460 | 280 | 550 | 490 | 1150^b | 410 | 250 | 403 | 236 | 299 |
| 14 | 400 | 1240^b | 560 | 450 | 650 | 530 | 500 | 440 | 200 | 466 | 625 | 343 |
| 1 | 370 | 610 | 620 | 410 | 690 | 1070^b | 630^b | 660 | 330 | 599 | 413 | 387 |
| 16 | 580 | 670 | 250 | 430 | 910 | 700 | 860^b | 940^b | 300 | 627 | 413 | 387 |
| 3 | 80 | 190 | 140 | 90 | 130 | 160 | 230 | 220 | 100 | 149 | 341 | 405 |
| 6 | 950 | 940 | 1060 | 1130 | 1040 | 750 | 1460 | 1320 | 810 | 1051 | 618 | 485 |
| 7 | 660 | 930 | 1080 | 870 | 840 | 1320 | 1490 | 2420 | 490 | 960 | 685 | 528 |
| 2 | 1100 | 1340 | 1320 | 1440 | 1260 | 1720 | 2080 | 2130 | 890 | 1476 | 931 | 595 |
| 17 | 1290 | 1520 | 1460 | 970 | 1800 | 2520 | 1470 | 870 | 1250 | 1460 | 931 | 595 |
| 4 | 860 | 680 | 950 | 870 | 980 | 1120 | 1460 | 820 | 590 | 926 | 1070 | 653 |
| 12 | 810 | 1190 | 1130 | 810 | 1630 | 1390 | 1880 | 1120 | 870 | 1203 | 1070 | 653 |
| 11 | 1260 | 1540 | 1220 | 1980 | 1760 | 1530 | 1660 | 1210 | 840 | 1444 | 965 | 714 |
| 18 | 1010 | 1600 | 1390 | 1000 | 1720 | 1860 | 1520 | 2150 | 890 | 1452 | 965 | 714 |
| 8 | 1360 | 1520 | 1580 | 1110 | 1700 | 3180 | 1400 | 2780 | 520 | 1683 | 894 | 752 |
| 9 | 830 | 1180 | 1130 | 1150 | 1130 | 1780 | 1340 | 980 | 690 | 1134 | 802 | 792 |
| 19 | 1640 | 2130 | 2800 | 2660 | 2330 | 1850 | 3390 | 2740 | 1830 | 2374 | 2000 | 1027 |
| 10 | 2440 | 2840 | 2910 | 1740 | 2150 | 1800 | 2690 | 2490 | 1210 | 2252 | 1890 | 1080 |

^a ND = Not detected.^b Outlier; not used in average calculation.

(a) For a ligand that specifically binds at one receptor site, the slope of the resulting competition curve should theoretically be -1.0 . If the slope of the curve for a given assay is outside of the acceptable range of -0.8 to -1.2 , linearity of the assay will be compromised and quantification of the unknowns will be incorrect.

(b) RSDs of triplicate CPMs for standards should be below 30% as variability may affect the slope calculation and thereby quantification of samples.

(c) If the IC_{50} is out of the acceptable range ($2.0 \text{ nM} \pm 30\%$) then the assay should be considered suspect and rerun, as a shift in the curve will result in over- or underestimation of sample concentrations.

(d) QC check should be $3 \text{ nM STX} \pm 30\%$ (in-well concentration). Assays with a QC check sample out of specifications should trigger a check of the IC_{50} value.

The following criteria must be met for acceptability of a sample measurement:

(a) Sample quantification should be done only on dilutions that fall within B/B_0 of 0.2 – 0.7 . In the event that all sample dilutions fall below B/B_0 0.2 (i.e., concentration is too high), further dilutions must be made and the sample reanalyzed. In the event that the sample concentration is too low to be quantified (i.e., $B/B_0 > 0.7$), the sample is reported as below LOD. If more

Table 2011.27F. Dilution series to prepare bulk solutions for standard curve

| | Stock, M | In-assay, M |
|---|----------------------|---------------------|
| 100 μL 268.8 μM STX + 4.38 mL 0.003 M HCl | 6×10^{-6} | 1×10^{-6} |
| 500 μL 6×10^{-6} M + 4.5 mL 0.003 M HCl | 6×10^{-7} | 1×10^{-7} |
| 1.5 mL 6×10^{-7} M + 3.5 mL 0.003 M HCl | 1.8×10^{-7} | 3×10^{-8} |
| 500 μL 6×10^{-7} M + 4.5 mL 0.003 M HCl | 6×10^{-8} | 1×10^{-8} |
| 500 μL 1.8×10^{-7} M + 4.5 mL 0.003 M HCl | 1.8×10^{-8} | 3×10^{-9} |
| 500 μL 6×10^{-8} M + 4.5 mL 0.003 M HCl | 6×10^{-9} | 1×10^{-9} |
| 500 μL 6×10^{-9} M + 4.5 mL 0.003 M HCl | 6×10^{-10} | 1×10^{-10} |
| 5 mL 0.003 M HCl | 0 | Reference |

Table 2011.27G. Recommended microplate layout for ease of handling triplicate wells of standard curve, QC check sample, and unknown samples; each sample is run at three dilutions (1:10, 1:50, 1:200); standard curve is run in columns 1–3 (values are in M STX)^a

| Microplate row | Microplate column | | | | | | | | | | | |
|----------------|----------------------|----------------------|----------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| A | 10 ⁻⁶ | 10 ⁻⁶ | 10 ⁻⁶ | QC | QC | QC | U3 | U3 | U3 | U6 | U6 | U6 |
| | | | | | | | 1:50 | 1:50 | 1:50 | 1:10 | 1:10 | 1:10 |
| B | 10 ⁻⁷ | 10 ⁻⁷ | 10 ⁻⁷ | U1 | U1 | U1 | U3 | U3 | U3 | U6 | U6 | U6 |
| | | | | 1:10 | 1:10 | 1:10 | 1:200 | 1:200 | 1:200 | 1:50 | 1:50 | 1:50 |
| C | 3 × 10 ⁻⁸ | 3 × 10 ⁻⁸ | 3 × 10 ⁻⁸ | U1 | U1 | U1 | U4 | U4 | U4 | U6 | U6 | U6 |
| | | | | 1:50 | 1:50 | 1:50 | 1:10 | 1:10 | 1:10 | 1:200 | 1:200 | 1:200 |
| D | 10 ⁻⁸ | 10 ⁻⁸ | 10 ⁻⁸ | U1 | U1 | U1 | U4 | U4 | U4 | U7 | U7 | U7 |
| | | | | 1:200 | 1:200 | 1:200 | 1:50 | 1:50 | 1:50 | 1:10 | 1:10 | 1:10 |
| E | 3 × 10 ⁻⁹ | 3 × 10 ⁻⁹ | 3 × 10 ⁻⁹ | U2 | U2 | U2 | U4 | U4 | U | U7 | U7 | U7 |
| | | | | 1:10 | 1:10 | 1:10 | 1:200 | 1:200 | 1:200 | 1:50 | 1:50 | 1:50 |
| F | 10 ⁻⁹ | 10 ⁻⁹ | 10 ⁻⁹ | U2 | U2 | U2 | U5 | U5 | U5 | U7 | U7 | U7 |
| | | | | 1:50 | 1:50 | 1:50 | 1:10 | 1:10 | 1:10 | 1:200 | 1:200 | 1:200 |
| G | 10 ⁻¹⁰ | 10 ⁻¹⁰ | 10 ⁻¹⁰ | U2 | U2 | U2 | U5 | U5 | U5 | | | |
| | | | | 1:200 | 1:200 | 1:200 | 1:50 | 1:50 | 1:50 | | | |
| H | REF | REF | REF | U3 | U3 | U3 | U5 | U5 | U5 | | | |
| | | | | 1:10 | 1:10 | 1:10 | 1:200 | 1:200 | 1:200 | | | |

^a REF = Reference; QC = quality control check; U = unknown sample. [Note: The same standard curve may be used for multiple plates (i.e., 11 samples can be run on subsequent plates in a series if the standard curve is not included).]

than one dilution falls on the linear part of the curve, an average value calculated from all dilutions should be used. If there is disagreement between different dilutions in final concentration reported, check for error in the sample dilution process.

(b) RSD of the sample CPMs should be ≤30%.

Reference: *J. AOAC Int.* **95**, 795(2012)

Results and Discussion

Sample Characterization

All shellfish homogenates (MLV1–16) were analyzed by




Figure 2011.27. Sigmoidal dose response curve. Dashed lines indicate log IC₅₀.

HPLC using the precolumn oxidation method (AOAC Method **2005.06**) to determine toxin congener profiles and quantify total PST as µg STX diHCl equiv./kg prior to initiation of the study (Table 2). It is noteworthy that the clear majority of samples, irrespective of shellfish species and location, were dominated largely by STX and GTX2,3 whereas the N1-hydroxylated congeners NEO and GTX1,4 were virtually absent, except in blue mussel from the U.S. west coast. The most unusual profile was observed in green mussel, which was dominated by the weakly toxic N-sulfo-carbamoyl congeners C1,2. The samples were analyzed by the AOAC mouse bioassay (AOAC Method **959.08**) by three laboratories that routinely perform the mouse bioassay for regulatory purposes (Table 3). The mouse bioassay detection limit is approximately 400 µg STX diHCl equiv./kg (one laboratory reported values as low as 290 µg STX equiv./kg). Because the study design included samples that bracketed the lower regulatory limit of 400 µg STX diHCl equiv./kg, several samples were reported as being below the mouse bioassay detection limit. For samples in which all values were above the detection threshold, the between-laboratory RSD_R of the mouse bioassay was 18.9%.

Data Reporting and Initial RBA Data Review

Nine of the 10 laboratories that received the study materials completed the study and reported results. All nine carried out the practice assay and reported results to the coordinating laboratory, which evaluated the results and provided feedback to the participating laboratories before initiating the full study. Following completion of the full study, the participating laboratories provided all raw and calculated data for each of

the three assays performed via e-mail to the coordinating laboratory. The calculated results sheets were reviewed by the coordinating laboratory for obvious errors in sample dilutions and calculations, and for the use of the prescribed curve-fitting model. One laboratory used a sigmoidal curve-fitting model with the slope set to 1 (one-site binding curve in Prism), rather than the prescribed four-parameter logistic fit. In this case, the raw data were reanalyzed by the coordinating laboratory using the prescribed method. Obvious errors in calculation were corrected, such as accounting for the two-fold sample dilution resulting from the extraction process. In some cases, the participating laboratory carried out a fourth assay due to variability or inconsistency among dilutions for selected samples. In these cases, the value reported from the repeat (fourth) assay was used. One laboratory had consistent disagreement between the 1/50 and 1/200 dilutions when both fell within B/B_0 , 0.2–0.7. In all cases the 1/200 dilution overestimated almost two-fold relative to the 1/50 dilution, suggesting a systematic dilution error. In standard practice, these samples should be rerun. However, the instructions did not direct the participants to do so. Therefore, where there was corroborative evidence for the value reported by the 1/50 dilution, based on the 1/10 dilution, the 1/200 dilution was omitted. Where there was no basis on which to exclude the 1/200 value, an average value was calculated. This tended to result in an overestimate, and in two cases resulted in statistical outliers.

Overall Performance of the Method: Reproducibility

Table 2011.27A summarizes the results obtained for 21 individual shellfish samples analyzed in three RBAs, determined by nine participating laboratories. Samples 1–7 were analyzed in the first assay, samples 8–14 in the second assay, and samples 15–21 in the third assay. Among these samples were five blind duplicates, treated here as individual unknown samples. One sample (marked by an footnote a in Table 2011.27A) had a high variability in CPM between wells that was not attributable to any known cause, and was, therefore, omitted from analysis. Outliers identified by Grubbs test ($P < 0.01$) were excluded from the analysis (marked by footnote b in Table 2011.27A). The overall RSD_R among all 21 independent samples was 33.2%, resulting in an average HorRat value of 2.0 (Table 2011.27A). The HorRat values on individual samples ranged from 1.4 to 3.3, with a median value of 1.8. There was no apparent trend in reproducibility according to sample concentration or among shellfish species. If only the laboratories that are routine users of the RBA for PST (Laboratories 1–5) are included in the analysis, the average RSD_R is 23.1%, resulting in an average HorRat value of 1.4. Laboratory 9 tended to report the lowest values among the participating laboratories (14 of 21 samples), and although its individual sample values were not found to be statistical outliers, removing the results of this laboratory reduces all but one HorRat value (which remains unchanged), yielding an average HorRat value of 1.8 (range 1.0–2.8; Table 2011.27A). Removal of any other single laboratory's results does not appreciably change the overall study performance. The reason for the systematically low values reported by Laboratory 9 is not clear, since the assay parameters fall well within those reported by the other laboratories. Given that assay parameters are within normal range, one possible source of systematic error

could be incomplete extraction or pH adjustment of extracts, either of which would result in lower toxicity values.

A comparison of the RBA reproducibility with that of existing AOAC *Official Methods* is instructive. The AOAC collaborative study of the mouse bioassay (11), which entailed the analysis of seven samples representing three levels of STX-spiked shellfish by 11 participating laboratories, yielded a similar average RSD_R of 22%. More recent proficiency tests of the mouse bioassay performed in European regulatory laboratories report RSD_R of 2.3–38.3% on three samples run by eight laboratories (2) and RSD_R of 18.1–44.8% on two samples run by 20 laboratories (12). The mouse bioassay RSD_R values obtained in the current study ranged from 1.1 to 46.3% (average 19%) for three laboratories. The collaborative studies of the HPLC methods report reproducibility values for individual PST congeners, but do not report reproducibility of the composite toxic potency values. Collaborative study of the precolumn oxidation HPLC method (AOAC Method 2005.06) resulted in an average RSD_R of 27.0% and HorRat value of 1.3 (range 0.8–2.1) for STX following C18 cleanup, but the reproducibility of other congeners varied considerably, with the maximum HorRat value (4.7), exceeding the highest HorRat value obtained by RBA (3.3).

Because composite toxic potency values were not reported in the studies of the HPLC methods, it is uncertain how this variability influences the composite toxic potency calculated from these methods. The average and ranges of HorRat values obtained for different congeners were: neoSTX–1.7 (range 1.2–2.5); dcSTX–1.1 (range 0.6–2.1); GTX1,4–1.9 (range 1.1–4.2), GTX2,3–1.4 (range 0.8–1.9); B1–1.1 (range 0.7–1.9); and C1,2–1.6 (range 0.9–4.5). Because of the variability obtained in neoSTX, GTX1,4, C3,4, and B2, AOAC Method 2005.06 calls for a second SPE-COOH cleanup of samples suspected of containing these congeners, after which reproducibility improved somewhat: neoSTX–1.8 (range 1.3–2.1); GTX1,4–1.3 (range 1.0–2.1); and C3,4–1.2 (range 0.8–1.8). The postcolumn oxidation HPLC method (AOAC Method 2011.02) reported an average HorRat value of 0.6 for STX. In this method, neoSTX with an average HorRat of 1.9 (range 0.6–4.0) and GTX4 with an average HorRat of 1.6 (range 1.0–2.9) had reproducibility values that may affect the overall composite potency values. The maximum HorRat value (4.0) reported in this study also exceeded the maximum value reported in the RBA.

In summary, with the removal of Laboratory 9, the overall reproducibility of the RBA falls within the performance measures achieved by the established AOAC *Official Methods* for PST. The difference in reproducibility achieved by the laboratories that are routine users of the assay and participants who are not routine users of the method highlights the importance of training if this method were to be implemented in a regulatory setting.

Within-Laboratory Repeatability

Within-laboratory variability (RSD_r) was determined on five samples that were provided as blind duplicates. Participants were unaware that blind duplicates were included among the coded samples received. The duplicate samples were coded so that they were analyzed in separate assays, with different duplicate pairs falling into different assays (Table 1). One outlier was found among the results of the blind duplicates by Cochran's

test, $P < 0.025$ (Laboratory 7, sample MLV11) using the AOAC INTERNATIONAL Interlaboratory Study Workbook for Blind Duplicates, v2.0. An overall RSD_r of 25.1% was observed, with an RSD_R of 32.9%, yielding a HorRat value of 2.0, similar to that of the overall study (Table 2011.27B). When the performance of individual laboratories was evaluated separately, the average RSD_r was 22.2%, with individual laboratories varying from 11.8 to 34.4% (Table 2011.27C). Routine users of the microplate format of the PST RBA (Laboratories 1–5) obtained an average RSD_r of 17.1%, which is similar to that obtained in the SLV study (10), and lower than that obtained by nonroutine users (Laboratories 6–9), which averaged 26.1% and ranged as high as 34.4%. The AOAC collaborative study of the mouse bioassay (11) did not report RSD_r ; however, analysis of the data from that study using AOAC INTERNATIONAL's Interlaboratory Study Workbook for Blind Duplicates results in an average RSD_r of 16.5% for three STX-spiked samples. Proficiency testing of the mouse bioassay performed in eight French laboratories reported an average RSD_r of 8.3% on three samples (2). The analysis of blind duplicates in the collaborative study of the precolumn oxidation HPLC method (AOAC Method 2005.06) resulted in an RSD_r of 15.2% for STX following SPE C18 cleanup and an average RSD_r of 16.4% across all congeners, which ranged from 6.0 to 31.7%. Following SPE-COOH cleanup, repeatability was similar, with RSD_r of 17.2% across all congeners. The intralaboratory repeatability values obtained in the postcolumn oxidation HPLC method (AOAC Method 2011.02) averaged 6.4% for STX; most other congeners were similar, with neoSTX being the only congener that showed a somewhat higher RSD_r of 23.3%.

In summary, the within-laboratory repeatability of the RBA was found to be acceptable, with all but two laboratories achieving an RSD_r of 23.3% or less, and the routine users of the assay achieving an average RSD_r of 17.1%.

Spike Recovery

Three samples included in the study were homogenates of blue mussel spiked with STX diHCl at concentrations intended to bracket the regulatory limits of 800 μg STX equiv./kg used by most countries and 400 μg STX equiv./kg imposed in the Philippines. Nominal concentrations in the spiked samples were 200, 500, and 1200 μg STX equiv./kg. Also included in the study was the blue mussel homogenate to which the STX spikes had been added, which was determined to be negative for STX by the precolumn oxidation HPLC method. The negative control homogenate was reported as nondetectable by eight of nine laboratories. Recovery of spiked STX by the RBA was 84.4, 93.3, and 88.1%, respectively, for the 200, 500, and 1200 μg STX diHCl equiv./kg spike levels, and yielded a slope of 0.87 and r^2 of 0.86 (Figure 2). In the current study, the mouse bioassay reported < detection limit, and 68.6 and 40.5% recovery for the 200, 500, and 1200 μg STX diHCl equiv./kg spike levels. The AOAC collaborative study of the mouse bioassay (11) reported recoveries of 62.3% at spike levels similar to those in the current study (equivalent to 1000 μg STX diHCl equiv./kg) but higher recoveries of 81.5 and 96.0% were achieved at higher spike levels equivalent to 4000 and 8000 μg STX diHCl equiv./kg.

The observed poor recovery in the mouse bioassay at concentrations near and below the regulatory limit has been observed in other studies (2), and has been attributed to a

salt or protective effect of the shellfish matrix, which, for concentrations at or below the regulatory limit of 800 $\mu\text{g}/\text{kg}$, is injected undiluted into the mouse. The spike recovery observed in the precolumn HPLC method in this study is also somewhat low, with 54.0, 62, and 51.5% recovery at the 200, 500, and 1200 μg STX diHCl equiv./kg spike levels, respectively. The AOAC collaborative study of the precolumn HPLC method reported 74.4–76.8% at similar spike levels following SPE C18 cleanup and 63.7–68.2% following SPE-COOH cleanup (3, 4). In comparison, the postcolumn HPLC method reported 88–104% recovery of STX spiked at levels somewhat lower than the current study. The higher recovery of the RBA than the HPLC method in the current study may reflect the use of the 0.1 M HCl extraction method in the RBA as compared to the acetic acid extraction used in the HPLC methods.

We previously established in the SLV study that the RBA performs well with shellfish extracted using either method (10). In that study, the RBA reported slightly higher toxicity values for shellfish extracts made using the 0.1 M HCl method than the acetic acid extraction, yielding a correlation of 0.99 with a slope of 1.23 (10). The higher toxicity reported by the RBA in 0.1 M HCl extracts may reflect the hydrolysis of less toxic congeners to more toxic congeners.

Assay Parameters and Quality Metrics

Table 2011.27D summarizes the assay parameters and quality metrics for all laboratories. Eight of nine laboratories used microplate scintillation counters. Laboratory 4 used the manual counting method in which the microplate well filters are punched out, using an eight-place punch system, into traditional 4 mL scintillation vials and counted. Its performance using the manual counting method (RSD_r 17.4%) was similar to or better than that of the laboratories using the microplate method, indicating that using the manual counting method does not affect the performance of the assay. Similarly, there was no apparent difference in assay parameters when the Packard Top Count (single detector) was used, compared to the Wallac Microbeta (coincidence detector), although the reference CPM values obtained on the Top Count generally were somewhat lower due to differences in counting efficiency inherent in the differences in detector geometry. Eight of nine laboratories used GraphPad Prism for curve-fitting, while only Laboratory 5 used Wallac MultiCalc software. Values reported by Laboratory 5 fell well within the range of values reported by laboratories using Prism.

All assays resulted in slopes between -0.8 and -1.2 , as specified in the protocol. This specification reflects the fact that in a competitive binding assay for a ligand that interacts specifically at a single receptor site, the slope of the resulting standard curve should theoretically be 1.0. Although curve-fitting software packages often include a one-site binding curve that fixes the slope at 1.0, we specified in the protocol the use of the four-parameter logistic fit (also known as sigmoidal dose-response with variable slope), because it more readily identifies problems with the standard curve that may skew results. Laboratory 9 reported results using a one-site binding curve fit; in this case, the coordinating laboratory recalculated their raw data using the four-parameter logistic fit. The protocol also calls for $RSD\% < 30$ on all standards. Most analysts did not experience variability problems in the standard wells. Infrequent high RSD s were most often associated with the well

Table 2. Congener profiles in shellfish homogenates included in the collaborative study^a

| Sample name | Species | STX | NEO | dcSTX | GTX1,4 | GTX2,3 | dcGTX2,3 | B1 | C1,2 | C3,4 | Total PSP | µg STX diHCl equiv./kg |
|-------------|------------------------------|--------|-------|-------|--------|--------|----------|-------|--------|------|-----------|------------------------|
| MLV01 | Surf clam | 639.8 | | 74.0 | | 226.2 | 207.0 | | | | 1146.9 | 894.3 |
| MLV02 | Almeja clam | 298.3 | | | | 1290.1 | | 266.6 | | | 1855.0 | 802.1 |
| MLV03 | Chorito mussel | 77.6 | | | | 310.4 | | | | | 388.0 | 195.5 |
| MLV04 | Atlantic sea scallop | 831.6 | | | | 2785.6 | | | | | 3617.3 | 1890.2 |
| MLV05 | Atlantic sea scallop | 193.8 | | | | 576.2 | | | | | 770.0 | 412.8 |
| MLV06 | California mussel | 912.8 | | 10.9 | | 0.0 | | 233.8 | | | 1157.5 | 931.3 |
| MLV07 | Blue mussel, U.S. east coast | 548.2 | | | | 1097.3 | | | | | 1645.5 | 965.2 |
| MLV08 | Green mussel | 164.2 | | 63.5 | | | 272.3 | 454.8 | 3629.0 | | 4419.6 | 340.8 |
| MLV09 | Blue mussel, U.S. west coast | 432.3 | 124.9 | 8.7 | 353.7 | 727.8 | | 506.4 | | | 2153.9 | 1070.9 |
| MLV10 | Butter clam | 1763.5 | | 40.6 | | 533.2 | | 203.5 | | | 2540.8 | 2000.9 |
| MLV11 | Almeja clam | 159.1 | | 12.2 | | 185.5 | | | | | 356.8 | 236.9 |
| MLV12 | Blue mussel spike | 108.4 | | | | | | | | | 108.4 | 108.4 |
| MLV13 | Blue mussel spike | 310.2 | | | | | | | | | 310.2 | 310.2 |
| MLV14 | Blue mussel spike | 618.5 | | | | | | | | | 618.5 | 618.5 |
| MLV15 | Blue mussel blank | | | | | | | | | | 0.0 | 0.0 |
| MLV16 | Chorito mussel | 389.8 | | 14.3 | | 754.1 | | | | | 1158.1 | 684.9 |

^a Values for individual congeners are in µg/kg. Values for composite toxicity are in µg STX diHCl equiv./kg. Abbreviations for congeners are as follows: STX – saxitoxin; NEO – neosaxitoxin; dcSTX – decarbamoyl saxitoxin; GTX1,4 – gonyautoxin 1 and gonyautoxin 4; GTX2,3 – gonyautoxin 2 and gonyautoxin 3; B1 – gonyautoxin 5 (also known as sulfocarbamoyl STX B1); C1,2 – sulfocarbamoyl STX C1 and sulfocarbamoyl STX C2; C3,4 – sulfocarbamoyl STX C3 and sulfocarbamoyl STX C4.

Table 3. Mouse bioassay results on collaborative study samples from three laboratories^a

| Sample No. | Sample ID | MBA Lab A | MBA Lab B | MBA Lab C | MBA Avg. | MBA s _R | MBA RSD _R , % |
|------------|-----------|-----------|------------------|-----------|----------|--------------------|--------------------------|
| 1 | MLV05 | 400 | 415 | 340 | 385 | 39.7 | 10.3 |
| 2 | MLV06 | 550 | 597 | 540 | 562 | 30.4 | 5.4 |
| 3 | MLV08 | 440 | <dl ^b | 370 | 405 | 49.5 | 12.2 |
| 4 | MLV09 | 670 | 612 | 760 | 681 | 74.6 | 11.0 |
| 5 | MLV12 | <dl | <dl | <dl | — | — | — |
| 6 | MLV14 | 489 | 489 | 480 | 486 | 5.2 | 1.1 |
| 7 | MLV16 | 585 | 585 | 470 | 547 | 66.4 | 12.1 |
| 8 | MLV01 | 750 | 716 | 600 | 689 | 78.6 | 11.4 |
| 9 | MLV02 | 670 | 1115 | 590 | 792 | 282.9 | 35.7 |
| 10 | MLV04 | 2040 | <dl | 1080 | 1560 | 678.8 | 43.5 |
| 11 | MLV07 | 1480 | 748 | 670 | 966 | 446.8 | 46.3 |
| 12 | MLV09 | — | 594 | 670 | 602 | 11.3 | 1.9 |
| 13 | MLV11 | 380 | 379 | <dl | 380 | — | — |
| 14 | MLV13 | <dl | 343 | <dl | 343 | — | — |
| 15 | MLV03 | 400 | 364 | <dl | 382 | — | — |
| 16 | MLV05 | — | 396 | 370 | 383 | 18.4 | 4.8 |
| 17 | MLV06 | — | 702 | 630 | 666 | 50.9 | 7.6 |
| 18 | MLV07 | — | <dl | 690 | 690 | — | — |
| 19 | MLV10 | 1320 | 890 | 870 | 1027 | 254.2 | 24.8 |
| 20 | MLV11 | — | 364 | 290 | 327 | 52.3 | 16.0 |
| 21 | MLV15 | <dl | <dl | <dl | — | — | — |

^a Values are in µg STX diHCl equiv./kg.

^b dl = Detection limit.

in column 1 of the 96-well plate. Most analysts removed the suspect well from the curve-fitting process. When the RSD for a given standard was near the stated cutoff (e.g., 31–33%), and left in the curve-fitting process, there was no apparent effect on the curve parameters listed as criteria for assay acceptance.

The average IC₅₀ among all 27 assays was 1.9 + 0.45 nM (RSD_R 23.5%). The other assay quality metric called for by the protocol is the analysis of the QC check sample, which should be 3 ± 0.9 nM STX (30% RSD, in-well concentration). Four of the 27 assays had QC values outside the stated limits, with no obvious error responsible for the variability. Among these, Laboratory 7 reported 6.5 nM for the QC check in assay 3 and an IC₅₀ of 3.4 nM, which was outside the norm. Similarly, Laboratory 8 reported a QC of 1.5 nM in assay 2 and a low IC₅₀ of 1.4 nM, which is at the lower edge of acceptability. In general practice, these values would trigger repeating the assay. However, because of the minimal number of laboratories participating in the study, both of these assays were retained in the study. In neither case were the reported sample values systematically higher or lower than those reported in the other assays.

LOD and LOQ

The LOD was calculated based on the measurement of the negative control shellfish matrix (MLV15) using the blank + 3×SD approach according to Eurachem guidelines (13), as

recently applied to AOAC Method **2006.02**, an ELISA for domoic acid in shellfish using a similar four-parameter logistic curve (14). All laboratories reported <dl for this sample using the prescribed cutoff of B/B₀ <0.7 for quantification, with the exception of Laboratory 8, which was removed as an outlier as determined by Grubbs test (*P* < 0.01). If these samples are instead quantified using the B/B₀ values obtained, a mean of 5.5 ng/mL is obtained with an SD of 5.7 ng/mL, resulting in an LOD of 45 µg STX diHCl equiv./kg. Using the blank + 10×SD definition, an LOQ of 126 µg STX di HCl equiv./kg is thus obtained. We previously established empirically that a 1/10 dilution of shellfish extracts is sufficient to remove matrix effects in the RBA (10), when a quantification cutoff of B/B₀ <0.7 is used. This is the basis for the ten-fold minimum sample dilution used in the current study. The IC₇₀ values (B/B₀ 0.7) for all standard curves run in the study are presented in Table **2011.27D**. An average of 0.80 ± 0.188 nM STX diHCl was obtained across all assays, following the removal of one outlier based on the Grubbs test (*P* < 0.01). Applying the blank + 3×SD to this value, an LOD of 64 µg STX diHCl equiv./kg is obtained; applying the blank + 10×SD to this value results in an LOQ of 131 µg STX diHCl equiv./kg for a sample diluted 1/10 and extracted as indicated in the study, in fair agreement with the value calculated above.

Correlation with HPLC and Mouse Bioassay

Comparison of the RBA results with the mouse bioassay

| Nominal | Avg | S _R | RSD _R , % | Recovery, % |
|---------|------|----------------|----------------------|-------------|
| 200 | 169 | 58 | 34.6 | 84.4 |
| 500 | 466 | 133 | 28.5 | 93.3 |
| 1200 | 1057 | 228 | 21.7 | 88.1 |




Figure 2. Recovery of spiked STX diHCl in homogenates of blue mussel. Values are in $\mu\text{g STX diHCl equiv./kg}$.

results yielded an r^2 of 0.84 and a slope of 1.64, indicating that the RBA reports somewhat higher STX equivalents in shellfish, relative to the mouse bioassay (Figure 3). This overestimate has been previously reported for both RBA and HPLC methods (2, 9) at the STX levels near or below the regulatory limit, which are the focus of the current study. Consistent with these findings, the HPLC method also reported higher values than the mouse bioassay in this study, with a slope of 1.33 and an r^2 of 0.84. RBA results correlated better with the precolumn oxidation HPLC method, with a slope of 1.20 and an r^2 of 0.92.

RBA Yielded No False Negatives Relative to the Regulatory Limit

When the data from the three methods were sorted by increasing $\mu\text{g STX diHCl equiv./kg}$ as reported by the mouse bioassay, the RBA did not report any false negatives when compared to the regulatory limit of 800 $\mu\text{g STX equiv./kg}$ (Table 2011.27E). When compared with the precolumn oxidation HPLC method, only Laboratory 9 reported values lower than the HPLC method. The fact that the RBA reports somewhat higher toxicity than the mouse bioassay or HPLC at levels near or below the regulatory limit is beneficial from a food safety standpoint. The higher values reported presumably arise from better recoveries, as demonstrated above. From a shellfish producer's perspective, the improved detection limits relative to the mouse bioassay and better recovery of low toxin levels compared to the HPLC can help to provide advance warning of developing toxicity, allowing producers to harvest early, delay harvest, or move cultures, as appropriate.

Participants' Comments

Laboratory 6 participated in the study without previous

experience running receptor assays, and in doing so, identified several points needing clarification that have since been added to the proposed *Official Method* as enumerated in this report: (1) The vacuum required for filtration was not specified at 4–8" Hg, which is critical because insufficient vacuum pressure results in too slow a clearance of the wells, whereas too much pressure results in an airlock and no filtration at all. (2) Scintillation counting time for the microplates is 1 min/well. (3) Instructions have been added regarding how to calculate sample concentration if more than one dilution falls within B/B₀ 0.2–0.7; specifically, an average value should be calculated from all sample dilutions falling within B/B₀ 0.2–0.7. When corrected for dilution, serial sample dilutions should yield similar quantification. The absence of linearity between sample dilutions indicates either error in dilution or sample matrix interference; however, at the minimum sample dilutions recommended in the proposed *Official Method*, matrix effects from shellfish homogenates have not been encountered (10). In the current study, the nonlinearity of dilutions experienced in several samples by Laboratory 8 was not observed by the other laboratories, suggesting a systematic sample dilution issue rather than a sample matrix problem. Although experienced in RBAs in general, Laboratory 8 had not previously run the microplate filtration format of the assay for PST.

Laboratory 9, which reported generally lower values than the other laboratories, although familiar with the assay, had not performed it in more than a year. The lower values reported do not appear to be associated with conduct of the assay, or scintillation conduct of the assay, or scintillation counting, since the assay metrics are well within the averages reported by the other laboratories. Insufficient boiling or pH adjustment of sample extracts are a possible explanation. These points identified by the study participants should be added to the critical steps identified in the SLV study (10) that can affect precision and accuracy of the assay results, including: (1) ensure that the water is strongly boiling during extraction; (2) carefully adjust pH of extracts; (3) ensure even distribution of the membrane preparation across the microplate by frequent vortex-mixing or pipetting before and during its addition to the plate; (4) the wells must clear within 2–5 s during filtration; (5) the wash buffer should be ice-cold to minimize the rate of toxin release from the receptor; and (6) following addition of scintillant to the wells, incubate a minimum of 30 min to ensure that the scintillant fully penetrates the filters before counting.

Recommendations

The collaborative study of the RBA for PST was completed by nine laboratories representing six countries. Collaborators quantified PST as a composite toxicity value reported in $\mu\text{g STX di HCl equiv./kg}$ in a variety of shellfish species from different regions of the world, containing varied toxin congener profiles. The study included laboratories with extensive experience as well as others with little or no previous experience. The study also included both microplate and scintillation counters as end points, because either instrument type could potentially be used by test laboratories. The study demonstrates that the RBA yields adequate repeatability, reproducibility, and recovery for routine determination and monitoring of PST in shellfish. The greater precision attained by laboratories that received prior training on the RBA and routinely implement this assay suggests that




Figure 3. Correlation of the RBA results on PSP toxins in shellfish homogenates with mouse bioassay (A) and HPLC (B). Correlation between the current AOAC Official Methods, mouse bioassay, and HPLC (C).

the overall interlaboratory reproducibility can be further improved. It is recommended that this method be accepted by AOAC INTERNATIONAL as Official First Action for the determination of PST in shellfish.

Acknowledgments

We would like to thank Laurie Bean (Maine Department of Marine Resources), Stacey DeGrasse (U.S. Food and Drug Administration), Patrick Holland (Cawthron Institute), Gregg Langlois (California Department of Health Services), Bob Lona (Washington State Department of Health), and Benjamin

Suarez (University of Chile) for providing the shellfish material used in the study. We are grateful to Barbara Niedzwiadek and Dorothea Rawn (Health Canada) for HPLC analyses and to Laurie Bean and Darcie Couture (Maine Department of Marine Resources), Benjamin Suarez, and Supanoi Subsinserm (Thailand Department of Fisheries) for performing mouse bioassays. We are indebted to the following collaborators for their dedication and perseverance in carrying out the RBAs for this study:

Leanne Flewelling, Florida Wildlife and Marine Research Institute, St. Petersburg, FL

Stacey DeGrasse, U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, College Park, MD

Patrick Holland and Paul McNabb, Cawthron Institute, Nelson, New Zealand

Gregg Langlois and Melisa Masuda, California Department of Public Health, Richmond, CA

Richard Lewis and Åsa Andersson, University of Queensland, Queensland, Australia

Christina Mikulski, NOAA Marine Biotoxins Program, Charleston, SC

Elvira Sombrito and Aileen DeLeon (Philippine Nuclear Research Institute, Manila, the Philippines)

Kanitha Srisuksawad and Boonsom Porntepkasemsan, Thailand Nuclear Research Institute, Bangkok, Thailand

Aurelia Tubaro and Valeria Dell'Ovo, Dipartimento dei Materiali e Risorsa Naturali, Trieste, Italy

This project was funded by the International Atomic Energy Agency Interregional Project INT7017 9001 and NOAA Marine Biotoxins Program Project 02E0017. FDA saxitoxin diHCl used for tritiation by IICH and STX diHCl reference standard (NIST RM 8642) were provided by Sherwood Hall, FDA Office of Seafoods.

References

- (1) *Official Methods of Analysis* (1999) 17th Ed., AOAC INTERNATIONAL, Gaithersburg, MD, Method **959.08**
- (2) LeDoux, M., & Hall, S. (2000) *J. AOAC Int.* **83**, 305–310
- (3) Lawrence, J.F., Niedzwiadek, B., & Menard, C. (2005) *J. AOAC Int.* **88**, 1714–1732
- (4) *Official Methods of Analysis* (2005) 18th Ed., AOAC INTERNATIONAL, Gaithersburg, MD, Method **2005.06**
- (5) *Official Methods of Analysis* (2011) AOAC INTERNATIONAL, Gaithersburg, MD, Method **2011.02**
- (6) Jellett, J.F., Robert, R.L., Laycock, M.V., Quilliam, M.A., & Barrett, R.E. (2002) *Toxicon* **40**, 1407–1425. [http://dx.doi.org/10.1016/S0041-0101\(02\)00153-8](http://dx.doi.org/10.1016/S0041-0101(02)00153-8)
- (7) Hall, S., Strichartz, G., Moczydlowski, E., Ravindran, A., & Reichardt, P.B. (1990) in *Marine Toxins: Origin, Structure and Molecular Pharmacology*, S. Hall & G. Strichartz (Eds), ACS Symposium Series No. 418, American Chemical Society, Washington, DC, pp 29–65
- (8) Llewellyn, L.E. (2006) *Chem. Res. Toxicol.* **19**, 661–667. <http://dx.doi.org/10.1021/tx050277i>
- (9) Doucette, G.J., Logan, M.L., Ramsdell, J.S., & Van Dolah, F.M. (1997) *Toxicon* **35**, 625–636. [http://dx.doi.org/10.1016/S0041-0101\(96\)00189-4](http://dx.doi.org/10.1016/S0041-0101(96)00189-4)
- (10) Van Dolah, F.M., Leighfield, T.A., Doucette, G.J., Bean, L., Niedzwiadek, B., & Rawn, D.F.K. (2009) *J. AOAC Int.* **92**, 1705–1713
- (11) McFarran, E.F. (1959) *J. AOAC Int.* **42**, 263–271
- (12) EU Reference Laboratory for Marine Biotoxins (2010) *Report*

on the EURLMB 2010 proficiency testing on saxitoxin group (PSP) toxins determination, Vigo, Spain

- (13) Eurachem Guide (1998) *The Fitness for Purpose of Analytical Methods: A Laboratory Guide to Method Validation and Related Topics*, <http://www.eurachem.org/index.php/publications/guides/mv>
- (14) Kleivdahl, H., Kristiansen, S.-I., Nilson, M.A., Goksoyr, A., Briggs, L., Holland, P., & McNabb, P. (2007) *J. AOAC Int.* **90**, 1011–1027

Appendix: Rat Brain Membrane Preparation

The rat brain membrane preparation used in this assay can be produced in bulk, aliquotted, and stored at -80°C until use. Under this storage condition, the preparation is stable for a minimum of 6 months. The following protocol provides sufficient membrane preparation for a minimum of 125 plates and can be scaled up or down as needed.

A. Apparatus

- (a) *Teflon/glass homogenizer*.—Motorized tapered Teflon pestle and glass tube, 15 mL.
- (b) *Motorized tissue homogenizer*.—Polytron or small hand-held blender.
- (c) *High-speed centrifuge and fixed angle rotor*.—Capable of $20\,000 \times g$ (rcf).
- (d) *Centrifuge tubes*.—12–15 mL rated for $>20\,000 \times g$ (rcf).
- (e) *Plastic cryovials*.—2 mL.
- (f) *Graduated beaker*.—300 or 500 mL.
- (g) *Pipets*.—Disposable 5 and 10 mL.
- (h) *Forceps*.

B. Reagents

- (a) *20 Rat brains*.—Male, 6-week-old Sprague-Dawley (Hilltop Lab Animals, Inc., Scottsdale, PA; <http://hilltoplabs.com>) or equivalent.
- (b) *MOPS*.—pH 7.4 (Sigma, St. Louis, MO; Cat. No. M3183-500G).
- (c) *Choline chloride*.—100 mM (Sigma; Cat. No. C7527-500G).
- (d) *Phenyl methylsulfonyl fluoride (PMSF)*.—Sigma; Cat. No. P7626.
- (e) *Isopropanol*.

C. Procedure

(1) Prepare 1 L 100 mM MOPS buffer, pH 7.4, containing 100 mM choline chloride (detailed protocol in E, above) and 0.1 mM PMSF. PMSF must first be dissolved in isopropanol; dissolve 0.174 g PMSF in 10 mL isopropanol to make 100 mM stock. Aliquot and store at -20°C . Add PMSF (1/1000, 0.1 mM final concentration) to the MOPS/choline chloride buffer fresh on the day of use.

(2) Remove medulla and cerebellum from each brain using forceps and discard. Place the cerebral cortex (see Figure 1) in a small amount of ice-cold buffer and place on ice.

(3) Place one cerebral cortex in 12.5 mL MOPS/choline Cl/PMSF, pH 7.4, in glass/teflon homogenizer (two brains in 25 mL buffer will fit into 30 mL homogenizer tube). Homogenize at 70% full speed (385 rpm) with at least 10 up and down strokes (more if necessary to homogenize brain; there should be no visible chunks remaining in the homogenate). Keep tube in ice at all times. Pour homogenized tissue into 250 mL beaker on ice and repeat procedure with remaining cortices.




Figure 1. Rat brain.

(4) Transfer pooled homogenized tissue to centrifuge tubes, balance the tubes (pairwise; use ice-cold buffer to balance), and centrifuge at $20\,000 \times g$ for 15 min at 4°C .

(5) Aspirate the supernatant and resuspend the pellets in ice-cold MOPS/choline Cl/PMSF buffer, using an adequate amount (~ 5 mL) to fully resuspend the pellet (can use clean glass stir rod to break up pellet), not exceeding 10 mL per brain.

(6) Pool resuspended membrane preparation in a small beaker. Rinse centrifuge tubes with a small amount of ice-cold buffer to recover all of the membrane preparation. Bring total volume to 200 mL total (keep on ice).

(7) Keeping the beaker on ice, Polytron (or use a small hand-held blender at low speed) at 70% full speed for 20 s to obtain a consistent homogenate.

(8) Aliquot 2 mL/tube into cryovials. It is critical to keep the preparation well mixed while dispensing, e.g., prior to each aliquot to ensure equal allocation of protein/receptors to each vial. Keep cryotubes on ice.

(9) Freeze and store at -80°C . This preparation is stable for at least 6 months. Use a permanent marker to label the preparation date on the storage container.

D. Protein Assay

(a) Determine protein concentration of membrane preparation using Pierce Micro BCA Protein Assay Reagent Kit No. 23235 (microplate method) or No. 23225 (tube method) protein assay kit or equivalent protein assay (Thermo Fisher, Rockford, IL). The above protocol should yield 6–8 mg protein/mL of rat membrane preparation.

(b) Determine membrane dilution needed for the assay. The protein concentration in the daily working stock for the assay should be 1 mg/mL (this is diluted in the assay to yield 0.5 mg/mL in-assay concentration). Based on the protein concentration determined in the protein assay, determine the dilution needed to achieve 1 mg/mL. This is the dilution used in section E(e) above for all assays using this lot of membrane preparation. The protocol above typically yields a protein concentration that requires a dilution of 1/6–1/8. (Do not use less than 1/4 dilution or filtration wells may become clogged.) Protein concentration will need to be determined for each new batch of membrane preparation.

AOAC Official Method 2011.27
Paralytic Shellfish Toxins (PSTs) in Shellfish
Receptor Binding Assay
First Action 2011

[Applicable to the determination of paralytic shellfish toxins (PSTs), as μg STX diHCl equiv./kg, in shellfish (mussels, clams, scallops) at levels $>149 \mu\text{g}$ STX diHCl equiv./kg, with a limit of detection (LOD) of 45 STX diHCl equiv./kg shellfish and a limit of quantification (LOQ) of 126 μg STX diHCl equiv./kg shellfish.]

Caution: Wear disposable gloves and protective laboratory coat while performing the assay. PSTs are neurotoxins that are harmful if ingested. The assay uses a tritium labeled tracer, [^3H] STX, at low concentration. All laboratories performing the assay must have approved radiation laboratory space and must follow procedures prescribed by their nuclear regulatory agency for receipt, use, and disposal of isotopes.

See Tables 2011.27A–E for the results of the interlaboratory study supporting acceptance of the method.

A. Principle

Test portions of shellfish homogenates are extracted using the AOAC mouse bioassay extraction protocol (959.08), modified by scale. The PST receptor assay is a competitive binding assay in which [^3H] STX competes with unlabeled STX in standards or mixtures of PST in samples for a finite number of available receptor sites (site 1 on the voltage gated sodium channel) in a rat brain membrane preparation. Following establishment of binding equilibrium at 4°C, unbound [^3H] STX is removed by filtration and bound [^3H] STX is quantified by liquid scintillation counting. A standard curve is generated using increasing concentrations of STX standard from 10^{-10} to 10^{-6} M STX, which results in a reduction in bound [^3H] STX that is directly proportional to the amount of unlabeled toxin present. The concentration of toxin in samples is determined in reference to the standard curve. Incubation is carried out in a microplate format to minimize sample handling and the amount of radioactivity used. Bound [^3H] STX (as counts per minute; CPM) can be determined either by conventional or by microplate scintillation counting. Both methods are included in this protocol.

B. Apparatus and Supplies

- (a) *Traditional or microplate scintillation counter.*
- (b) *Micropipettors.*—1–1000 μL variable volumes and disposable tips.
- (c) *Eight channel pipettor.*—5–200 μL variable volume and disposable tips.
- (d) *96-Well microtiter filter plate.*—With 1.0 μm pore size type GF/B glass fiber filter/0.65 μm pore size Durapore support membrane (Millipore, Bedford, MA, USA; Cat. No. MSFB N6B 50).
- (e) *MultiScreen vacuum manifold.*—Millipore; Cat. No. NSVMHTS00.
- (f) *Vacuum pump.*
- (g) *Centrifuge tubes.*—15 and 50 mL, conical, plastic.
- (h) *Mini dilution tubes in 96-tube array.*
- (i) *Reagent reservoirs.*
- (j) *Ice bucket and ice.*
- (k) *Vortex mixer.*

- (l) *Sealing tape.*—Millipore; Cat. No. MATA HCL00.
- (m) *Volumetric flask.*—1 L.
- (n) *–80°C freezer.*
- (o) *Refrigerator.*

For traditional scintillation counter only:

- (p) *MultiScreen punch device.*—Millipore; Cat. No. MAMP 096 08.
 - (q) *MultiScreen disposable punch tips.*—Millipore; Cat. No. MADP 196 10.
 - (r) *MultiScreen punch kit B for 4 mL vials.*—Millipore; Cat. No. MAPK 896 0B.
 - (s) *Scintillation vials.*—4 mL.
- For sample extraction:
- (t) *Pipets.*
 - (u) *Centrifuge tubes.*—15 mL, conical, plastic.
 - (v) *Vacuum pump or house vacuum.*
 - (w) *pH meter or pH paper.*
 - (x) *Hot plate.*
 - (y) *Graduated centrifuge tubes.*—15 mL.
 - (z) *Centrifuge and rotor for 15 mL tubes.*

C. Reagents

- (a) [^3H] STX.—0.1 mCi/mL, ≥ 10 Ci/mmol, $\geq 90\%$ radiochemical purity (American Radiolabeled Chemicals, St. Louis, MO, USA, or International Isotopes Clearinghouse, Leawood, KS, USA).
 - (b) STX diHCl.—NIST RM 8642 (www.nist.gov).
 - (c) 3-Morpholinopropanesulfonic acid (MOPS).—Sigma (St. Louis, MO, USA; Cat. No. M3183-500G), or equivalent.
 - (d) Choline chloride.—Sigma (Cat. No. C7527-500G), or equivalent.
 - (e) *Rat brain membrane preparation.*—Appendix 1 [J. AOAC Int. (future issue)].
- For traditional counter:
- (f) *Scintiverse BD liquid scintillation cocktail.*—Fisher Scientific (Waltham, MA, USA; Cat. No. SX-18), or equivalent.
- For microplate counter:
- (g) *Optiphase liquid scintillation cocktail.*—PerkinElmer Life Sciences (Downers Grove, IL, USA; Cat. No. 1200-139), or equivalent.
- For sample extraction:
- (h) *Hydrochloric acid (HCl).*—1.0 and 0.1 M.
 - (i) *Sodium hydroxide.*—0.1 M.
 - (j) *Water.*—Distilled or deionized (18 $\mu\Omega$).

D. Sample Extraction

Accurately weigh 5.0 g tissue homogenate into a tared 15 mL conical tube. Add 5.0 mL of 0.1 M HCl, vortex, and check pH. If necessary, adjust pH to 3.0–4.0 as determined by a pH meter or pH paper. To lower pH, add 1 M HCl dropwise with mixing; to raise pH, add 0.1 M NaOH dropwise with mixing to prevent local alkalization and consequent destruction of toxin. Place the tube in a beaker of boiling water on hot plate for 5 min with the caps loosened. Remove and cool to room temperature. Check pH and adjust cooled mixture to pH 3.0–4.0 as described above. Transfer entire contents to graduated centrifuge tube and dilute volumetrically to 10 mL. Gently stir contents to homogeneity and allow to settle until portion of supernatant is translucent and can be decanted free of solid particles. Pour approximately 5 to 7 mL of the translucent supernatant into a centrifuge tube. Centrifuge at $3000 \times g$ for 10 min. Retain clarified supernatant and transfer to a clean centrifuge tube. Store extracts at -20°C until tested in

Table 2011.27A. Receptor binding assay results on individual samples (values are in µg STX diHCl equiv./kg shellfish tissue); summary statistics on all samples; summary statistics excluding Laboratory 9

| Assay | Sample | | | | | | | | | | All labs | | | | Labs 1-8 | | | | |
|-------|-----------------------|-------|------------------|-------------------|------|------|------|------|-------------------|-------------------|----------|------|----------------|----------------------|----------|------|----------------|----------------------|--------|
| | No. | ID | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Mean | S _R | RSD _R , % | HorRat | Mean | S _R | RSD _R , % | HorRat |
| Day 1 | 1 | MLV05 | 370 | 610 | 620 | 410 | 690 | 1070 | 630 | 660 | 330 | 599 | 222 | 37.1 | 2.2 | 633 | 212 | 33.5 | 2.0 |
| | 2 | MLV06 | 1100 | 1340 | 1320 | 1440 | 1260 | 1720 | 2080 | 2130 | 890 | 1476 | 422 | 28.6 | 1.9 | 1549 | 386 | 24.9 | 1.7 |
| Day 2 | 3 | MLV08 | 80 | 190 | 140 | 90 | 130 | 160 | 230 | 220 | 100 | 149 | 55 | 37.2 | 1.8 | 155 | 56 | 36.0 | 1.7 |
| | 4 | MLV09 | 860 | 680 | 950 | 870 | 980 | 1120 | 1460 | 820 | 590 | 926 | 255 | 27.5 | 1.7 | 968 | 237 | 24.5 | 1.5 |
| Day 3 | 5 | MLV12 | 180 ^a | 200 | 200 | 150 | 150 | 100 | 150 | 290 | 100 | 168 | 62 | 37.2 | 1.8 | 177 | 60 | 34.1 | 1.7 |
| | 6 | MLV14 | 950 | 940 | 1060 | 1130 | 1040 | 750 | 1460 | 1320 | 810 | 1051 | 228 | 21.7 | 1.4 | 1081 | 224 | 20.7 | 1.3 |
| Day 3 | 7 | MLV16 | 660 | 930 | 1080 | 870 | 840 | 1320 | 1490 | 2420 ^b | 490 | 960 | 329 | 34.3 | 2.1 | 1027 | 291 | 28.3 | 1.8 |
| | 8 | MLV01 | 1360 | 1520 | 1580 | 1110 | 1700 | 3180 | 1400 | 2780 | 520 | 1683 | 818 | 48.6 | 3.3 | 1829 | 739 | 40.4 | 2.8 |
| Day 3 | 9 | MVL02 | 830 | 1180 | 1130 | 1150 | 1130 | 1780 | 1340 | 980 | 690 | 1134 | 311 | 27.4 | 1.8 | 1190 | 281 | 23.6 | 1.5 |
| | 10 | MLV04 | 2440 | 2840 | 2910 | 1740 | 2150 | 1810 | 2690 | 2490 | 1210 | 2253 | 572 | 25.4 | 1.8 | 2384 | 446 | 18.7 | 1.3 |
| Day 3 | 11 | MLV07 | 1260 | 1540 | 1220 | 1980 | 1760 | 1530 | 1660 | 1210 | 840 | 1444 | 345 | 23.9 | 1.6 | 1520 | 279 | 18.3 | 1.2 |
| | 12 | MLV09 | 810 | 1190 | 1130 | 810 | 1630 | 1390 | 1880 | 1120 | 870 | 1203 | 372 | 30.9 | 2.0 | 1245 | 375 | 30.1 | 2.0 |
| Day 3 | 13 | MLV11 | 270 | 370 | 480 | 340 | 640 | 490 | 240 | 600 | 110 | 393 | 174 | 44.3 | 2.4 | 429 | 148 | 34.4 | 1.9 |
| | 14 | MLV13 | 400 | 1240 ^b | 560 | 450 | 650 | 530 | 500 | 440 | 200 | 466 | 133 | 28.5 | 1.6 | 504 | 85 | 16.8 | 1.0 |
| Day 3 | 15 | MLV03 | 330 | 270 | 410 | 180 | 590 | 680 | 370 | 1570 ^b | 90 | 365 | 197 | 54.0 | 2.9 | 404 | 176 | 43.5 | 2.4 |
| | 16 | MLV05 | 580 | 670 | 250 | 430 | 910 | 700 | 860 | 940 | 300 | 627 | 257 | 41.1 | 2.4 | 668 | 242 | 36.2 | 2.1 |
| Day 3 | 17 | MLV06 | 1290 | 1520 | 1460 | 970 | 1800 | 2520 | 1470 | 870 | 1250 | 1461 | 488 | 33.4 | 2.2 | 1488 | 515 | 34.6 | 2.3 |
| | 18 | MLV07 | 1010 | 1600 | 1390 | 1000 | 1720 | 1860 | 1520 | 2150 | 890 | 1460 | 429 | 29.4 | 2.0 | 1531 | 397 | 26.0 | 1.7 |
| Day 3 | 19 | MLV10 | 1640 | 2130 | 2800 | 2660 | 2330 | 1850 | 3390 | 2740 | 1830 | 2374 | 570 | 24.0 | 1.7 | 2443 | 569 | 23.3 | 1.7 |
| | 20 | MLV11 | 430 | 350 | 460 | 280 | 550 | 620 | 1149 ^b | 410 | 250 | 419 | 127 | 30.2 | 1.7 | 443 | 115 | 26.0 | 1.4 |
| Day 3 | 21 | MLV15 | ND ^c | ND | ND | ND | ND | ND | ND | 180 | ND | — | — | — | — | — | — | — | — |
| | Avg. RSD _R | | | | | | | | | | | | | 33.2 | 2.0 | | | 28.7 | |
| | Avg. HorRat | | | | | | | | | | | | | | | | | | |

^a CV 41%, not used in calculations.

^b Outlier; not used in calculations.

^c ND = Not detected.

Table 2011.27B. Summary statistics on blind duplicates, run in separate assays (values are in μg STX diHCl equiv./kg)

| Lab | MLV05 | | MLV06 | | MLV07 | | MLV09 | | MLV11 | | Avg. |
|--------------------|---------|---------|---------|---------|---------|---------|---------|---------|------------------|-------------------|------|
| | Assay 1 | Assay 2 | Assay 1 | Assay 2 | Assay 1 | Assay 2 | Assay 1 | Assay 2 | Assay 1 | Assay 2 | |
| 1 | 370 | 580 | 1100 | 1290 | 1260 | 1010 | 860 | 810 | 270 | 430 | |
| 2 | 610 | 670 | 1340 | 1520 | 1540 | 1530 | 680 | 1190 | 370 | 350 | |
| 3 | 620 | 250 | 1320 | 1460 | 1220 | 1390 | 950 | 1130 | 480 | 401 | |
| 4 | 410 | 430 | 1440 | 970 | 1980 | 1000 | 870 | 810 | 340 | 280 | |
| 5 | 690 | 910 | 1260 | 1790 | 1760 | 1720 | 980 | 1630 | 640 | 550 | |
| 6 | 1070 | 700 | 1720 | 2520 | 1530 | 1860 | 1120 | 1390 | 490 | 620 | |
| 7 | 630 | 880 | 2090 | 1240 | 1750 | 1150 | 1460 | 1830 | 230 ^a | 1149 ^a | |
| 8 | 660 | 940 | 2130 | 870 | 1210 | 2150 | 820 | 1120 | 600 | 410 | |
| 9 | 330 | 300 | 890 | 1250 | 840 | 890 | 590 | 870 | 110 | 250 | |
| Avg. | | 614 | | 1453 | | 1433 | | 1062 | | 416 | |
| S_r | | 169 | | 432 | | 366 | | 247 | | 83 | |
| S_R | | 239 | | 444 | | 387 | | 338 | | 152 | |
| RSD _r % | | 27.5 | | 29.4 | | 25.5 | | 23.3 | | 20.0 | 25.1 |
| RSD _R % | | 38.9 | | 30.2 | | 27.0 | | 31.9 | | 36.5 | 32.9 |
| HorRat | | 2.3 | | 2.0 | | 1.8 | | 2.0 | | 2.0 | 2.0 |

^a Outlier; not used in calculation.

receptor assay.

E. Preparation of Stock Solutions and Standards

(a) *Assay buffer*.—100 mM MOPS/100 mM choline chloride, pH 7.4. Weigh out 20.9 g MOPS and 13.96 g choline chloride and add to 900 mL dH₂O. Adjust pH to 7.4 with NaOH while stirring and bring to a final volume of 1 L with dH₂O. Store at 4°C.

(b) *Radioligand solution*.—Calculate the concentration of [³H] STX stock provided by the supplier, which may vary between lots. Suppliers generally provide the specific activity in Ci/mmol (generally 10–30 Ci/mmol) and activity in mCi/mL (0.05–0.1 mCi/mL), from which the molar concentration can be calculated. Prepare 4 mL of a 15 nM working stock of [³H] STX fresh daily in 100 mM MOPS/100 mM choline chloride buffer. This will provide sufficient volume for one 96-well plate at an in-well concentration of 2.5 nM. Measure total counts of each working stock prior to running an assay: add 35 μL of the working stock [³H] STX in buffer to a liquid scintillation vial with 4 mL scintillant and count on a traditional liquid scintillation counter. This is done to confirm correct dilution prior to running the assay. Depending on the efficiency of the scintillation counter used, the corresponding CPM will vary, but should be consistent day-to-day and within 15% of the expected value.

(c) *Unlabeled STX standard working solution*.—The STX diHCl standard is provided at a concentration of 268.8 μM (100 $\mu\text{g}/\text{mL}$). A “bulk” standard curve can be made up in advance and stored at 4°C for up to 1 month. The use of a bulk standard curve minimizes the pipetting needed for setting up an assay routinely and improves day-to-day repeatability. Make up 3 mM HCl (e.g., from a 3 M stock, 50 μL in 50 mL), then perform the serial dilutions (see Table 2011.27F) of NIST RM 8642 STX diHCl (100 $\mu\text{g}/\text{mL}$ = 268.8 μM) to make up the standard curve in 3 mM HCl. These standard stock solutions will be diluted 1/6 in the assay to yield the designated in-assay concentrations (see Table 2011.27F).

(d) *Interassay calibration standard (QC check)*.—Prepare a

reference standard containing 1.8×10^{-8} M STX standard (3.0×10^{-9} M STX in assay) in advance in 3 mM HCl and keep frozen (–80°C) in 1 mL aliquots for long-term storage. Aliquots should be thawed and stored at 4°C for routine use (stable up to 1 month) and analyzed in each assay. This serves as a QC check and confirms day-to-day performance of the assay.

(e) *Rat brain membrane preparation*.—Prepare rat brain membrane preparation in bulk [Appendix I; J. AOAC Int. (future issue)] and store at –80°C until used in the assay. Thaw an aliquot of rat brain membrane preparation on ice. Dilute membrane preparation with cold (4°C) 100 mM MOPS/100 mM choline chloride, pH 7.4, to yield a working stock with a protein concentration of 1.0 mg/mL (this will be diluted in the assay plate to 0.5 mg/mL in-well concentration). Vortex vigorously to achieve a visibly homogeneous suspension. Keep the diluted membrane preparation on ice until ready to use.

F. Performing the Assay

(a) *Plate setup*.—When possible, use a multichannel pipet to minimize pipetting effort and increase consistency. Standard curve, QC check, and sample extracts are run in triplicate wells. Multiple dilutions of sample extracts should be analyzed in order to obtain a value that falls between 0.2–0.7 B/B₀ on the standard curve for quantification. For ease of analysis, it is convenient to use a standard plate layout that maximizes the number of samples and standards that can be analyzed on one plate. For shellfish extracts, a minimum dilution of 1:10 is used, which minimizes potential matrix effects, while still providing an LOQ of approximately 126 $\mu\text{g}/\text{kg}$ shellfish (see Table 2011.27G).

(b) *Addition of samples and standards*.—Add in the following order to each of the 96 wells: 35 μL assay buffer; 35 μL STX standard, QC check, or sample extract; 35 μL [³H] STX; 105 μL membrane preparation. The assay buffer is added first in order to wet the filter membrane. It is critical to continuously mix the membrane preparation by careful up-and-down pipetting immediately prior to

Table 2011.27C. Performance of individual laboratories on blind duplicates (values are in µg STX diHCl equiv./kg)

| Laboratory | ID | Day 1 | Day 2 | Mean | s _p | RSD _p , % |
|--------------|-------|------------------|-------------------|------|----------------|----------------------|
| 1 | MLV05 | 370 | 580 | 475 | 148 | 31.3 |
| | MLV06 | 1100 | 1290 | 1195 | 134 | 11.2 |
| | MLV07 | 1260 | 1010 | 1135 | 177 | 15.6 |
| | MLV09 | 860 | 810 | 835 | 35 | 4.2 |
| | MLV11 | 270 | 430 | 350 | 113 | 32.3 |
| Avg. | | | | | | 18.9 |
| 2 | MLV05 | 605 | 670 | 638 | 46 | 7.2 |
| | MLV06 | 1340 | 1520 | 1430 | 127 | 8.9 |
| | MLV07 | 1540 | 1530 | 1535 | 7 | 0.5 |
| | MLV09 | 680 | 1190 | 935 | 361 | 38.6 |
| | MLV11 | 370 | 350 | 360 | 14 | 3.9 |
| Avg. | | | | | | 11.8 |
| 3 | MLV05 | 620 | 250 | 435 | 262 | 60.1 |
| | MLV06 | 1320 | 1460 | 1390 | 99 | 7.1 |
| | MLV07 | 1220 | 1303 | 1262 | 59 | 4.7 |
| | MLV09 | 950 | 1130 | 1040 | 127 | 12.2 |
| | MLV11 | 480 | 460 | 470 | 14 | 3.0 |
| Avg. | | | | | | 17.4 |
| 4 | MLV05 | 410 | 430 | 420 | 14 | 3.4 |
| | MLV06 | 1440 | 970 | 1205 | 332 | 27.6 |
| | MLV07 | 1980 | 1000 | 1490 | 693 | 46.5 |
| | MLV09 | 870 | 810 | 840 | 42 | 5.1 |
| | MLV11 | 340 | 280 | 310 | 42 | 13.7 |
| Avg. | | | | | | 19.2 |
| 5 | MLV05 | 690 | 910 | 800 | 156 | 19.4 |
| | MLV06 | 1260 | 1790 | 1525 | 375 | 24.6 |
| | MLV07 | 1760 | 1720 | 1740 | 28 | 1.6 |
| | MLV09 | 980 | 1630 | 1305 | 460 | 35.2 |
| | MLV11 | 640 | 550 | 595 | 64 | 10.7 |
| Avg. | | | | | | 18.3 |
| 6 | MLV05 | 1070 | 700 | 885 | 262 | 29.6 |
| | MLV06 | 1720 | 2520 | 2120 | 566 | 26.7 |
| | MLV07 | 1530 | 1860 | 1695 | 233 | 13.8 |
| | MLV09 | 1120 | 1390 | 1255 | 191 | 15.2 |
| | MLV11 | 490 | 620 | 555 | 92 | 16.6 |
| Avg. | | | | | | 20.4 |
| 7 | MLV05 | 630 | 880 | 755 | 177 | 23.4 |
| | MLV06 | 2090 | 1240 | 1665 | 601 | 36.1 |
| | MLV07 | 1750 | 1150 | 1450 | 424 | 29.3 |
| | MLV09 | 1460 | 1830 | 1645 | 262 | 15.9 |
| | MLV11 | 230 ^a | 1150 ^a | | | |
| Avg. | | | | | | 26.2 |
| 8 | MLV05 | 660 | 940 | 800 | 198 | 24.7 |
| | MLV06 | 2130 | 870 | 1500 | 891 | 59.4 |
| | MLV07 | 1210 | 2150 | 1680 | 665 | 39.6 |
| | MLV09 | 820 | 1120 | 970 | 212 | 21.9 |
| | MLV11 | 600 | 410 | 505 | 134 | 26.6 |
| Avg. | | | | | | 34.4 |
| 9 | MLV05 | 330 | 300 | 315 | 21 | 6.7 |
| | MLV06 | 890 | 1250 | 1070 | 255 | 23.8 |
| | MLV07 | 840 | 890 | 865 | 35 | 4.1 |
| | MLV09 | 590 | 870 | 730 | 198 | 27.1 |
| | MLV11 | 110 | 250 | 180 | 99 | 55.0 |
| Avg. | | | | | | 23.3 |
| Overall avg. | | | | | | 22.2 |

^a Outlier; not used in calculations.

dispensing into the 96-well plate to maintain an even suspension across the entire plate. Cover and incubate plate at 4°C for 1 h.

(c) *Assay filtration.*—Attach the vacuum manifold to the vacuum pump with an in-line side arm flask to catch filtrate from the plate filtration process. Set the vacuum pressure gauge on the pump or vacuum manifold to 4–8" Hg (135–270 millibar), as specified in the instructions provided with the filtration plates. Place the 96-well plate on the vacuum manifold. Fill empty wells with 200 µL MOPS/choline chloride buffer to ensure even vacuum pressure and filtration across the plate. Turn on vacuum. Optimum vacuum will pull the wells to dryness in 2–5 s. Pull contents of all wells through until all liquid is removed. (*Note:* Too low a vacuum will result in slow well clearance, but too high will result in an airlock and no well clearance.) With vacuum pump running, quickly rinse each well twice with 200 µL ice cold MOPS/choline chloride buffer using multichannel pipet. Maintain vacuum until liquid is removed.

(d) *Preparation of the assay for counting.*—Remove the plastic bottom from the plate. Blot the bottom once on absorbent toweling.

(1) *For counting in microplate scintillation counter.*—Place the microplate in a counting cassette. Seal the bottom of the 96-well plate with sealing tape. Add 50 µL Optiphase scintillation cocktail per well using multichannel pipet. Seal the top of the plate with sealing tape. Allow to incubate 30 min at room temperature. Place the plate in a counting cassette and count in a microplate scintillation counter for 1 min/well.

(2) *For counting in traditional scintillation counter.*—Place the microplate in the MultiScreen punch system apparatus. Place the disposable punch tips on top of the microplate. Punch the filters from the wells into scintillation vials and fill with 4 mL scintillation cocktail (Scintiverse or equivalent). Place caps on the vials and vortex. Allow vials to sit overnight in the dark, then count using a tritium window in a traditional scintillation counter.

G. Analysis of Data

For assays performed using the traditional counter, curve fitting is performed using a four-parameter logistic fit, also known as a sigmoidal dose response curve (variable slope; *see* Figure 2011.27), or Hill equation:

$$y = \min + \frac{\max - \min}{1 + 10^{(x - \log IC_{50}) \text{Hill slope}}}$$

where max is the top plateau representing maximum binding in CPM in the absence of competing nonradiolabeled STX, also known as B₀; min is the bottom plateau, equal to nonspecific binding (in CPM) in the presence of saturating nonradiolabeled toxin; IC₅₀ is the inhibitory concentration at which CPM are 50% of max-min (dashed lines; Figure 2011.27); Hill slope is the slope of the curve; x axis is the log concentration of STX; and y axis is total ligand binding in CPM (here represented as B/B₀, or bound/max bound). A curve fitting package such as Prism (Graph Pad Software, Inc.) is recommended. For the microplate counter users, receptor assay applications provided by the manufacturer may be used (e.g., MultiCalc; PerkinElmer Wallac, Gaithersburg, MD, USA).

(a) *Sample quantification.*—Sample quantification is carried out only on dilutions that fall within B/B₀ of 0.2–0.7, where B represents the bound [³H]STX (in CPM) in the sample and B₀ represents the max bound [³H]STX (in CPM). Where more than one dilution falls within B/B₀ of 0.2–0.7 on the curve, all sample wells corresponding to these dilutions are used to calculate sample concentration. Sample concentration is calculated in µg STX diHCl

Table 2011.27D. Calibration curve and QC check parameters in three receptor binding assays performed in nine participant laboratories

| Lab | Assay day | Slope | IC ₅₀ ^a , nM | QC, nM | Reference, CPM | IC ₇₀ ^a , nM | Standards where RSD >30%; action | Curve fitting software | Scintillation counter | Manual/microplate |
|-----|-----------|-------|------------------------------------|------------------|----------------|------------------------------------|----------------------------------|------------------------|-----------------------|-------------------|
| 1 | 1 | -0.9 | 1.9 | 2.4 | 720 | 0.90 | None | Prism v 3.02 | Packard Top Count | Microplate |
| | 2 | -1.0 | 2.0 | 2.6 | 733 | 0.96 | None | | | |
| | 3 | -1.1 | 2.1 | 3.2 | 1038 | 0.92 | None | | | |
| 2 | 1 | -1.1 | 1.8 | 3.8 | 1160 | 0.66 | 3 nM; 1 well removed | Prism v 5.0 | Packard Top Count | Microplate |
| | 2 | -1.2 | 2.2 | 3.9 | 1260 | 0.85 | None | | | |
| | 3 | -1.0 | 1.6 | 3.2 | 1262 | 0.46 | 3 nM, 1 nM removed | | | |
| 3 | 1 | -1.0 | 2.0 | 2.3 | 2529 | 0.41 | First column removed | Prism v 5.0 | Wallac Microbeta | Microplate |
| | 2 | -0.9 | 2.0 | 2.5 | 1463 | 0.92 | 1000 nM; 1 well removed | | | |
| | 3 | 1.0 | 1.6 | 2.8 | 2088 | 0.80 | None | | | |
| 4 | 1 | -0.9 | 1.7 | 3.4 | 1125 | 0.61 | None | Prism v 3.03 | PerkinElmer Tricarb | Manual |
| | 2 | -1.2 | 1.7 | 3.2 ^a | 1611 | 0.77 | None | | | |
| | 3 | -0.9 | 1.2 | 2.9 | 1324 | 0.45 | 30 nM 35%; 1 well removed | | | |
| 5 | 1 | -0.9 | 1.4 | 3.3 | 1566 | 0.64 | 1.0 nM; 1 well removed | MultiCalc | Wallac Microbeta | Microplate |
| | 2 | -1.2 | 1.8 | 3.6 | 1528 | 1.05 | 0.1 nM and 30 nM; 1 well removed | | | |
| | 3 | -1.2 | 1.8 | 2.9 | 1052 | 0.67 | None | | | |
| 6 | 1 | -1.1 | 2.6 | 3.0 | 670 | 1.15 | None | Prism v 4.0 | Wallac Microbeta | Microplate |
| | 2 | -1.0 | 2.0 | 4.0 ^b | 1124 | 1.08 | None | | | |
| | 3 | -1.1 | 3.4 | 6.5 ^b | 1030 | 2.04 ^c | None | | | |
| 7 | 1 | -0.8 | 1.0 | 2.8 ^a | 919 | 0.33 | None | Prism | Wallac Microbeta | Microplate |
| | 2 | -1.0 | 1.6 | 2.7 | 619 | 0.70 | None | | | |
| | 3 | -0.9 | 2.1 | 3.2 ^a | 693 | 0.82 | None | | | |
| 8 | 1 | -1.2 | 1.7 | 3.7 | 1146 | 0.86 | None | Prism | Wallac Microbeta | Microplate |
| | 2 | -1.1 | 1.4 | 1.5 ^b | 1095 | 0.78 | None | | | |
| | 3 | -1.1 | 2.4 | 2.3 | 886 | 1.04 | None | | | |
| 9 | 1 | -1.0 | 2.2 | 4.0 ^b | 1363 | 0.97 | None | Prism | Wallac Microbeta | Microplate |
| | 2 | -1.0 | 2.0 | 3.2 | 1380 | 0.85 | 100 nM 33%; left in | | | |
| | 3 | -1.0 | 2.1 | 3.7 | 1532 | 0.92 | None | | | |

^a One well removed.

^b Outside of specifications.

^c Outlier by Grubbs test.

Table 2011.27E. Results of the receptor binding assay (RBA), mouse bioassay (MBA), and HPLC analyses of 21 shellfish extracts, sorted by mouse bioassay value (all values are in μg STX diHCl equiv./kg shellfish tissue; results in bold indicate toxicity above the 800 μg STX diHCl equiv./kg regulatory limit; all other results indicate toxicity below the regulatory limit)

| Sample | Lab 1 | Lab 2 | Lab 3 | Lab 4 | Lab 5 | Lab 6 | Lab 7 | Lab 8 | Lab 9 | RBA, avg. | HPLC | MBA |
|--------|-----------------|-------------------------|-------------|-------------|-------------|-------------------------|-------------------------|-------------------------|-------------|-------------|-------------|-------------|
| 21 | ND ^a | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| 5 | 180 | 200 | 200 | 150 | 150 | 100 | 150 | 290 | 100 | 168 | 108 | ND |
| 15 | 330 | 270 | 410 | 180 | 590 | 680 | 370 | 1570^b | 90 | 365 | 196 | 182 |
| 13 | 270 | 370 | 480 | 340 | 640 | 290 | 240 | 600 | 110 | 371 | 236 | 299 |
| 20 | 430 | 350 | 460 | 280 | 550 | 490 | 1150^b | 410 | 250 | 403 | 236 | 299 |
| 14 | 400 | 1240^b | 560 | 450 | 650 | 530 | 500 | 440 | 200 | 466 | 625 | 343 |
| 1 | 370 | 610 | 620 | 410 | 690 | 1070^b | 630^b | 660 | 330 | 599 | 413 | 387 |
| 16 | 580 | 670 | 250 | 430 | 910 | 700 | 860^b | 940^b | 300 | 627 | 413 | 387 |
| 3 | 80 | 190 | 140 | 90 | 130 | 160 | 230 | 220 | 100 | 149 | 341 | 405 |
| 6 | 950 | 940 | 1060 | 1130 | 1040 | 750 | 1460 | 1320 | 810 | 1051 | 618 | 485 |
| 7 | 660 | 930 | 1080 | 870 | 840 | 1320 | 1490 | 2420 | 490 | 960 | 685 | 528 |
| 2 | 1100 | 1340 | 1320 | 1440 | 1260 | 1720 | 2080 | 2130 | 890 | 1476 | 931 | 595 |
| 17 | 1290 | 1520 | 1460 | 970 | 1800 | 2520 | 1470 | 870 | 1250 | 1460 | 931 | 595 |
| 4 | 860 | 680 | 950 | 870 | 980 | 1120 | 1460 | 820 | 590 | 926 | 1070 | 653 |
| 12 | 810 | 1190 | 1130 | 810 | 1630 | 1390 | 1880 | 1120 | 870 | 1203 | 1070 | 653 |
| 11 | 1260 | 1540 | 1220 | 1980 | 1760 | 1530 | 1660 | 1210 | 840 | 1444 | 965 | 714 |
| 18 | 1010 | 1600 | 1390 | 1000 | 1720 | 1860 | 1520 | 2150 | 890 | 1452 | 965 | 714 |
| 8 | 1360 | 1520 | 1580 | 1110 | 1700 | 3180 | 1400 | 2780 | 520 | 1683 | 894 | 752 |
| 9 | 830 | 1180 | 1130 | 1150 | 1130 | 1780 | 1340 | 980 | 690 | 1134 | 802 | 792 |
| 19 | 1640 | 2130 | 2800 | 2660 | 2330 | 1850 | 3390 | 2740 | 1830 | 2374 | 2000 | 1027 |
| 10 | 2440 | 2840 | 2910 | 1740 | 2150 | 1800 | 2690 | 2490 | 1210 | 2252 | 1890 | 1080 |

^a ND = Not detected.

^b Outlier; not used in average calculation.

equiv./kg shellfish, using the following formulas:

$$(\text{nM STX equiv.}) \times (\text{sample dilution}) \times \frac{(210 \mu\text{L total volume})}{35 \mu\text{L sample}} = \text{nM STX equiv. in extract}$$

$$(\text{nM STX diHCl equiv. in extract}) \times \frac{1 \text{ L}}{1000 \text{ mL}} \times \frac{372 \text{ ng}}{\text{nmol}} \times \frac{1 \mu\text{g}}{1000 \text{ ng}} = \mu\text{g STX diHCl equiv./mL}$$

$$\mu\text{g STX diHCl equiv./mL} \times \frac{\text{mL extract}}{\text{g shellfish}} \times \frac{1000 \text{ g}}{\text{kg}} = \mu\text{g STX diHCl equiv./kg}$$

H. Assay Performance Standards

The following criteria must be met for assay acceptance:

(a) For a ligand that specifically binds at one receptor site, the slope of the resulting competition curve should theoretically be -1.0 . If the slope of the curve for a given assay is outside of the acceptable range of -0.8 to -1.2 , linearity of the assay will be compromised and quantification of the unknowns will be incorrect.

(b) RSDs of triplicate CPMs for standards should be below 30% as variability may affect the slope calculation and thereby quantification of samples.

(c) If the IC_{50} is out of the acceptable range ($2.0 \text{ nM} \pm 30\%$)

then the assay should be considered suspect and rerun, as a shift in the curve will result in over- or underestimation of sample concentrations.

(d) QC check should be $3 \text{ nM STX} \pm 30\%$ (in-well concentration).

Table 2011.27F. Dilution series to prepare bulk solutions for standard curve

| | Stock, M | In-assay, M |
|---|----------------------|---------------------|
| 100 μL 268.8 μM STX + 4.38 mL 0.003 M HCl | 6×10^{-6} | 1×10^{-6} |
| 500 μL 6×10^{-6} M + 4.5 mL 0.003 M HCl | 6×10^{-7} | 1×10^{-7} |
| 1.5 mL 6×10^{-7} M + 3.5 mL 0.003 M HCl | 1.8×10^{-7} | 3×10^{-8} |
| 500 μL 6×10^{-7} M + 4.5 mL 0.003 M HCl | 6×10^{-8} | 1×10^{-8} |
| 500 μL 1.8×10^{-7} M + 4.5 mL 0.003 M HCl | 1.8×10^{-8} | 3×10^{-9} |
| 500 μL 6×10^{-8} M + 4.5 mL 0.003 M HCl | 6×10^{-9} | 1×10^{-9} |
| 500 μL 6×10^{-9} M + 4.5 mL 0.003 M HCl | 6×10^{-10} | 1×10^{-10} |
| 5 mL 0.003 M HCl | 0 | Reference |

Table 2011.27G. Recommended microplate layout for ease of handling triplicate wells of standard curve, QC check sample, and unknown samples; each sample is run at three dilutions (1:10, 1:50, 1:200); standard curve is run in columns 1–3 (values are in M STX)^a

| Microplate row | Microplate column | | | | | | | | | | | |
|----------------|----------------------|----------------------|----------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| A | 10 ⁻⁶ | 10 ⁻⁶ | 10 ⁻⁶ | QC | QC | QC | U3 1:50 | U3 1:50 | U3 1:50 | U6 1:10 | U6 1:10 | U6 1:10 |
| B | 10 ⁻⁷ | 10 ⁻⁷ | 10 ⁻⁷ | U1 1:10 | U1 1:10 | U1 1:10 | U3 1:200 | U3 1:200 | U3 1:200 | U6 1:50 | U6 1:50 | U6 1:50 |
| C | 3 × 10 ⁻⁸ | 3 × 10 ⁻⁸ | 3 × 10 ⁻⁸ | U1 1:50 | U1 1:50 | U1 1:50 | U4 1:10 | U4 1:10 | U4 1:10 | U6 1:200 | U6 1:200 | U6 1:200 |
| D | 10 ⁻⁸ | 10 ⁻⁸ | 10 ⁻⁸ | U1 1:200 | U1 1:200 | U1 1:200 | U4 1:50 | U4 1:50 | U4 1:50 | U7 1:10 | U7 1:10 | U7 1:10 |
| E | 3 × 10 ⁻⁹ | 3 × 10 ⁻⁹ | 3 × 10 ⁻⁹ | U2 1:10 | U2 1:10 | U2 1:10 | U4 1:200 | U4 1:200 | U 1:200 | U7 1:50 | U7 1:50 | U7 1:50 |
| F | 10 ⁻⁹ | 10 ⁻⁹ | 10 ⁻⁹ | U2 1:50 | U2 1:50 | U2 1:50 | U5 1:10 | U5 1:10 | U5 1:10 | U7 1:200 | U7 1:200 | U7 1:200 |
| G | 10 ⁻¹⁰ | 10 ⁻¹⁰ | 10 ⁻¹⁰ | U2 1:200 | U2 1:200 | U2 1:200 | U5 1:50 | U5 1:50 | U5 1:50 | | | |
| H | REF | REF | REF | U3 1:10 | U3 1:10 | U3 1:10 | U5 1:200 | U5 1:200 | U5 1:200 | | | |

^a REF = Reference; QC = quality control check; U = unknown sample. [Note: The same standard curve may be used for multiple plates (i.e., 11 samples can be run on subsequent plates in a series if the standard curve is not included).]




Figure 2011.27. Sigmoidal dose response curve. Dashed lines indicate log IC₅₀.

Assays with a QC check sample out of specifications should trigger a check of the IC₅₀ value.

The following criteria must be met for acceptability of a sample measurement:

(a) Sample quantification should be done only on dilutions that fall within B/B₀ of 0.2–0.7. In the event that all sample dilutions fall below B/B₀ 0.2 (i.e., concentration is too high), further dilutions must be made and the sample reanalyzed. In the event that the sample concentration is too low to be quantified (i.e., B/B₀ > 0.7), the sample is reported as below LOD. If more than one dilution falls on the linear part of the curve, an average value calculated from all dilutions should be used. If there is disagreement between different dilutions in final concentration reported, check for error in the sample dilution process.

(b) RSD of the sample CPMs should be ≤30%.

Reference: *J. AOAC Int.* (future issue)



Report of Investigation

Reference Material 8642

FDA Saxitoxin Dihydrochloride Solution

This Reference Material (RM) is intended for use in calibrating the mouse bioassay used in AOAC International Official Method 959.08 Paralytical Shellfish Poison [1] and for other similar uses. RM 8642 FDA Saxitoxin Dihydrochloride Solution was prepared by the U.S. Food and Drug Administration's (FDA's) Center for Food Safety and Applied Nutrition (CFSAN), where it was identified as Lot 089. The RM is saxitoxin dihydrochloride (CAS No. 35554-08-6) in a solution containing a hydrochloric acid concentration of 5 mmol/L in 20 % ethanol in water (volume fraction). A unit of RM 8642 consists of ten amber, borosilicate glass ampoules, each containing approximately 1.2 mL of solution.

Reference Mass Fraction Value: The reference value for the mass fraction of saxitoxin hydrochloride in solution in RM 8642, identified by FDA as lot 089, is 103 $\mu\text{g/g}$ with an expanded uncertainty of 4 $\mu\text{g/g}$. Reference values are noncertified values that are estimates of the true value; however, the values do not meet the NIST criteria for certification and are provided with associated uncertainties that may reflect only measurement precision, may not include all sources of uncertainty, or may reflect a lack of sufficient statistical agreement among multiple analytical methods [2]. The reference mass fraction value is based on the gravimetric preparation of a stock solution and gravimetric dilution to produce the final material, and uncertainties associated with the associated weighings. The uncertainty is expressed as an expanded uncertainty, $U = ku_c$, at the 95 % level of confidence, $k = 2$, and includes a 2 % Type B purity uncertainty component as well as the gravimetric uncertainty [3]. Values are reported on an "as-received" basis in mass fraction units [4].

Expiration of Value Assignment: The reference value for RM 8642 is valid, within the measurement uncertainty specified, until **01 July 2013**, provided the RM is handled and stored in accordance with instructions given in this report (see "Instructions for Use"). This report is nullified if the RM is damaged, contaminated, or otherwise modified.

Maintenance of RM: NIST will monitor this RM over the period of its validity. If substantive technical changes occur that affect the value assignment before the expiration of this report, NIST will notify the purchaser. Registration (see attached sheet) will facilitate notification.

The technical and support aspects involved in the preparation and issuance of this Reference Material were coordinated through K.E. Sharpless of the NIST Analytical Chemistry Division and M.P. Cronise of the NIST Measurement Services Division.

The solution was prepared and characterized by S. Hall of the Division of Bioanalytical Chemistry, Office of Regulatory Science, CFSAN, FDA.

Statistical analysis was provided by J.H. Yen of the NIST Statistical Engineering Division.

Support aspects involved in the issuance of this SRM were coordinated through the NIST Measurement Services Division.

Stephen A. Wise, Chief
Analytical Chemistry Division

Robert L. Watters, Jr., Chief
Measurement Services Division

Gaithersburg, MD 20899
Report Issue Date: 09 December 2010
Report Revision History on last page.

NOTICE AND WARNING TO USERS

Warning: For laboratory use only.

Storage: Unopened ampoules should be stored upright under normal laboratory conditions inside the original container supplied by NIST.

INSTRUCTIONS FOR USE

Gently tap the ampoule prior to opening to allow any solution in the tip to drain into the body of the ampoule.

Prepare a working solution as follows: On a top-loading balance, record the tare weight of an appropriate plastic bottle to 0.1 g or better. To the bottle, add approximately 100 mL water that has been acidified to pH 3 with hydrochloric acid. To minimize error due to evaporation, be prepared to immediately transfer the RM solution to this bottle after opening the ampoule. To open, hold the ampoule steady and grasp the stem at the metallic band with thumb and forefinger; **minimal** thumb pressure should be applied to the stem to snap it. Correctly done, the stem should break easily where pre-scored. Aspirate the RM solution into a dry, clean, disposable plastic syringe, 2 mL to 5 mL capacity, fitted with a suitable needle (such as 18 G \times 1 1/2"), weigh the syringe and its contents to 1 mg or better, and dispense the solution into the bottle of acidified water. Do not rinse the syringe. Reweigh the emptied syringe to determine the mass of RM solution transferred to the bottle. Add sufficient acidified water (pH 3, HCl) to adjust the concentration to 1 μ g/g. Weigh the bottle and its contents to determine the mass of solution prepared and the exact concentration of the working solution.

Because of the volatility of ethanol, the reference value is not applicable to material in ampoules that have been previously opened. The concentration of the working solution should be stable for more than one month if the solution is protected from evaporation. Dilution by mass is preferred but, if dilution by volume must be performed, the density of the solution is 0.971 g/mL and the concentration of this standard is 100 μ g/mL with an expanded uncertainty of 4 μ g/mL. This uncertainty is calculated as described above.

Source and Preparation of Material: Saxitoxin was extensively purified on three low-pressure preparative columns, each containing a different stationary phase. The saxitoxin was converted to the dihydrochloride form by passage through an ion exchange resin in the chloride form. Purity was assessed at FDA by proton nuclear magnetic resonance spectroscopy, combustion analysis, and optical rotation. RM 8642, identified by FDA as lot 089, was prepared by dissolving the saxitoxin dihydrochloride in a solution of hydrochloric acid (5 mmol/L) in 20 % ethanol in water (volume fraction).

REFERENCES

- [1] AOAC International; *Official Methods of Analysis of AOAC International*, 18th Edition, Gaithersburg, MD (2005).
- [2] May, W.; Parris, R.; Beck II, C.; Fassett, J.; Greenberg, R.; Guenther, F.; Kramer, G.; Wise, S.; Gills, T.; Colbert, J.; Gettings, R.; MacDonald, B.; *Definition of Terms and Modes Used at NIST for Value-Assignment of Reference Materials for Chemical Measurements*; NIST Special Publication 260-136 (2000); available at <http://ts.nist.gov/MeasurementServices/ReferenceMaterials/PUBLICATIONS.cfm> (accessed Nov 2010).
- [3] JCGM 100:2008; *Evaluation of Measurement Data — Guide to the Expression of Uncertainty in Measurement* (ISO GUM 1995 with Minor Corrections); Joint Committee for Guides in Metrology (2008); available at http://www.bipm.org/utis/common/documents/jcgm/JCGM_100_2008_E.pdf (accessed Nov 2010); see also Taylor, B.N.; Kuyatt, C.E.; *Guidelines for Evaluating and Expressing the Uncertainty of NIST Measurement Results*; NIST Technical Note 1297; U.S. Government Printing Office: Washington, DC (1994); available at <http://www.nist.gov/physlab/pubs/index.cfm> (accessed Nov 2010).
- [4] Thompson, A.; Taylor, B.N.; *Guide for the Use of the International System of Units (SI)*; NIST Special Publication 811; U.S. Government Printing Office: Washington, DC (2008); available at: http://ts.nist.gov/WeightsAndMeasures/Metric/mpo_pubs.cfm (accessed Nov 2010).

Report Revision History: 09 December 2010 (Extension of the period of validity; editorial changes.); 09 June 2010 (Original report date).

Users of this RM should ensure that the Report of Investigation in their possession is current. This can be accomplished by contacting the SRM Program: telephone (301) 975-2200; fax (301) 926-4751; e-mail srminfo@nist.gov; or via the Internet at <http://www.nist.gov/srm>.

Appendix VI




101 ARC Dr.
St. Louis, MO 63146 U.S.A.
Ph. (314) 991-4545 or (800) 331-6661
Fax (314) 991-4692 or (800) 999-9925
Web: <http://www.arc-inc.com>
E-mail: arcinc@arc-inc.com

TECHNICAL DATA SHEET ART 1301 Saxitoxin [$^{11}\text{-}^3\text{H}$]

LOT SPECIFIC TECHNICAL DATA:

Lot number: 120814
Specific activity: estimated 20-30 Ci/mmol
Solvent: Methanol
Radioactive concentration: 0.05 mCi/ml
Molecular weight: 299.2



PACKAGING INFORMATION:

ART 1301 is packaged as a solution in methanol in a sealed ampoule. It is shipped in dry ice.

STABILITY AND STORAGE RECOMMENDATIONS:

A working stock of 1/50 dilution in methanol can be stored at 4°C. Long-term storage should be carried out at -80°C, based on the previous commercially available Saxitoxin [^3H], which was not stable at -20°C. The rate of degradation at -80°C is approximately 0.3-1% for the first month.

RADIOCHEMICAL AND CHEMICAL PURITY:


Radiochemical Purity: 99.56%

Column: Zorbax SB-AQ (250 x 3.0mm)

Mobile Phase: water:isopropanol:
heptafluorobutyric acid
(99.5 : 0.5 : 0.005)

Flow Rate: 0.5 ml/min

Detector: β -RAM [^3H]



| Name | Start (mm:ss) | End (mm:ss) | Retention (mm:ss) | Height (cps) | Area (Counts) | %ROI (%) |
|----------|---------------|-------------|-------------------|--------------|---------------|----------|
| Bkg 1 | 0:02 | 0:16 | 0:13 | 183.0 | | |
| Region 1 | 4:31 | 7:08 | 5:07 | 158.0 | 1375.5 | 0.36 |
| Region 2 | 7:08 | 8:11 | 7:29 | 32767.0 | 384313.4 | 99.56 |
| Region 3 | 8:11 | 9:58 | 8:14 | 136.0 | 320.3 | 0.08 |
| 3 Peaks | | | | | 386009.1 | 100.00 |

At the time of shipment all products are guaranteed to be free from defects in material and workmanship and to conform to the accompanying technical specifications and purity data. ARC will offer a 30 day money back guarantee of free replacement of products that are found to be unsatisfactory in respect to product specifications and purity. ARC makes no other warranty, expressed or implied, pertaining to the suitability of the product for any specific application. In case of breach of this warranty the entire liability of ARC will be limited to the invoice price of the goods. In no case will ARC be liable for any special, incidental or consequential damages resulting from the use of its products. ARC hereby expressly disclaims any warranty regarding results obtained through use of the products, including without limitation any claim of inaccurate, invalid, or incomplete results. Products are not suitable for human use.